Stat3 dimerization inhibitors

ABSTRACT

The subject matter disclosed herein relates to compositions and methods of making and using the compositions. In a further aspect, the subject matter disclosed herein relates to inhibitors of STAT3 dimerization. Methods of making these compositions as well as compositions comprising these compositions are also disclosed. Also disclosed are methods of treating or preventing certain cancers by administering to an individual in need thereof and effective amount of the compounds disclosed herein. Still further, disclosed herein are methods of inhibiting STAT3 by contacting a cell with a compound or composition as disclosed herein.

CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of U.S. application Ser. No.15/818,071, filed Nov. 20, 2017, which is a divisional of U.S.application Ser. No. 14/435,471, filed Apr. 14, 2015, now U.S. Pat. No.9,822,135, which is a national stage application filed under 35 U.S.C. §371 of PCT/US2013/067450, filed Oct. 30, 2013, which claims the benefitof priority to U.S. Provisional Application No. 61/720,234, filed Oct.30, 2012, which are incorporated by reference herein in theirentireties.

ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant no CA140681awarded by the National Institutes of Health. The government has certainrights in this invention.

BACKGROUND

Signal Transducer and Activator of Transcription 3 (STAT3) is a signaltransducer and activator of transcription that transmits signals fromcell surface receptors to the nucleus. STAT3 is frequentlyhyperactivated in many human cancers. Under normal conditions, STAT3activation is transient and tightly regulated. Upon cellular stimulationby ligands such as growth factors or cytokines, STAT3 becomephosphorylated on critical tyrosine residue (Tyr705) and consequentlyinduce STAT3 dimerization through two reciprocal phosphotyrosine(pTyr)-Src-homology 2 (SH2) interactions. The STAT3 dimers thentranslocate to the nucleus and bind to specific DNA-response elements inthe promoters of target genes thereby activating transcription. Theassociation of aberrant STAT3 activation with many types of humanmalignancies and solid tumors has made STAT3 an attractive moleculartarget for the development of novel cancer therapeutics. (See Darnell,Science 1997; 277:630-1635; Darnell, Nat. Med. 2005; 11:595-596;Bromberg, Oncogene 2000; 19:2468-2473; Yu, Nat. Rev. Cancer 2004;4:97-105; Bowman, Oncogene 2000; 19:2474-2488; Yue, Expert Opin. Inv.Drug 2009; 18:45-56.)

STAT3 is found to be constitutively activated in tumor cells andcontribute to tumor progression through the modulation of some targetgenes, such as antiapoptotic genes Bcl-xL, Bcl-2, Mcl-1 and survivinalong with genes driving cell cycle progression, c-Myc and cyclin-D1.(Id.; Buettner, Clin. Cancer Res. 2002; 8:945-954.) Aberrant activationof STAT3 is most frequent in almost all blood malignancies and solidtumors, including lymphoma and leukemia, breast, prostate, lung head andneck, brain and colon cancer. (See Turkson, Expert Opin. Ther. Tar.2004; 8:409-422. Burke, et al., Oncogene 2001; 20:7925-7934; Berishaj,et al., Breast Cancer Res 2007; 9:R³²; Barton, et al., Mol. Cancer Ther.2004; 3:11-20; Krueger, et al., Oncogene 1991:6; 245-56; Chaturvedi,Mol. Cell. Biol. 1997; 17:3295-3304; Song, Oncogene 2000; 19:2489-2495.)These features have made STAT3 an attractive target for the developmentof anticancer agents.

The design of compounds that target STAT3 has been the subject ofseveral recent reviews. (See Mankan, et al., Expert Opin. Inv. Drug2011; 20:1263-1275; Lavecchia, et al., Curr. Med. Chem. 2011;18:2359-2375; Yap, Med. Chem. Comm 2012; 3:541-551; Masciocchi, et al.,Future Medicinal Chemistry 2011; 3:567-597; Zhao, et al., Curr. Med.Chem. 2011, 18, 4012-4018.) The direct targeting of STAT3 is aparticularly attractive way to inhibit its function. Several approacheshave been taken to inhibit the dimerization of phosphorylated STAT3 byblocking the SH2 domain binding site of the phosphorylated STAT3tyrosine-705 residue. The first inhibitors of STAT3 dimerization werepeptides and phosphopeptides (Turkson, et al., J. Biol. Chem. 2001;276:45443-45455; Coleman, et al., J. Med. Chem. 2005; 48:6661-6670).Significant advances have been made by the groups of McMurray (Mandal,et al., J. Med. Chem. 2011; 54:3549-3563; Mandal, et al., J. Med. Chem.2009; 52:2429-2442; Mandal, et al., J. Med. Chem. 2009; 52:6126-6141)and Wang (Chen, et al., ACS Med. Chem. Lett. 2010; 1:85-89) by usingstructure-based approaches resulting in potent peptide-like inhibitorsincorporating a phosphotyrosine residue. These potent cell permeableSTAT3 dimerization inhibitors have considerable ADME liabilities sincethe high affinity SH2 domain binding derives, at least in part, from thenecessary presence of a hydrolyzable phosphate group.

As an alternative approach considerable attention has been paid to thediscovery of non-peptidic small molecule drug-like inhibitors of STAT3dimerization to avoid some of the ADME challenges inherent in thedevelopment of peptide-like inhibitors. (See Fletcher, et al., Chem.Bio. Chem. 2009; 10:1959-1964; Hao, et al., Bioorg. Med. Chem. Lett.2008; 18:4988-4992; Matsuno, et al., ACS Med. Chem. Lett. 2010;1:371-375; Ren, et al., ACS Med. Chem. Lett. 2010; 1:454-459; Schust etal., Chem. Biol. 2006; 13:1235-1242; Shahani, et al., ACS Med. Chem.Lett. 2011; 2:79-84; Siddiquee, et al., ACS Chem. Biol. 2007; 2:787-798;Song, et al., P. Natl. Acad. Sci. USA 2005; 102:4700-4705; Uehara, etal., Biochem. Biophys. Res. Commun. 2009; 380:627-631.) What are neededare new STAT3 inhibitors and methods of making and using same. Thecompounds, compositions, and methods disclosed herein address these andother needs.

SUMMARY

The subject matter disclosed herein relates to compositions and methodsof making and using the compositions. In a further aspect, the subjectmatter disclosed herein relates to inhibitors of STAT3 dimerization.Methods of making these compositions as well as compositions comprisingthese compositions are also disclosed. Also disclosed are methods oftreating or preventing certain cancers by administering to an individualin need thereof and effective amount of the compounds disclosed herein.Still further, disclosed herein are methods of inhibiting STAT3 bycontacting a cell with a compound or composition as disclosed herein.

Additional advantages of the disclosed subject matter will be set forthin part in the description that follows and the Figures, and in partwill be obvious from the description, or can be learned by practice ofthe aspects described below. The advantages described below will berealized and attained by means of the elements and combinationsparticularly pointed out in the appended claims. It is to be understoodthat both the foregoing general description and the following detaileddescription are exemplary and explanatory only and are not restrictive.

BRIEF DESCRIPTION OF THE FIGURES

The accompanying figures, which are incorporated in and constitute apart of this specification, illustrate several aspects described below.

FIG. 1 is a chemical scheme showing the structures of S3I-201 (1,NSC-74859) and scaffolds 2 and 3.

FIGS. 2A-2C show the docking of phosphonic acid 17d and salicylic acids20f and 20g to the STAT3 SH2 domain. FIG. 2A is an overlay of the dockedposes of phosphonate 17d and salicylic acids 20f and 20g with hydrogenatoms omitted. FIG. 2B is a surface rendering of 17d docked to the STAT3p-Tyr binding site. FIG. 2C is a schematic binding mode of 17d to theSTAT3 SH2 domain showing the hydrogen bonds and hydrophobicinteractions.

FIG. 3 is a surface rendering of phosphonic acid 17d docked to the STAT3p-Tyr binding site overlaid with the STAT3 peptide (X-ray).

FIGS. 4A and 4B show the salicylic acid 20f docked to the STAT3 SH2domain. FIG. 4A is a surface rendering of 20f docked to the STAT3 p-Tyrbinding site. FIG. 4B is a schematic binding mode of 20f to the STAT3SH2 domain showing the hydrogen bonds and hydrophobic interactions.

FIG. 5A shows the chemical structures of S3I-1757 (compound 20g) andS3I-1756 (compound 20b). FIG. 5B shows the effects of S3I-1757 andS3I-1756 on the binding of STAT3 to fluorescein-labelled GpYLPQTVphophotyrosine peptide was determined by FP assays. Solvent accessiblesurface (probe radius of 0.75 A) of the STAT3 SH2 domain color coded byelectrostatic potential calculated using the APBS plugin in PyMol.

FIG. 6A shows results from a co-immuno-precipitation assay. HEK293 cellsstably co-expressing FLAG- and HA-tagged STAT3 were treated with eithervehicle, Ac-G{pTYR}LPQTV-AAVLLPVLLAAP-NH₂ (phospho-peptide with MTS)(SEQ ID NO.:3), Ac-GYLPQTV-AAVLLPVLLAAP-NH₂ (non-phospho-peptide withMTS) (SEQ ID NO.:4), 531-1757 or S3I-1756 at the indicatedconcentration, processed for immuno-precipitation with HA antibody andimmuno-blotting with FLAG antibody. FLAG-STAT3 coimmuno-precipitatedwith HA-STAT3 in HEK293 cells that co-express HA-STAT3 and FLAG-STAT3but not in vector transfected HEK293 cells.Ac-G{pTYR}LPQTV-AAVLLPVLLAAP-NH2 (phosphol9 peptide) but notAc-GYLPQTV-AAVLLPVLLAAP-NH2 inhibited the binding of FLAG-STAT3 toHASTAT3. S3I-1757 but not S3I-1756 inhibited the binding of FLAG-STAT3to HA-STAT3. FIG. 6B shows HEK293 cells stably co-expressing FLAG- andHA-tagged STAT3 were treated as described in (FIG. 6A) except that priorto treating with S3I-1757, they were first treated either with vehicleor EGF. The cells were then immuno-precipitated with HA antibody andblotted with antibodies to EGFR, P-Y-705-STAT3, FLAG, HA or total STAT3as described in Methods. Results are representative of 3 independentexperiments. FIG. 6C shows results from a co-localization assay whereHEK293 cells stably co-expressing FLAG- and HAtagged STAT3 were platedon cover slides over night and then treated with either vehicle,S3I-1757 or S3I-1756 for 0, 1, 2 or 4 hours and processed forco-localization studies with HA-STAT3 and FLAG-STAT3 as described underMethods. Data are representative of 3 independent experiments.

FIGS. 7A and 7B show results from where MDA-MB-468 cells were plated oncover slides over night and then treated with either vehicle, S3I-1757or S3I-1756 at the indicated concentration for either 2 or 4 hours (FIG.7A) or 18 hours (FIG. 7B) and processed for P-STAT3 immuno-fluorescence.FIG. 7C shows results from where MDAMB-468 and A-549 cells were treatedwith either vehicle, S3I-1757 or S3I-1756 for the indicated interval oftime and the nuclear extract isolated from the treated cells. Thenuclear extracts were then incubated with a biotin labeled STAT3 DNAbinding probe and the complexes isolated by a STAT3-DNA binding assay.Results are representative of 4 independent experiments.

FIG. 8A shows results from where MDA-MB-468 cells were transientlytransfected with pLucSRE, pLucTKS3 or STAT3C along with β-gal and thenwere treated with vehicle, S3I-1756 or S3I-1757. The cytosolic extractswere prepared and analyzed for luciferase activity. The results arerepresentative of 2 independent experiments. FIG. 8B shows results fromwhere MDA-MB-468 cells were treated for 18 hours with the indicatedconcentrations of S3I-1757 or S3I-1756 and processed for westernimmuno-blotting with the indicated antibodies. The results arerepresentative of 3 independent experiments.

FIG. 9A shows results from where H358, A549, MDA-MB-468 and MDA-MB-231cells (high P-STAT3) and H460, MDA-MB-453, HEK293, and MCF-10A cells(lowP-STAT3) were plated in 96-well plates and treated with theindicated concentrations of 531-1757 or 531-1756 for 48 hours andprocessed for MTT assays. The levels of P-STAT3 were analyzed by westernblotting with a P-Y-705-STAT3 antibody. FIG. 9B shows results from wherecells were treated exactly as described for (FIG. 9A) except that thecells were plated in 12-well plates and treated for 21 days. FIG. 9Cshows results from where the cells were treated exactly as described for(FIG. 9B) except that they were first seeded at 2000 cells per well inregular growth media containing 0.3% agar (Sigma) and S3I-1757 was addedthe following day, and colonies were allowed to grow for 3-4 weeks. Theexperiment was performed once in triplicates.

FIG. 10A shows results from a migration assay where MDA-MB-231, A549 andH460 cells were seeded and allowed to grow overnight prior to scratchingthe cells with pipette tips. Cells were then treated with vehicle,S3I-1756 or S3I-1757 and allowed to migrate into the scratched area for16 hours in regular growth medium. FIG. 10B shows results from aninvasion assay where H460, A549, MDA-MB-468 and MDA-MB-231 cells wereseeded over the Matrigel in the top chamber of insert, and treated withvehicle, S3I-1756, or S3I-1757 the following day. The cells wereincubated for 48 hours, and the invaded cells were fixed with methanol,stained with crystal violet and photographed. Experiments were performedin triplicates with identical results.

FIGS. 11A and 11B show results from where MDA-MB-468 cells weretransiently transfected with vector or STAT3C then were treated withS3I-1757. The cells were then processed for western immuno-blotting(FIG. 11A) and for MTT assays (FIG. 11B).

FIGS. 12A and 12B show results from where MDAMB-468 cells weretransiently transfected with vector or STAT3C, plated either formigration (FIG. 12A) or invasion (FIG. 12B) and then treated withS3I-1757. The cells were then processed for migration (FIG. 12A) andinvasion (FIG. 12B) assays.

DETAILED DESCRIPTION

The materials, compounds, compositions, articles, and methods describedherein may be understood more readily by reference to the followingdetailed description of specific aspects of the disclosed subject matterand the Examples and Figures included therein.

Before the present materials, compounds, compositions, and methods aredisclosed and described, it is to be understood that the aspectsdescribed below are not limited to specific synthetic methods orspecific reagents, as such may, of course, vary. It is also to beunderstood that the terminology used herein is for the purpose ofdescribing particular aspects only and is not intended to be limiting.

Also, throughout this specification, various publications arereferenced. The disclosures of these publications in their entiretiesare hereby incorporated by reference into this application in order tomore fully describe the state of the art to which the disclosed matterpertains. The references disclosed are also individually andspecifically incorporated by reference herein for the material containedin them that is discussed in the sentence in which the reference isrelied upon.

General Definitions

In this specification and in the claims that follow, reference will bemade to a number of terms, which shall be defined to have the followingmeanings:

Throughout the description and claims of this specification the word“comprise” and other forms of the word, such as “comprising” and“comprises,” means including but not limited to, and is not intended toexclude, for example, other additives, components, integers, or steps.

As used in the description and the appended claims, the singular forms“a,” “an,” and “the” include plural referents unless the context clearlydictates otherwise. Thus, for example, reference to “a composition”includes mixtures of two or more such compositions, reference to “thecompound” includes mixtures of two or more such compounds, reference to“an agent” includes mixture of two or more such agents, and the like.

“Optional” or “optionally” means that the subsequently described eventor circumstance can or cannot occur, and that the description includesinstances where the event or circumstance occurs and instances where itdoes not.

Ranges can be expressed herein as from “about” one particular value,and/or to “about” another particular value. When such a range isexpressed, another aspect includes from the one particular value and/orto the other particular value. Similarly, when values are expressed asapproximations, by use of the antecedent “about,” it will be understoodthat the particular value forms another aspect.

As used herein, by a “subject” is meant an individual. Thus, the“subject” can include domesticated animals (e.g., cats, dogs, etc.),livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratoryanimals (e.g., mouse, rabbit, rat, guinea pig, etc.), and birds.“Subject” can also include a mammal, such as a primate or a human.

By “reduce” or other forms of the word, such as “reducing” or“reduction,” is meant lowering of an event or characteristic (e.g.,tumor growth). It is understood that this is typically in relation tosome standard or expected value, in other words it is relative, but thatit is not always necessary for the standard or relative value to bereferred to. For example, “reduces tumor growth” means reducing the rateof growth of a tumor relative to a standard or a control.

By “prevent” or other forms of the word, such as “preventing” or“prevention,” is meant to stop a particular event or characteristic, tostabilize or delay the development or progression of a particular eventor characteristic, or to minimize the chances that a particular event orcharacteristic will occur. Prevent does not require comparison to acontrol as it is typically more absolute than, for example, reduce. Asused herein, something could be reduced but not prevented, but somethingthat is reduced could also be prevented. Likewise, something could beprevented but not reduced, but something that is prevented could also bereduced. It is understood that where reduce or prevent are used, unlessspecifically indicated otherwise, the use of the other word is alsoexpressly disclosed.

By “treat” or other forms of the word, such as “treated” or “treatment,”is meant to administer a composition or to perform a method in order toreduce, prevent, inhibit, or eliminate a particular characteristic orevent (e.g., tumor growth or survival). The term “control” is usedsynonymously with the term “treat.”

The term “anticancer” refers to the ability to treat or control cellularproliferation and/or tumor growth at any concentration.

It is understood that throughout this specification the identifiers“first” and “second” are used solely to aid in distinguishing thevarious components and steps of the disclosed subject matter. Theidentifiers “first” and “second” are not intended to imply anyparticular order, amount, preference, or importance to the components orsteps modified by these terms.

Chemical Definitions

As used herein, the term “substituted” is contemplated to include allpermissible substituents of organic compounds. In a broad aspect, thepermissible substituents include acyclic and cyclic, branched andunbranched, carbocyclic and heterocyclic, and aromatic and nonaromaticsubstituents of organic compounds. Illustrative substituents include,for example, those described below. The permissible substituents can beone or more and the same or different for appropriate organic compounds.For purposes of this disclosure, the heteroatoms, such as nitrogen, canhave hydrogen substituents and/or any permissible substituents oforganic compounds described herein which satisfy the valences of theheteroatoms. This disclosure is not intended to be limited in any mannerby the permissible substituents of organic compounds.

Also, the terms “substitution” or “substituted with” include theimplicit proviso that such substitution is in accordance with permittedvalence of the substituted atom and the substituent, and that thesubstitution results in a stable compound, e.g., a compound that doesnot spontaneously undergo transformation such as by rearrangement,cyclization, elimination, etc.

“Z¹,” “Z²,” “Z²,” “Z³,” and “Z⁴” are used herein as generic symbols torepresent various specific substituents. These symbols can be anysubstituent, not limited to those disclosed herein, and when they aredefined to be certain substituents in one instance, they can, in anotherinstance, be defined as some other substituents.

The term “aliphatic” as used herein refers to a non-aromatic hydrocarbongroup and includes branched and unbranched, alkyl, alkenyl, or alkynylgroups.

The term “alkyl” as used herein is a branched or unbranched saturatedhydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl,n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl,octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, eicosyl,tetracosyl, and the like. The alkyl group can also be substituted orunsubstituted. The alkyl group can be substituted with one or moregroups including, but not limited to, alkyl, halogenated alkyl, alkoxy,alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid,ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo,sulfonyl, sulfone, sulfoxide, or thiol, as described below.

Throughout the specification “alkyl” is generally used to refer to bothunsubstituted alkyl groups and substituted alkyl groups; however,substituted alkyl groups are also specifically referred to herein byidentifying the specific substituent(s) on the alkyl group. For example,the term “halogenated alkyl” specifically refers to an alkyl group thatis substituted with one or more halide, e.g., fluorine, chlorine,bromine, or iodine. The term “alkoxyalkyl” specifically refers to analkyl group that is substituted with one or more alkoxy groups, asdescribed below. The term “alkylamino” specifically refers to an alkylgroup that is substituted with one or more amino groups, as describedbelow, and the like. When “alkyl” is used in one instance and a specificterm such as “alkylalcohol” is used in another, it is not meant to implythat the term “alkyl” does not also refer to specific terms such as“alkylalcohol” and the like.

This practice is also used for other groups described herein. That is,while a term such as “cycloalkyl” refers to both unsubstituted andsubstituted cycloalkyl moieties, the substituted moieties can, inaddition, be specifically identified herein; for example, a particularsubstituted cycloalkyl can be referred to as, e.g., an“alkylcycloalkyl.” Similarly, a substituted alkoxy can be specificallyreferred to as, e.g., a “halogenated alkoxy,” a particular substitutedalkenyl can be, e.g., an “alkenylalcohol,” and the like. Again, thepractice of using a general term, such as “cycloalkyl,” and a specificterm, such as “alkylcycloalkyl,” is not meant to imply that the generalterm does not also include the specific term.

The term “alkoxy” as used herein is an alkyl group bound through asingle, terminal ether linkage; that is, an “alkoxy” group can bedefined as —O^(Z) where Z¹ is alkyl as defined above.

The term “alkenyl” as used herein is a hydrocarbon group of from 2 to 24carbon atoms with a structural formula containing at least onecarbon-carbon double bond. Asymmetric structures such as (Z¹Z²)C═C(Z³Z⁴)are intended to include both the E and Z isomers. This can be presumedin structural formulae herein wherein an asymmetric alkene is present,or it can be explicitly indicated by the bond symbol C═C. The alkenylgroup can be substituted with one or more groups including, but notlimited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl,heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide,hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide,or thiol, as described below.

The term “alkynyl” as used herein is a hydrocarbon group of 2 to 24carbon atoms with a structural formula containing at least onecarbon-carbon triple bond. The alkynyl group can be substituted with oneor more groups including, but not limited to, alkyl, halogenated alkyl,alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylicacid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo,sulfonyl, sulfone, sulfoxide, or thiol, as described below.

The term “aryl” as used herein is a group that contains any carbon-basedaromatic group including, but not limited to, benzene, naphthalene,phenyl, biphenyl, phenoxybenzene, and the like. The term “heteroaryl” isdefined as a group that contains an aromatic group that has at least oneheteroatom incorporated within the ring of the aromatic group. Examplesof heteroatoms include, but are not limited to, nitrogen, oxygen,sulfur, and phosphorus. The term “non-heteroaryl,” which is included inthe term “aryl,” defines a group that contains an aromatic group thatdoes not contain a heteroatom. The aryl or heteroaryl group can besubstituted or unsubstituted. The aryl or heteroaryl group can besubstituted with one or more groups including, but not limited to,alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl,aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone,nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol asdescribed herein. The term “biaryl” is a specific type of aryl group andis included in the definition of aryl. Biaryl refers to two aryl groupsthat are bound together via a fused ring structure, as in naphthalene,or are attached via one or more carbon-carbon bonds, as in biphenyl.

The term “cycloalkyl” as used herein is a non-aromatic carbon-based ringcomposed of at least three carbon atoms. Examples of cycloalkyl groupsinclude, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, etc. The term “heterocycloalkyl” is a cycloalkyl group asdefined above where at least one of the carbon atoms of the ring issubstituted with a heteroatom such as, but not limited to, nitrogen,oxygen, sulfur, or phosphorus. The cycloalkyl group and heterocycloalkylgroup can be substituted or unsubstituted. The cycloalkyl group andheterocycloalkyl group can be substituted with one or more groupsincluding, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl,heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide,hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide,or thiol as described herein.

The term “cycloalkenyl” as used herein is a non-aromatic carbon-basedring composed of at least three carbon atoms and containing at least onedouble bound, i.e., C═C. Examples of cycloalkenyl groups include, butare not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl,cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like. The term“heterocycloalkenyl” is a type of cycloalkenyl group as defined above,and is included within the meaning of the term “cycloalkenyl,” where atleast one of the carbon atoms of the ring is substituted with aheteroatom such as, but not limited to, nitrogen, oxygen, sulfur, orphosphorus. The cycloalkenyl group and heterocycloalkenyl group can besubstituted or unsubstituted. The cycloalkenyl group andheterocycloalkenyl group can be substituted with one or more groupsincluding, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl,heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide,hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide,or thiol as described herein.

The term “cyclic group” is used herein to refer to either aryl groups,non-aryl groups (i.e., cycloalkyl, heterocycloalkyl, cycloalkenyl, andheterocycloalkenyl groups), or both. Cyclic groups have one or more ringsystems that can be substituted or unsubstituted. A cyclic group cancontain one or more aryl groups, one or more non-aryl groups, or one ormore aryl groups and one or more non-aryl groups.

The term “aldehyde” as used herein is represented by the formula —C(O)H.Throughout this specification “C(O)” or “CO” is a short hand notationfor C═O, which is also referred to herein as a “carbonyl.”

The terms “amine” or “amino” as used herein are represented by theformula —NZ¹Z², where Z¹ and Z² can each be substitution group asdescribed herein, such as hydrogen, an alkyl, halogenated alkyl,alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl,heterocycloalkyl, or heterocycloalkenyl group described above. “Amido”is —C(O)NZ¹Z².

The term “carboxylic acid” as used herein is represented by the formula—C(O)OH. A “carboxylate” or “carboxyl” group as used herein isrepresented by the formula —C(O)O⁻.

The term “ester” as used herein is represented by the formula —OC(O)Z¹or —C(O)OZ¹, where Z¹ can be an alkyl, halogenated alkyl, alkenyl,alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl,or heterocycloalkenyl group described above.

The term “ether” as used herein is represented by the formula Z¹OZ²,where Z¹ and Z² can be, independently, an alkyl, halogenated alkyl,alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl,heterocycloalkyl, or heterocycloalkenyl group described above.

The term “ketone” as used herein is represented by the formula Z¹C(O)Z²,where Z¹ and Z² can be, independently, an alkyl, halogenated alkyl,alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl,heterocycloalkyl, or heterocycloalkenyl group described above.

The term “halide” or “halogen” as used herein refers to the fluorine,chlorine, bromine, and iodine.

The term “hydroxyl” as used herein is represented by the formula —OH.

The term “nitro” as used herein is represented by the formula —NO₂.

The term “silyl” as used herein is represented by the formula —SiZ¹Z²Z³,where Z¹, Z², and Z³ can be, independently, hydrogen, alkyl, halogenatedalkyl, alkoxy, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl,cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group describedabove.

The term “sulfonyl” is used herein to refer to the sulfo-oxo grouprepresented by the formula —S(O)₂Z¹, where Z¹ can be hydrogen, an alkyl,halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl,cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group describedabove.

The term “sulfonylamino” or “sulfonamide” as used herein is representedby the formula —S(O)₂NH—.

The term “thiol” as used herein is represented by the formula —SH.

The term “thio” as used herein is represented by the formula —S—.

“R¹,” “R²,” “R³,” “R^(n),” etc., where n is some integer, as used hereincan, independently, possess one or more of the groups listed above. Forexample, if R¹ is a straight chain alkyl group, one of the hydrogenatoms of the alkyl group can optionally be substituted with a hydroxylgroup, an alkoxy group, an amine group, an alkyl group, a halide, andthe like. Depending upon the groups that are selected, a first group canbe incorporated within second group or, alternatively, the first groupcan be pendant (i.e., attached) to the second group. For example, withthe phrase “an alkyl group comprising an amino group,” the amino groupcan be incorporated within the backbone of the alkyl group.Alternatively, the amino group can be attached to the backbone of thealkyl group. The nature of the group(s) that is (are) selected willdetermine if the first group is embedded or attached to the secondgroup.

Unless stated to the contrary, a formula with chemical bonds shown onlyas solid lines and not as wedges or dashed lines contemplates eachpossible isomer, e.g., each enantiomer, diastereomer, and meso compound,and a mixture of isomers, such as a racemic or scalemic mixture.

Reference will now be made in detail to specific aspects of thedisclosed materials, compounds, compositions, articles, and methods,examples of which are illustrated in the accompanying Examples andFigures.

Compounds

Disclosed herein are compounds having Formula I

wherein, R¹ is H, C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl,benzyl, 4-piperidyl, 3-(4-pyridyl), pyridinyl, or

wherein R⁴ is OH, Cl, F, Br, I, cyclohexyl, OC₁-C₁₀ alkyl, C₁-C₁₀ alkyl,C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl),morpholinyl, pyridinyl, OPh, PO(OEt)₂, or PO(OH)₂; R² is null, H, OH,Cl, F, Br, I, NH₃, OC₁-C₁₀ alkyl, cyclohexyl, C₁-C₁₀ alkyl, C(O)C₁-C₁₀alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl,pyridinyl, phenyl, halogenated phenyl, PO(OEt)₂, PO(OH)₂ or

wherein X is O, NH, S, or CH₂, and R⁵ is H, OH, Cl, F, Br, I,cyclohexyl, or C₁-C₁₀ alkyl; R³ is H, OH, Cl, F, Br, I, OC₁-C₁₀ alkyl,C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, NO₂, NH₃, or CN; and R⁶is H, C₁-C₁₀ alkyl, or a pharmaceutically acceptable counterion; each Yis, independent of the others, CH or N; and Z is C or N; or apharmaceutically acceptable salt thereof.

In certain examples, compounds of Formula I can have R¹ as H, C₁-C₁₀alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, benzyl, 4-piperidyl,3-(4-pyridyl), or pyridinyl. In other examples, R¹ can be

where each Y is CH, and R⁴ is OH, Cl, F, Br, I, cyclohexyl, C₁-C₁₀alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl, pyridinyl, or OPh. Instill other examples, R¹ can be

wherein each Y is CH, and R⁴ is cyclohexyl, C₁-C₁₀ alkyl, 4-piperidyl,3-(4-pyridyl), morpholinyl, or pyridinyl, more preferably R⁴ iscyclohexyl and each Y is CH.

In certain examples, compounds of Formula I can have R² as OH, Cl, F,Br, I, OCH₃, C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl,phenyl, or pyridinyl. In still other examples, R² can be

wherein each Y is CH, and R⁵ is H, OH, Cl, F, Br, or I. In a preferredexample, X can be O, for example, when R² is OPh.

In certain examples, compounds of Formula I can have R³ is H or OCH₃.

Specific examples of compounds of Formula I are shown in Table 3. Onepreferred compound has the following compound.

Disclosed herein are compounds that have Formula II:

wherein R¹ is H, C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl,benzyl, 4-piperidyl, 3-(4-pyridyl), pyridinyl, or

wherein R⁴ is OH, Cl, F, Br, I, cyclohexyl, OC₁-C₁₀ alkyl, C₁-C₁₀ alkyl,C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl),morpholinyl, pyridinyl, OPh, PO(OEt)₂, or PO(OH)₂; R² is null, H, OH,Cl, F, Br, I, NH₃, OC₁-C₁₀ alkyl, cyclohexyl, C₁-C₁₀ alkyl, C(O)C₁-C₁₀alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl,pyridinyl, phenyl, halogenated phenyl, PO(OEt)₂, PO(OH)₂ or

wherein X is O, NH, S, or CH₂, and R⁵ is H, OH, Cl, F, Br, I,cyclohexyl, or C₁-C₁₀ alkyl; R³ is H, OH, Cl, F, Br, I, OC₁-C₁₀ alkyl,C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, NO₂, NH₃, or CN; R⁷ isCH₂PO(OH)₂, PO(OEt)₂, or PO(OH)₂; each Y is, independent of the others,CH or N; and Z is C or N; or a pharmaceutically acceptable salt thereof.

In certain examples, compounds of Formula II can have R¹ as H, C₁-C₁₀alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, benzyl, 4-piperidyl,3-(4-pyridyl), or pyridinyl. In still other examples, compounds ofFormula II can have R¹ as

where each Y is CH, and R⁴ is OH, Cl, F, Br, I, cyclohexyl, C₁-C₁₀alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl, pyridinyl, or OPh. In aother examples, R¹ can be

wherein each Y is CH, and R⁴ is cyclohexyl, C₁-C₁₀ alkyl, 4-piperidyl,3-(4-pyridyl), morpholinyl, or pyridinyl, more preferably R⁴ can becyclohexyl and each Y can be CH.

In certain examples, compounds of Formula II can have R² as OH, Cl, F,Br, I, OCH₃, C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl,phenyl, or pyridinyl. In still other examples, compounds of Formula IIcan have R² as

wherein each Y is CH, and R⁵ is H, OH, Cl, F, Br, or I. In a preferredexample, X can be O, such as when R² is OPh.

In certain examples, compounds of Formula II can have R³ as H or OCH₃.

Also, disclosed herein are compounds having Formula III:

wherein R¹ is H, C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl,benzyl, 4-piperidyl, 3-(4-pyridyl), pyridinyl, or

wherein R⁴ is OH, Cl, F, Br, I, cyclohexyl, OC₁-C₁₀ alkyl, C₁-C₁₀ alkyl,C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl),morpholinyl, pyridinyl, OPh, PO(OEt)₂, or PO(OH)₂; R² is null, H, OH,Cl, F, Br, I, NH₃, OC₁-C₁₀ alkyl, cyclohexyl, C₁-C₁₀ alkyl, C(O)C₁-C₁₀alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl,pyridinyl, phenyl, halogenated phenyl, PO(OEt)₂, PO(OH)₂ or

wherein X is O, NH, S, or CH₂, and R⁵ is H, OH, Cl, F, Br, I,cyclohexyl, or C₁-C₁₀ alkyl; R³ is H, OH, Cl, F, Br, I, OC₁-C₁₀ alkyl,C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, NO₂, NH₃, or CN; and R⁶is H, C₁-C₁₀ alkyl, or a pharmaceutically acceptable counterion; R⁸ isH, C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, or benzyl; each Yis, independent of the others, CH or N; and Z is C or N; or apharmaceutically acceptable salt thereof.

In certain examples, compounds of Formula III can have R¹ as H, C₁-C₁₀alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, benzyl, 4-piperidyl,3-(4-pyridyl), or pyridinyl. In still other examples, compounds ofFormula III can have R¹ as

where each Y is CH, and R⁴ is OH, Cl, F, Br, I, cyclohexyl, C₁-C₁₀alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl, pyridinyl, or OPh. Instill other examples, R¹ can be

wherein each Y is CH, and R⁴ is cyclohexyl, C₁-C₁₀ alkyl, 4-piperidyl,3-(4-pyridyl), morpholinyl, or pyridinyl. In a preferred example, R⁴ canbe cyclohexyl.

In certain examples, compounds of Formula III can have R² as OH, Cl, F,Br, I, OCH₃, C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl,phenyl, or pyridinyl. In still other examples, compounds of Formula IIIcan have R² as

wherein each Y is CH, and R⁵ is H, OH, Cl, F, Br, or I. In a preferredexample, compounds of Formula III can have X as O, such as when R² isOPh.

In certain examples, compounds of Formula III can have R³ is H or OCH₃.In a preferred example, compounds of Formula III can have R⁸ as methylor benzyl.

The first demonstration that STAT3 is involved in malignanttransformation (Yu, et al., Science 1995; 169(5220):81-83) was reportedin 1995 only a year after its discovery (Zhong, et al., Science 1994;264(5155):95-98). Less than 6 years later peptides and peptide mimics ofthe phosphotyrosine peptide PpYLKTK that bind STAT3 SH2 domain wereshown to inhibit STAT3 dimerization in vitro and STAT3 activity inintact cells (Turkson, et al., J. Biol. Chem. 2001;276(48):45443-45455). Yet, years later, there are no small moleculeSTAT3 dimerization inhibitors in clinical trials. One of the majorreasons for this is that STAT3-STAT3 dimerization is a protein-proteininteraction that involves a large surface area which is difficult totarget with drug-like small molecules. The second reason, which is evenmore challenging, is that the negatively charged phospho-tyrosine whichis required for binding to the SH2 domain is difficult to mimic withmoieties that can be easily taken up by cells. Nevertheless, because ofthe critical role of STAT3 in oncogenesis, several groups have put majorefforts towards developing STAT3 dimerization inhibitors based onPhospho-peptide mimics as novel anti cancer drugs (Debnath, et al., J.Med. Chem. 2012:doi.10.1021/jm300207s; Masciocchi, et al., Future Med.Chem. 2011: 3(5)567-597). For example, McMurray and colleagues havesucceeded at obtaining cell permeable peptidomimetics of pYLPQ where pYwas replaced by phosphocinnamide derivatives to improve peptidaseresistance and used the pivaloyloxymethyl prodrug strategy to improvecellular uptake which lead to potent inhibition of STAT3 activity inwhole cells (Mandal, et al., J. Med. Chem. 2011; 54(10):3549-3563).Similarly, Wang and colleagues (Chen, et al., ASC Med. Chem. Lett. 2010;1(2):85-59) have also succeeded at designing a conformationallyconstrained pYLPQTV peptidomimetic with a long hydrocarbon chain toimprove cell permeability. Although these are outstanding achievements,there still remain physicochemical challenges concerning the use ofphospho-tyrosine peptidomimetics in vivo. Therefore, non-peptidic smallmolecules capable of disrupting STAT3-STAT3 dimerization is anattractive alternative approach to inhibiting STAT3 directly.

STAT3 inhibitor S3I-201 (NSC-74859) (Siddiquee, et al., P. Natl. Acad.Sci. USA 2007; 104:7391-7396) (FIG. 1) was identified from the NCIchemical collection by using structure-based virtual screening with amodel based on the X-ray crystal structure of the STAT3 homodimer (pdbcode 1BG1) (Becker, et al., Nature 1998; 394:145-151.). S3I-201inhibited STAT3:STAT3 complex formation and STAT3 DNA-binding andtranscriptional activities. Furthermore, S3I-201 has been shown to exertantitumor effects against human breast and liver cancer xenografts inmouse models via mechanisms that are consistent with inhibition of STAT3dimerization.

Disclosed herein are analogs of S3I-201 (1). Gunning and Turkson havedeveloped a series of analogs of 1 based on an N-sulfonylglycinescaffold as in 2 (Fletcher, et al., ChemBioChem 2009; 10:1959-1964;Fletcher, et al., Chem. Med. Chem. 2011; 6:1459-1470; Zhang, et al., P.Natl. Acad. Sci. USA 2012; 109:9623-9628).

In the compounds disclosed herein there is a replacement of thepotentially reactive O-sulfonylglycine portion of 1, and it is shownthat the sulfonyloxy linker separating the two aryl groups by 5 atomscan be replaced by a shorter linker as in 3, leading to STAT3dimerization inhibitors with improved potency. It is also shown hereinthat the phosphotyrosine mimicking 4-amino-2-hydroxybenzoic acid can bereplaced by its isomeric partner 5-amino-2-hydroxybenzoic acid.

First, the reductive amination of para-substituted arylaldehydes 5 withmethyl 5-aminosalicylate (4) provided the correspondingN-arylmethylaminosalicylates 6 in good to excellent yields. The couplingreaction of the series of anilines 6 with N-sulfonylglycine derivatives7 was conveniently achieved following a modified procedure withdichlorotriphenylphosphorane (PPh₃C₁₂) to furnish the tertiary amides 8in very good yields (Azumaya, et al., Tetrahedron 2003; 59:2325-2331).Subsequent hydrolysis of the methyl esters under basic conditions(NaOH-THF-H₂O) resulted in the formation of the desired salicylic acids9. The N-sulfonylglycine derivatives 7 were prepared from eitherN-benzyl or N-methyl glycine (10 and 11 respectively) viaN-sulfonylation with a range of substituted arylsulfonyl chlorides tofirst provide the sulfonamides 12 which were then hydrolyzed.

A library of related N-benzamides lacking the potentially reactivemethylenoxysulfonyl group of 1, incorporating an arylphosphonate(examples 17a and 17b) or benzylphosphonate (examples 17c and 17d) as aphosphotyrosine mimetic, (Burke, et al., Biochemistry 1994; 33:6490-4)was prepared as shown in Scheme 2. The amino diethyl phosphonate esters13a,b,d were prepared by similar methods, whilst phosphonate 13c wascommercially available. The phosphonate-containing amides 14a-d wereprepared by coupling the amines 13a-d with 4-phenoxybenzoic acid in thepresence of EDC and catalytic amount of DMAP in DCM. This was followedby N-alkylation by treatment with sodium hydride and1-(bromomethyl)-4-cyclohexylbenzene (15) in THF to provide the tertiaryamides 16a-d. The final phosphonic acids 17a-d were obtained bytreatment of 16a-d with bromotrimethylsilane (TMSBr) (10 eq.) indichloromethane. Similarly hydrolysis of the intermediate amides 14a-cprovided the phosphonic acid-containing amides 18a-c. The library ofN-benzamides 20 in which the phosphonic acid of 17 is replaced by asalicylic acid was prepared as shown in Scheme 2.

The amide library 19, incorporating a methyl salicylate, was preparedfrom the amine library 6 (Scheme 1) via reaction with either acarboxylic acid and dichlorotriphenylphosphorane or directly with anacyl chloride. Finally, hydrolysis of the methyl salicylate ester oflibrary 19, performed in a sealed tube on a heating block, provided thedesired library of salicylic acids 20 in good yields.

The ability of the libraries 9, 17 and 20 to inhibit STAT3 dimerizationwas evaluated by a competitive, fluorescence-polarization (FP)-basedassay, as developed by Schust and Berg (Schust, et al., Chem. Biol.2006; 13:1235-1242; Schust, et al., Anal. Biochem. 2004; 330:114-118)using full length STAT3 (N-terminal GST, SignalChem, Richmond, BC,Canada) and the fluorescent probe peptide 5-FAM-G(pTyr)LPQTV-CONH₂(GenScript, Piscataway, N.J., USA)(Id.). This peptide, derived from thegp130 IL6 receptor binds to the STAT3 SH2 domain; blocking its bindingprovides a measure of inhibition of STAT3 dimerization which bindsthrough the sequence (pTyr)LKTKF (Ren, et al., Bioorg. Med. Chem. Lett.2003:13:633-636).

Table 1 shows the STAT3 inhibitory activities of the library ofsulfonamides 9 bearing a 5-amido-2-hydroxybenzoic acid group. Compound9a, which bears a tosyl group, equivalent to the sulfonyl B-ring ofS3I-201, and a benzyl group on each nitrogen atom, is weakly active (9a,IC₅₀=201.3±1.5 μM). When the tosyl group was replaced with abiphenylsulfonyl group, a 9-fold increase in the activity was observed(9b, IC₅₀=22±9.1 μM). Although, the biphenylsulfonyl group appeared tobe superior to the tosyl group, both series were prepared to furtherexplore SAR relationship among these analogs. The para-chlorobenzylderivative 9c is 4-fold more potent (IC₅₀=50±3.8 μM) than theunsubstituted analog 9a (IC₅₀=201.3±1.5 μM). Consistent with the aboveobservations, the biphenylsulfonyl derivate (9d, IC₅₀=15±1.2 μM) showedbetter activity than its tosyl analog 9c. Other groups such methoxy,cyclohexyl, n-heptyl, and iso-butyl groups at the para-position of theamido N-benzylated derivatives (9f, 9g, 9h and 9i respectively) resultedin activities similar to that of 9b and 9d (IC₅₀ values 17-23 μM). Theeffect of a methyl group as the R¹ group was next assessed. Thus thelibrary of N-methylsulfonamides 9j-s was prepared as shown in Scheme 1from commercially available sarcosine methyl ester (11). In most casesthe N-methylsulfonamides, are less active than the correspondingN-benzylsulfonamide (R¹=Bn) counterparts. For example the methyl groupin the biphenylsulfonyl example 9k (IC₅₀=57±13_M) and 91 (IC₅₀=61±6 μM),reduces activity compared to their respective benzyl analog 9b(IC₅₀=22±9.1 μM) and 9d (IC₅₀=15±1.2 μM). The presence of an alkylbenzyl group (R=cyclohexyl and n-heptyl, Table 1) in the N-methylsulfonamides 9n (IC₅₀=32±12 μM) and 9o (IC₅₀=22±8 μM) did not altertheir inhibitory as compared to the corresponding N-benzyl sulfonamides9g (IC₅₀=23.3±2 μM) and 9h (IC₅₀=19±3.5 μM). Indeed the presence of thecyclohexyl group dramatically improves the activity of the equivalent intosylsulfonamide 9m (IC₅o=45±12 μM) (cf. unsubstituted benzyl derivative9j, (IC₅₀>1000 μM). A chloro or fluoro biphenylsulfonamide group of themolecule (Ar) was tolerated (compounds 9p-9s) showing similar activitiesto their biphenylsulfonamide where made. A small number of heterocycliccontaining (as the R substituent) analogs 9t-9x were prepared to reducethe overall lipophilicity of the compounds and provide a basic site forsalt formation. The sulfonamides 9x (IC₅₀=35.3±12.7 μM) and 9u(IC₅₀=33.5±1.8 μM) possessing an N benzylamide bearing a meta-4-pyridylgroup had moderate inhibitory activity. The N-benzylamides 9t (IC₅₀>300μM), 9v (IC₅₀=94.7±0.32 μM) and 9w (14.4% inhibition at 50 μM) withheterocycles in the para position were significantly less active.

The size of the glycine linker of 1 was reduced to separate the two arylgroups by 2 atoms by using a simple amide group as shown in 3 (FIG. 1).The N-benzamides 17a and 17b, which incorporate an arylphosphonic acidas their non-hydrolyzable phosphotyrosine mimic, were made as shown inScheme 2. The para-substituted isomer 17a (IC₅o=42.0±0.8 μM) wasmoderately active and better than the meta isomer 17b (18% inhibition at50 μM) (Table 2). The two benzylphosphonic acids 17c (IC₅₀=28.4±2.9 μM)and 17d (IC₅₀=18.9±1.1 μM) showed improved activity compared to 17a. TheN-p-cyclohexylbenzyl group clearly contributes to the activity of17a,c,d since the unsubstituted amides 18a-c are all significantly lessactive. The STAT3 inhibitory activity of 17d indicated that thebenzamide scaffold merited further attention. Since the phosphonateslikely require a prodrug protection strategy to render them cellpermeable, salicylic acid containing N-benzamides 20 were prepared. Theanalog of 17d with a simple unsubstituted N-benzyl substitutent wasinactive (Table 3, 20a, 3% inhibition at 50 μM). The 4-methoxybenzylderivative 20b was weakly active (IC₅₀ 118.1±8.6 μM) as was its3,4-dimethoxy analog 20c. Some improvement in activity was observed whenthe R substituent was a halogen (20d, IC₅₀ 48±9.4 μM and 20e, IC₅₀52±4.3 μM). The presence of an alkyl group (R=n-heptyl and cyclohexyl,Table 3) resulted in further improvement (20f, IC₅₀ 12.8±0.5 μM and 20g,IC₅₀ 15±4.4 μM respectively). This effect of the para-alkyl group of theN benzylamide of 9g-i also resulted in analogs with similar activities(Table 1). Replacement of the phenoxybenzoyl group of 20f (IC₅₀ 12.8±0.5μM) by benzoyl (20h, IC₅₀ 32±4 μM) and 3-methoxybenzoyl (20i, IC₅₀33.3±1.6 μM) resulted in a two-fold reduction in activity in both cases.Substitution of the phenyl group of 20h by a pyridyl group as in 20j,20k and 201 resulted in significant reduction in activity.

TABLE 1 In vitro STAT3 dimerization inhibitory activity of library 9 9

Compound R R¹ Ar IC₅₀(μM) 9a H Bn

201.3 ± 1.5 9b H Bn

 22.2 ± 9.1 9c Cl Bn

  50 ± 3.8 9d Cl Bn

  15 ± 1.2 9f OCH₃ Bn

 22 ± 10 9g

Bn

23.3 ± 2  9h n-C₇H₁₃ Bn

 19 ± 3.5 9i iso-Butyl Bn

 17 ± 3.6 9j H Me

>1000 9k H Me

  57 ± 13 9l Cl Me

 61 ± 6 9m

Me

  45 ± 12 9n

Me

  32 ± 12 9o n-C₇H₁₃ Me

 22 ± 8 9p iso-Butyl Me

 20 ± 7.1 9q Cl Me

 43 ± 6 9r OCH₃ Me

 50 ± 9.1 9s n-C₇H₁₃ Me

 23 ± 0.3 9t 4-Piperidyl Bn

 >300 9u 3-(4-Pyridyl) Bn

 33.5 ± 1.8 9v 4-Morpholinyl Bn

  94.7 ± 0.32 9w 4-Piperidyl Me

 14.4 ± 0.6% inhibition at 50 μM 9x 3-(4-Pyridyl) Me

  35.3 ± 12.7

TABLE 2 In vitro STAT3 dimerization inhibitory activity phosphonatelibrary 17. Compound Structure IC₅₀ (μM) 17a

42.0 ± 0.8 17b

 17.9 ± 0.5% inhibition at 50 μM 17c

28.4 ± 2.9 17d

18.9 ± 1.1 18a

  7.0 ± 2.9% inhibition at 50 μM 18b

  9.0 ± 1.7% inhibition at 50 μM 18c

 32.8 ± 6.3% inhibition at 50 μM

TABLE 3 In vitro STAT3 dimerization inhibitory activity of library 20.20

IC₅₀ (μM) Compound R Ar unless otherwise specified 20a H

3% inhibition at 50 μM 20b OMe

118.1 ± 8.6   inhibition at 50 μM 20c 3,4-Di—OMe^(a)

13 ± 8% inhibition at 50 μM 20d Cl

48 ± 9.4 inhibition at 50 μM 20e Bn

52 ± 4.3 inhibition at 50 μM 20f Heptyl

12.8 ± 0.5   inhibition at 50 μM 20g Cyclohexyl

15 ± 4.4 inhibition at 50 μM 20h Heptyl

32 ± 4   inhibition at 50 μM 20i Heptyl

33.3 ± 1.6   inhibition at 50 μM 20j Heptyl

22 ± 5% inhibition at 50 μM 20k Heptyl

21 ± 3% inhibition at 50 μM 20l Heptyl

31 ± 6% inhibition at 50 μM ^(a:) indicates 3,4-disubstitution of thephenyl group bearing the R substituent.

The phosphonic acid 17d, and salicylic acids 20f and 20g were docked tothe STAT3 SH2 using GLIDE. The low-energy docking poses are shown inFIGS. 2A-2C position the acidic groups in the pTyr-705 binding site andare broadly similar. The superimposition of all three inhibitors 17d,20f, and 20g is shown in FIG. 2A. The meta-phosphonic acid group of 17doccupies the phenylphosphate binding pocket (FIG. 2B). Indeed, thephosphorus atom is only 0.2 A from the position of the STAT3 pTyr-705residue X-ray coordinates (see FIG. 3). Hydrogen bonds are formedbetween the three phosphate oxygen atoms and with residues Lys-591,Arg-609, Glu-612 and Ser-611 (FIG. 2C). Charged interactions are evidentbetween the phosphonate and the Lys-591 and Arg-609 residues. Thephenoxybenzoyl group is positioned with the terminal phenyl groupoccupying the pY+1 hydrophobic pocket. The p-cyclohexylbenzyl groupplaces the cyclohexyl group deep within the hydrophobic pY-X pocket.(Park, et al., J. Mol. Recognit. 2011; 24:254-265). The salicylic acids20f and 20g dock with their hydroxycarboxylic acid groups deep withinthe p-Tyr binding site. The docking pose of 20g positions itsp-cyclohexylbenzyl group in the pY-X pocket and the phenoxyphenyl groupin a region close to the pY+1 pocket. A similar pose is also obtainedfor salicylic acid 20f (shown in FIG. 2A) with the p-heptylbenzyl groupoccupying the pY-X pocket. The terminal phenyl group of thephenoxybenzoyl group is located in the pY+1 pocket (see FIG. 4A).Overall the docking shows that all three molecules are able to adoptreasonable conformations that results in polar interactions of the acidgroup with the p-Tyr binding pocket and hydrophobic interaction of eachof the sides chains in both the pY-X pocket and the area close to or inpY+1 pocket.

It demonstrated herein that the phosphotyrosine mimicking5-amino-2-hydroxybenzoic acid can be incorporated into analogs of 1 andprovide significantly active STAT3 dimerization inhibitors. A series ofN-benzylbenzamides 20 were prepared by removing the reactivesulfonyloxymethyl moiety of the linking group of 1, as STAT3dimerization inhibitors with improved potency. The equivalent potenciesof 20g and 17d further validates 5-amino-2-hydroxybenzoic acid as aphosphotyrosine mimic. 20g inhibits STAT3 dimerization in vitro and inintact cells and suppresses malignant transformation in human cancercells that depend on STAT3.

It is also demonstrated herein that S3I-1757 (also referred to herein as20g) inhibits STAT3 dimerization in vitro and in whole cells, STAT3tyrosine phosphorylation, nuclear accumulation, transcriptional activityand expression of STAT3-regulated genes as well as anchorage-dependentand -independent growth, migration and invasion. The ability of S3I-1757to displace fluorescein-GpYLPQTV in the FP assay in vitro indicates thatS3I-1757 binds the SH2 domain of STAT3 at the phospho-tyrosine-705binding site. Molecular modeling studies give further support to thismechanism. Molecular modeling indicates that S3I-1757 makes severalcontacts with Arg-609 and Lys-591, 2 critical amino acids in the SH2domain that are known to bind phospho-Tyr-705 of PpYLKTK of STAT3 aswell as phospho-Tyr-904 of GpYLPQTV of the gp-130 subunit of the IL-6receptor. In whole cells, S3I-1757 disrupted the binding of HA-STAT3 toFLAG-STAT3 as demonstrated both by co-immuno-precipitation andco-localization, consistent with the in vitro FP and molecular modelingresults. Taken together, these results indicate that S3I-1757 is aSTAT3-STAT3 dimerization inhibitor. The other analogs of S3I-1757disclosed herein are expected to have similar activities.

Furthermore, STAT3 is also known to associate with the EGF receptor(EGFR) through binding of the STAT3-SH2 domain to phospho-tyrosines 1068and 1086 on EGFR, and S3I-1757 inhibited the binding of STAT3 to EGFR.S3I-1757 also inhibited STAT3 tyrosine phosphorylation. This indicatesthat the ability of S3I-1757 to inhibit nuclear translocation, DNAbinding and transcriptional activation can be due to its ability todirectly disrupt STAT3-STAT3 dimerization as well as inhibition ofSTAT3-EGFR binding and subsequent suppression of STAT3 tyrosinephosphorylation which would also lead to preventing STAT3 dimerization.The fact that STAT3-C, a genetically engineered mutant of STAT3 thatforms a constitutively dimerized STAT3 through disulfide bonds in theabsence of tyrosine phosphorylation, was able to rescue from S3I-1757inhibition of transcriptional activity further solidifies the suggestionthat S3I-1757 is a STAT3 dimerization inhibitor.

S3I-1757 inhibited anchorage-dependent proliferation/survival and colonyformation as well as anchorage-independent soft agar growth, migrationand invasion, consistent with its ability to suppress the expression ofgenes that are known to drive these hallmarks of cancer such as cyclinD1, BclxL, survivin, and MMP9. The fact that S3I-1757 did not inhibitother signal transduction pathways such as those leading tohyper-activated P-Akt and P-Erk suggest that S3I-1757 induces theseeffects through inhibition of STAT3. Further support for this suggestioncomes from the fact that S3I-1757 inhibited anchorage-dependent and-independent tumor cell growth, migration and invasion selectively inhuman cancer cells that dependent on STAT3 over those that do not.S3I-1756, a closely related structural analogue of S3I-1757 that doesnot inhibit STAT3-STAT3 dimerization, STAT3 tyrosine phosphorylation,DNA binding and transcriptional activation, was not able to inhibitanchorage dependent and -independent tumor cell growth, migration andinvasion. The fact that STAT3-C, was able to rescue from S3I-1757induction of apoptosis and inhibition of gene expression, tumor cellgrowth, migration and invasion strongly supports the suggestion thatS3I-1757 mediates its effects through inhibition of STAT3.

Methods of Use

Further provided herein are methods of treating or preventing cancer ina subject, comprising administering to the subject a therapeuticallyeffective amount of a compound or composition as disclosed herein.Additionally, the method can further comprise administering atherapeutically effective amount of ionizing radiation to the subject.The disclosed compounds and compositions are suitable for cancers whereSTAT3 is persistently tyrosine phosphorylated and constitutivelyactivated in the cancer, such as, but not limited to, pancreatic cancer,breast cancer, lung cancer, prostrate cancer, ovarian cancer, coloncancer, gastric cancer, head and neck cancer, melanoma, leukemia,multiple myeloma or lymphoma

Methods of killing a tumor cell are also provided herein. The methodscomprise contacting a tumor cell with an effective amount of a compoundor composition as disclosed herein. The methods can further includeadministering a second compound or composition (e.g., an anticanceragent) or administering an effective amount of ionizing radiation to thesubject.

Also provided herein are methods of radiotherapy of tumors, comprisingcontacting the tumor with an effective amount of a compound orcomposition as disclosed herein and irradiating the tumor with aneffective amount of ionizing radiation. Methods of treating inflammationin a subject are further provided herein, the methods comprisingadministering to the subject an effective amount of a compound orcomposition as described herein. Optionally, the methods can furtherinclude administering a second compound or composition (e.g., ananti-inflammatory agent).

The disclosed subject matter also concerns methods for treating asubject having an oncological disorder or condition. In one embodiment,an effective amount of one or more compounds or compositions disclosedherein is administered to a subject having an oncological disorder andwho is in need of treatment thereof. The disclosed methods canoptionally include identifying a subject who is or can be in need oftreatment of an oncological disorder. The subject can be a human orother mammal, such as a primate (monkey, chimpanzee, ape, etc.), dog,cat, cow, pig, or horse, or other animals having an oncologicaldisorder. Means for administering and formulating compounds foradministration to a subject are known in the art, examples of which aredescribed herein. Oncological disorders include, but are not limited to,cancer and/or tumors of the anus, bile duct, bladder, bone, bone marrow,bowel (including colon and rectum), breast, eye, gall bladder, kidney,mouth, larynx, esophagus, stomach, testis, cervix, head, neck, ovary,lung, mesothelioma, neuroendocrine, penis, skin, spinal cord, thyroid,vagina, vulva, uterus, liver, muscle, pancreas, prostate, blood cells(including lymphocytes and other immune system cells), and brain.Specific cancers contemplated for treatment include carcinomas,Karposi's sarcoma, melanoma, mesothelioma, soft tissue sarcoma,pancreatic cancer, lung cancer, leukemia (acute lymphoblastic, acutemyeloid, chronic lymphocytic, chronic myeloid, and other), and lymphoma(Hodgkin's and non-Hodgkin's), and multiple myeloma.

Other examples of cancers that can be treated according to the methodsdisclosed herein are adrenocortical carcinoma, adrenocortical carcinoma,cerebellar astrocytoma, basal cell carcinoma, bile duct cancer, bladdercancer, bone cancer, brain tumor, breast cancer, Burkitt's lymphoma,carcinoid tumor, central nervous system lymphoma, cervical cancer,chronic myeloproliferative disorders, colon cancer, cutaneous T-celllymphoma, endometrial cancer, ependymoma, esophageal cancer, gallbladdercancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, germcell tumor, glioma, hairy cell leukemia, head and neck cancer,hepatocellular (liver) cancer, hypopharyngeal cancer, hypothalamic andvisual pathway glioma, intraocular melanoma, retinoblastoma, islet cellcarcinoma (endocrine pancreas), laryngeal cancer, lip and oral cavitycancer, liver cancer, medulloblastoma, Merkel cell carcinoma, squamousneck cancer with occult mycosis fungoides, myelodysplastic syndromes,myelogenous leukemia, nasal cavity and paranasal sinus cancer,nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, oralcancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreaticcancer, paranasal sinus and nasal cavity cancer, parathyroid cancer,penile cancer, pheochromocytoma, pineoblastoma and supratentorialprimitive neuroectodermal tumor, pituitary tumor, plasma cellneoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer,rectal cancer, renal cell (kidney) cancer, retinoblastoma,rhabdomyosarcoma, salivary gland cancer, Ewing's sarcoma, soft tissuesarcoma, Sezary syndrome, skin cancer, small cell lung cancer, smallintestine cancer, supratentorial primitive neuroectodermal tumors,testicular cancer, thymic carcinoma, thymoma, thyroid cancer,transitional cell cancer of the renal pelvis and ureter, trophoblastictumor, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer,Waldenström's macroglobulinemia, and Wilms' tumor.

Compositions, Formulations and Methods of Administration

In vivo application of the disclosed compounds, and compositionscontaining them, can be accomplished by any suitable method andtechnique presently or prospectively known to those skilled in the art.For example, the disclosed compounds can be formulated in aphysiologically- or pharmaceutically-acceptable form and administered byany suitable route known in the art including, for example, oral, nasal,rectal, topical, and parenteral routes of administration. As usedherein, the term parenteral includes subcutaneous, intradermal,intravenous, intramuscular, intraperitoneal, and intrasternaladministration, such as by injection. Administration of the disclosedcompounds or compositions can be a single administration, or atcontinuous or distinct intervals as can be readily determined by aperson skilled in the art.

The compounds disclosed herein, and compositions comprising them, canalso be administered utilizing liposome technology, slow releasecapsules, implantable pumps, and biodegradable containers. Thesedelivery methods can, advantageously, provide a uniform dosage over anextended period of time. The compounds can also be administered in theirsalt derivative forms or crystalline forms.

The compounds disclosed herein can be formulated according to knownmethods for preparing pharmaceutically acceptable compositions.Formulations are described in detail in a number of sources which arewell known and readily available to those skilled in the art. Forexample, Remington's Pharmaceutical Science by E. W. Martin (1995)describes formulations that can be used in connection with the disclosedmethods. In general, the compounds disclosed herein can be formulatedsuch that an effective amount of the compound is combined with asuitable carrier in order to facilitate effective administration of thecompound. The compositions used can also be in a variety of forms. Theseinclude, for example, solid, semi-solid, and liquid dosage forms, suchas tablets, pills, powders, liquid solutions or suspension,suppositories, injectable and infusible solutions, and sprays. Thepreferred form depends on the intended mode of administration andtherapeutic application. The compositions also preferably includeconventional pharmaceutically-acceptable carriers and diluents which areknown to those skilled in the art. Examples of carriers or diluents foruse with the compounds include ethanol, dimethyl sulfoxide, glycerol,alumina, starch, saline, and equivalent carriers and diluents. Toprovide for the administration of such dosages for the desiredtherapeutic treatment, compositions disclosed herein can advantageouslycomprise between about 0.1% and 99%, and especially, 1 and 15% by weightof the total of one or more of the subject compounds based on the weightof the total composition including carrier or diluent.

Formulations suitable for administration include, for example, aqueoussterile injection solutions, which can contain antioxidants, buffers,bacteriostats, and solutes that render the formulation isotonic with theblood of the intended recipient; and aqueous and nonaqueous sterilesuspensions, which can include suspending agents and thickening agents.The formulations can be presented in unit-dose or multi-dose containers,for example sealed ampoules and vials, and can be stored in a freezedried (lyophilized) condition requiring only the condition of thesterile liquid carrier, for example, water for injections, prior to use.Extemporaneous injection solutions and suspensions can be prepared fromsterile powder, granules, tablets, etc. It should be understood that inaddition to the ingredients particularly mentioned above, thecompositions disclosed herein can include other agents conventional inthe art having regard to the type of formulation in question.

Compounds disclosed herein, and compositions comprising them, can bedelivered to a cell either through direct contact with the cell or via acarrier means. Carrier means for delivering compounds and compositionsto cells are known in the art and include, for example, encapsulatingthe composition in a liposome moiety. Another means for delivery ofcompounds and compositions disclosed herein to a cell comprisesattaching the compounds to a protein or nucleic acid that is targetedfor delivery to the target cell. U.S. Pat. No. 6,960,648 and U.S.Application Publication Nos. 20030032594 and 20020120100 disclose aminoacid sequences that can be coupled to another composition and thatallows the composition to be translocated across biological membranes.U.S. Application Publication No. 20020035243 also describes compositionsfor transporting biological moieties across cell membranes forintracellular delivery. Compounds can also be incorporated intopolymers, examples of which include poly (D-L lactide-co-glycolide)polymer for intracranial tumors; poly[bis(p-carboxyphenoxy)propane:sebacic acid] in a 20:80 molar ratio (as used in GLIADEL);chondroitin; chitin; and chitosan.

For the treatment of oncological disorders, the compounds disclosedherein can be administered to a patient in need of treatment incombination with other antitumor or anticancer substances and/or withradiation and/or photodynamic therapy and/or with surgical treatment toremove a tumor. These other substances or treatments can be given at thesame as or at different times from the compounds disclosed herein. Forexample, the compounds disclosed herein can be used in combination withmitotic inhibitors such as taxol or vinblastine, alkylating agents suchas cyclophosamide or ifosfamide, antimetabolites such as 5-fluorouracilor hydroxyurea, DNA intercalators such as adriamycin or bleomycin,topoisomerase inhibitors such as etoposide or camptothecin,antiangiogenic agents such as angiostatin, antiestrogens such astamoxifen, and/or other anti-cancer drugs or antibodies, such as, forexample, GLEEVEC (Novartis Pharmaceuticals Corporation) and HERCEPTIN(Genentech, Inc.), respectively, or an immunotherapeutic such asipilimumab and bortezomib.

In certain examples, compounds and compositions disclosed herein can belocally administered at one or more anatomical sites, such as sites ofunwanted cell growth (such as a tumor site or benign skin growth, e.g.,injected or topically applied to the tumor or skin growth), optionallyin combination with a pharmaceutically acceptable carrier such as aninert diluent. Compounds and compositions disclosed herein can besystemically administered, such as intravenously or orally, optionallyin combination with a pharmaceutically acceptable carrier such as aninert diluent, or an assimilable edible carrier for oral delivery. Theycan be enclosed in hard or soft shell gelatin capsules, can becompressed into tablets, or can be incorporated directly with the foodof the patient's diet. For oral therapeutic administration, the activecompound can be combined with one or more excipients and used in theform of ingestible tablets, buccal tablets, troches, capsules, elixirs,suspensions, syrups, wafers, aerosol sprays, and the like.

The tablets, troches, pills, capsules, and the like can also contain thefollowing: binders such as gum tragacanth, acacia, corn starch orgelatin; excipients such as dicalcium phosphate; a disintegrating agentsuch as corn starch, potato starch, alginic acid and the like; alubricant such as magnesium stearate; and a sweetening agent such assucrose, fructose, lactose or aspartame or a flavoring agent such aspeppermint, oil of wintergreen, or cherry flavoring can be added. Whenthe unit dosage form is a capsule, it can contain, in addition tomaterials of the above type, a liquid carrier, such as a vegetable oilor a polyethylene glycol. Various other materials can be present ascoatings or to otherwise modify the physical form of the solid unitdosage form. For instance, tablets, pills, or capsules can be coatedwith gelatin, wax, shellac, or sugar and the like. A syrup or elixir cancontain the active compound, sucrose or fructose as a sweetening agent,methyl and propylparabens as preservatives, a dye and flavoring such ascherry or orange flavor. Of course, any material used in preparing anyunit dosage form should be pharmaceutically acceptable and substantiallynon-toxic in the amounts employed. In addition, the active compound canbe incorporated into sustained-release preparations and devices.

Compounds and compositions disclosed herein, including pharmaceuticallyacceptable salts, or hydrates thereof, can be administeredintravenously, intramuscularly, or intraperitoneally by infusion orinjection. Solutions of the active agent or its salts can be prepared inwater, optionally mixed with a nontoxic surfactant. Dispersions can alsobe prepared in glycerol, liquid polyethylene glycols, triacetin, andmixtures thereof and in oils. Under ordinary conditions of storage anduse, these preparations can contain a preservative to prevent the growthof microorganisms.

The pharmaceutical dosage forms suitable for injection or infusion caninclude sterile aqueous solutions or dispersions or sterile powderscomprising the active ingredient, which are adapted for theextemporaneous preparation of sterile injectable or infusible solutionsor dispersions, optionally encapsulated in liposomes. The ultimatedosage form should be sterile, fluid and stable under the conditions ofmanufacture and storage. the liquid carrier or vehicle can be a solventor liquid dispersion medium comprising, for example, water, ethanol, apolyol (for example, glycerol, propylene glycol, liquid polyethyleneglycols, and the like), vegetable oils, nontoxic glyceryl esters, andsuitable mixtures thereof. The proper fluidity can be maintained, forexample, by the formation of liposomes, by the maintenance of therequired particle size in the case of dispersions or by the use ofsurfactants. Optionally, the prevention of the action of microorganismscan be brought about by various other antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, sorbic acid,thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars, buffers or sodiumchloride. Prolonged absorption of the injectable compositions can bebrought about by the inclusion of agents that delay absorption, forexample, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating a compoundand/or agent disclosed herein in the required amount in the appropriatesolvent with various other ingredients enumerated above, as required,followed by filter sterilization. In the case of sterile powders for thepreparation of sterile injectable solutions, the preferred methods ofpreparation are vacuum drying and the freeze drying techniques, whichyield a powder of the active ingredient plus any additional desiredingredient present in the previously sterile-filtered solutions.

For topical administration, compounds and agents disclosed herein can beapplied in as a liquid or solid. However, it will generally be desirableto administer them topically to the skin as compositions, in combinationwith a dermatologically acceptable carrier, which can be a solid or aliquid. Compounds and agents and compositions disclosed herein can beapplied topically to a subject's skin to reduce the size (and caninclude complete removal) of malignant or benign growths, or to treat aninfection site. Compounds and agents disclosed herein can be applieddirectly to the growth or infection site. Preferably, the compounds andagents are applied to the growth or infection site in a formulation suchas an ointment, cream, lotion, solution, tincture, or the like.

Useful solid carriers include finely divided solids such as talc, clay,microcrystalline cellulose, silica, alumina and the like. Useful liquidcarriers include water, alcohols or glycols or water-alcohol/glycolblends, in which the compounds can be dissolved or dispersed ateffective levels, optionally with the aid of non-toxic surfactants.Adjuvants such as fragrances and additional antimicrobial agents can beadded to optimize the properties for a given use. The resultant liquidcompositions can be applied from absorbent pads, used to impregnatebandages and other dressings, or sprayed onto the affected area usingpump-type or aerosol sprayers, for example.

Thickeners such as synthetic polymers, fatty acids, fatty acid salts andesters, fatty alcohols, modified celluloses or modified mineralmaterials can also be employed with liquid carriers to form spreadablepastes, gels, ointments, soaps, and the like, for application directlyto the skin of the user.

Useful dosages of the compounds and agents and pharmaceuticalcompositions disclosed herein can be determined by comparing their invitro activity, and in vivo activity in animal models. Methods for theextrapolation of effective dosages in mice, and other animals, to humansare known to the art.

Also disclosed are pharmaceutical compositions that comprise a compounddisclosed herein in combination with a pharmaceutically acceptablecarrier. Pharmaceutical compositions adapted for oral, topical orparenteral administration, comprising an amount of a compound constitutea preferred aspect. The dose administered to a patient, particularly ahuman, should be sufficient to achieve a therapeutic response in thepatient over a reasonable time frame, without lethal toxicity, andpreferably causing no more than an acceptable level of side effects ormorbidity. One skilled in the art will recognize that dosage will dependupon a variety of factors including the condition (health) of thesubject, the body weight of the subject, kind of concurrent treatment,if any, frequency of treatment, therapeutic ratio, as well as theseverity and stage of the pathological condition.

Kits

The disclosed subject matter also concerns a packaged dosage formulationcomprising in one or more containers at least one inhibitor compound orcomposition disclosed herein. A packaged dosage formulation canoptionally comprise in one or more containers a pharmaceuticallyacceptable carrier or diluent. A packaged dosage formulation can alsooptionally comprise, in addition to an inhibitor compound or compositiondisclosed herein, other STAT3 inhibitors.

Depending upon the disorder or disease condition to be treated, asuitable dose(s) can be that amount that will reduce proliferation orgrowth of the target cell(s). In the context of cancer, a suitabledose(s) is that which will result in a concentration of the active agentin cancer tissue, such as a malignant tumor, which is known to achievethe desired response. The preferred dosage is the amount which resultsin maximum inhibition of cancer cell growth, without unmanageable sideeffects. Administration of a compound and/or agent can be continuous orat distinct intervals, as can be determined by a person of ordinaryskill in the art.

To provide for the administration of such dosages for the desiredtherapeutic treatment, in some embodiments, pharmaceutical compositionsdisclosed herein can comprise between about 0.1% and 45%, andespecially, 1 and 15%, by weight of the total of one or more of thecompounds based on the weight of the total composition including carrieror diluents. Illustratively, dosage levels of the administered activeingredients can be: intravenous, 0.01 to about 20 mg/kg;intraperitoneal, 0.01 to about 100 mg/kg; subcutaneous, 0.01 to about100 mg/kg; intramuscular, 0.01 to about 100 mg/kg; orally 0.01 to about200 mg/kg, and preferably about 1 to 100 mg/kg; intranasal instillation,0.01 to about 20 mg/kg; and aerosol, 0.01 to about 20 mg/kg of animal(body) weight.

Also disclosed are kits that comprise a composition comprising acompound disclosed herein in one or more containers. The disclosed kitscan optionally include pharmaceutically acceptable carriers and/ordiluents. In one embodiment, a kit includes one or more othercomponents, adjuncts, or adjuvants as described herein. In anotherembodiment, a kit includes one or more anti-cancer agents, such as thoseagents described herein. In one embodiment, a kit includes instructionsor packaging materials that describe how to administer a compound orcomposition of the kit. Containers of the kit can be of any suitablematerial, e.g., glass, plastic, metal, etc., and of any suitable size,shape, or configuration. In one embodiment, a compound and/or agentdisclosed herein is provided in the kit as a solid, such as a tablet,pill, or powder form. In another embodiment, a compound and/or agentdisclosed herein is provided in the kit as a liquid or solution. In oneembodiment, the kit comprises an ampoule or syringe containing acompound and/or agent disclosed herein in liquid or solution form.

EXAMPLES

The following examples are set forth below to illustrate the methods,compositions, and results according to the disclosed subject matter.These examples are not intended to be inclusive of all aspects of thesubject matter disclosed herein, but rather to illustrate representativemethods, compositions, and results. These examples are not intended toexclude equivalents and variations of the present invention, which areapparent to one skilled in the art.

Efforts have been made to ensure accuracy with respect to numbers (e.g.,amounts, temperature, etc.) but some errors and deviations should beaccounted for. Unless indicated otherwise, parts are parts by weight,temperature is in ° C. or is at ambient temperature, and pressure is ator near atmospheric. There are numerous variations and combinations ofreaction conditions, e.g., component concentrations, temperatures,pressures, and other reaction ranges and conditions that can be used tooptimize the product purity and yield obtained from the describedprocess. Only reasonable and routine experimentation will be required tooptimize such process conditions.

All reagents were purchased from commercial suppliers and used withoutfurther purification. Melting points were determined using a Barnsteadinternational melting point apparatus and remain uncorrected. Proton NMRspectra were recorded on an Agilent-Varian Mercury 400 MHz spectrometerwith CDCl₃ or DMSO-d₆ as the solvent. Carbon (¹³C) NMR spectra arerecorded at 100 MHz. The ¹³C spectrum of 1 was recorded at 150 MHz,using an Agilent VNMRS 600 spectrometer with cold probe (University ofSouth Florida Center for Drug Discovery and Innovation). All couplingconstants are measured in Hertz (Hz) and the chemical shifts (δ_(H) andδ_(C)) are quoted in parts per million (ppm) relative to TMS (δ0), whichwas used as the internal standard. High resolution mass spectroscopy wascarried out on an Agilent 6210 LC/MS (ESI-TOF). Low resolution massspectroscopy (LRMS) was performed on an Agilent single quad G1956A(Chemistry Department, University of South Florida). Microwave reactionswere performed in CEM 908005 model and Biotage initiator 8 machines. Allfinal compounds were purified to >95% purity as determined HPLC analysisusing a JASCO HPLC system equipped with a PU-2089 Plus quaternarygradient pump and a UV-2075 Plus UV-VIS detector, using an AlltechKromasil C-18 column (150×4.6 mm, 5 m) and Agilent Eclipse XDB-C18(150×4.6 mm, 5 μm). Melting points were recorded on an Optimeltautomated melting point system (Stanford Research Systems). Thin layerchromatography was performed using silica gel 60 F254 plates (Fisher),with observation under UV when necessary. Anhydrous solvents(acetonitrile, dimethylformamide, ethanol, isopropanol, methanol andtetrahydrofuran) were used as purchased from Aldrich. Burdick andJackson HPLC grade solvents (methanol, acetonitrile and water) werepurchased from VWR for HPLC and high resolution mass analysis. HPLCgrade TFA was purchased from Fisher.

Human breast cancer (MDA-MB-468, MDA-MB-231, MDA-MB-453), lung cancer(A549, H358, H460) cells, human non-tumorigenic epithelial cells(MCF10A) and human embryonic kidney cells (HEK293) were obtained fromATCC (the American Type Culture Collection, Manassas, Va., USA). HEK 293cell lines with stable transfection of HA-STAT3 and FLAG-STAT3 weregenerated as described below. Cells were grown in Dulbecco's modifiedEagle's medium (DMEM), RPMI 1640, and DMEM/F-12 containing 10%heat-inactivated fetal bovine serum. MCF10A was cultured in DMEM/F12,supplemented with 5% horse serum (Invitrogen, CA, USA), hydrocortisone(0.5 μg/ml), mouse epidermal growth factor (EGF; 20 ng/ml), insulin (10μg/ml), cholera toxin (100 ng/ml, Sigma, MO, USA). Primary antibodiesagainst pY705STAT3, pAKT, AKT, pErk1/2, Erk, MMP9, and Cyclin D1 werepurchased from Cell Signaling Technology (Danvers, Mass.). Primaryantibodies against STAT3, Bcl-xL, Survivin, HA (anti-mouse), and HA(anti-rabbit) were purchased from Santa Cruz Biotech (Santa Cruz,Calif.). Primary antibody against FLAG was purchased from Sigma (St.Louis, Mo., USA).

Synthesis of Benzylaminosalicylates 6

Methyl 5-(benzylamino)-2-hydroxybenzoate (6a)

To a stirred solution of methyl 5-aminosalicylate (4) (0.200 g, 1.196mmol) in MeOH (10 ml) over 4 Å molecular sieves was added benzaldehyde(0.121 mL, 1.196 mmol) followed by AcOH (0.106 mL). The solution washeated at 40° C. and then allowed to stir at room temperature for 1 h.The solution was cooled to 5-10° C. and NaCNBH₃ (0.097 g, 1.554 mmol)was slowly added in portions. The resulted mixture was stirred for 2 hat room temperature before being quenched by the addition of water. Thesolvents were evaporated and the crude mixture was taken up in CH₂Cl₂,washed with water, brine, dried (Na₂SO₄) and evaporated. Chromatographygave the ester 6a (0.268 g, 1.042 mmol, 87%). ¹H NMR (400 MHz, CDCl₃) δ10.18 (s, 1H), 7.38-7.26 (m, 5H), 7.08 (t, J=1.7 Hz, 1H), 6.84 (d, J=1.7Hz, 2H), 4.27 (s, 2H), 3.91 (s, 3H). HRMS (ESI−ve) Calcd for C₁₅H₁₆NO₃258.1124 [M+H]⁺, found 258.1127.

Methyl 5-(4-cyclohexylbenzylamino)-2-hydroxybenzoate (6b)

This was obtained as a yellow oil (0.246 g, 0.78 mmol, 35%) from methyl5-aminosalicylate (4) (0.411 g, 2.465 mmol) and 4-cyclohexylbenzaldehyde(0.464 g, 2.465 mmol) in the same manner as described for 6a. ¹H NMR(400 MHz, CDCl₃) δ 10.19 (s, 1H), 7.29 (d, J=8.2 Hz, 2H), 7.19 (d, J=8.0Hz, 2H), 7.10 (t, J=1.7 Hz, 1H), 6.85 (d, J=1.7 Hz, 2H), 4.23 (s, 2H),2.52-2.45 (m, J 1H), 1.9-1.68 (m, 5H), 1.50-1.14 (m, 5H). HRMS (ESI−ve)Calcd for C₂₁H₂₆N₂O₃ 340.1907 [M+H]⁺, found 340.1911.

Methyl 2-hydroxy-5-(4-methoxybenzylamino)benzoate (6c)

This was obtained as a solid from methyl 5-aminosalicylate (4) (1.00 g,5.98 mmol) and 4-methoxybenzaldehyde (0.726 mL, 5.98 mmol) in the samemanner as described for 6a. ¹H NMR (400 MHz, CDCl₃) δ 10.99 (s, 1H),7.59 (d, J=9.3 Hz, 1H), 7.25 (d, J=8.8 Hz, 2H), 6.88 (d, J=8.7 Hz, 2H),6.15-6.08 (m, 2H), 4.43 (t, J=4.5 Hz, 1H), 4.28 (d, J=5.3 Hz, 2H), 3.87(s, 3H), 3.81 (s, 3H). HRMS (ESI−ve) Calcd for C₁₆H₁₇NNaO₄ 310.1049[M+Na]⁺, found 310.1048.

Methyl 5-(4-chlorobenzylamino)-2-hydroxybenzoate (6d)

This was obtained as a solid from methyl 5-aminosalicylate (4) (1.00 g,5.98 mmol) and 4-chlorobenzaldehyde (0.840 g, 5.98 mmol) in the samemanner as described for 6a. ¹H NMR (400 MHz, CDCl₃) δ 10.98 (s, 2H),7.60 (d, J=8.7 Hz, 1H), 7.31 (d, J=8.4 Hz, 2H), 7.26 (d, J=8.8 Hz, 2H),6.11 (dd, J=8.7, 2.3 Hz, 1H), 6.07 (d, J=2.3 Hz, 1H), 4.53 (s, 1H), 4.34(d, J=5.0 Hz, 2H), 3.87 (s, 3H). HRMS (ESI−ve) Calcd for C₁₅H51NClO₃292.0735 [M+H]+, found 292.0727.

Methyl 2-hydroxy-5-(4-morpholinobenzylamino)benzoate (6e)

This was obtained as a solid (0.960 g, 80%) from methyl5-aminosalicylate (4) and 4-morpholinobenzaldehyde in the same manner asdescribed for 6a. ¹H NMR (400 MHz, CDCl₃) δ 10.19 (s, 1H), 7.27 (d,J=8.7 Hz, 2H), 7.08 (t, J=1.6 Hz, 1H), 6.89 (d, J=8.7 Hz, 1H), 6.84 (d,J=1.6 Hz, 2H), 4.18 (s, 2H), 3.92 (s, 3H), 3.88-3.84 (m, 4H), 3.19-3.09(m, 4H). HRMS (ESI−ve) Calcd for C₁₉H₂₂N₂NaO₄ 365.1471 [M+Na]⁺, found365.1471.

Methyl 2-hydroxy-5-(3-(pyridin-4-yl)benzylamino)benzoate (6f)

This was obtained as a solid from methyl 5-aminosalicylate (4) (0.500 g,2.99 mmol) and 3-(pyridin-4-yl)benzaldehyde (0.547 g, 2.99 mmol) in thesame manner as described for 6a. ¹H NMR (400 MHz, CDCl₃) δ 10.19 (s,1H), 8.65 (d, J=6.1 Hz, 1H), 7.65 (s, 1H), 7.56 (dt, J=7.0, 1.9 Hz, 1H),7.50 (d, J=6.2 Hz, 1H), 7.47-7.43 (m, 2H), 7.12-7.09 (m, 1H), 6.88-6.83(m, 2H), 4.37 (s, 2H), 3.91 (s, 3H). HRMS (ESI−ve) Calcd for C₂₀H₁₉N₂O₃335.1390 [M+H]+, found 335.1397.

Methyl 2-hydroxy-5-(4-isobutylbenzylamino)benzoate (6g)

This was obtained as an oil (40-45%) from methyl 5-aminosalicylate (4)(0.903 g, 5.41 mmol) and 4-isobutylbenzaldehyde (0.877 g, 5.41 mmol) inthe same manner as described for 6a. ¹H NMR (400 MHz, CDCl₃) δ 10.20 (s,1H), 7.28 (d, J=8.0 Hz, 2H), 7.13 (d, J=8.0 Hz, 2H), 7.10 (t, J=1.7 Hz,1H), 6.85 (d, J=1.6 Hz, 2H), 4.24 (s, 2H), 3.92 (s, 4H), 2.48 (d, J=7.2Hz, 2H), 1.92-1.83 (m, 1H), 0.91 (d, J=6.6 Hz, 6H).

Methyl 2-hydroxy-5-(4-(piperidin-1-yl)benzylamino)benzoate (6h)

This was obtained as a solid (0.800 g, 80%) from methyl5-aminosalicylate (4) (0.500 g, 2.99 mmol) and4-(piperidin-1-yl)benzaldehyde (0.566 g, 2.99 mmol) in the same manneras described for 6a. ¹H NMR (400 MHz, CDCl₃) δ 10.19 (s, 1H), 7.23 (d,J=8.7 Hz, 2H), 7.08 (t, J=1.7 Hz, 1H), 6.91 (d, J=8.7 Hz, 2H), 6.84 (d,J=1.7 Hz, 2H), 4.16 (s, 2H), 3.92 (s, 3H), 3.28-2.96 (m, 4H), 1.75-1.44(m, 6H). HRMS (ESI−ve) Calcd for C₂₀H₂₅N₂O₃ 341.1859 [M+H]⁺, found341.1865.

Methyl 5-(4-heptylbenzylamino)-2-hydroxybenzoate (6i)

This was obtained as an oil (1.04 g, 96%) from methyl 5-aminosalicylate(4) (0.500 g, 2.99 mmol) and 4-heptylbenzaldehyde (0.611 g, 2.99 mmol)in the same manner as described for 6a and was used withoutpurification. ¹H NMR (400 MHz, CDCl₃) δ 10.19 (s, 1H), 7.28-7.26 (m,3H), 7.15 (d, J=7.9 Hz, 1H), 7.10-7.09 (m, 1H), 6.85-6.84 (m, 2H), 4.23(s, 2H), 3.92 (s, 3H), 2.72-2.49 (m, 3H), 1.61-1.60 (m, 3H), 1.42-1.25(m, 10H), 0.88 (t, J=6.5 Hz, 3H).

Methyl 5-(4-bromobenzylamino)-2-hydroxybenzoate (6j)

This was obtained as a yellow solid (1.9 g, 60%) from methyl5-aminosalicylate (4)(0.903 g, 5.41 mmol) and 4-cyclohexylbenzaldehyde(1.9 g, 5.41 mmol) in the same manner as described for 6a. ¹H NMR (400MHz, CDCl₃) δ 10.20 (s, 1H), 7.46 (d, J=8.3 Hz, 2H), 7.24 (d, J=8.2 Hz,2H), 7.05 (d, J=2.3 Hz, 1H), 6.86-6.82 (m, 2H), 4.24 (s, 2H), 3.91 (s,3H).

Methyl 5-(3,4-dimethoxybenzylamino)-2-hydroxybenzoate (6k)

A solution of 3,4-dimethoxybenzaldehyde (0.546 g, 3.28 mmol), methyl4-aminosalicylic acid (4)(0.551 g, 3.29 mmol) and Et₃N (0.5 ml) inanhydrous methanol (12 mL), was heated under reflux overnight. Thesolvent was then removed under reduced pressure. The obtained solid wasthen suspended in methanol (12 mL) and NaBH₄ (0.239 g, 6.26 mmol) wasadded portion-wise. The reaction mixture was then stirred at roomtemperature overnight. The solvent was removed under reduced pressure,water (10 mL) was added and the mixture extracted with EtOAc (2×10 mL).The organic extracts were combined, dried (Na₂SO₄), filtered and thesolvent removed under reduced pressure to provide a brown solid. Theobtained crude material was slurried with Et₂O (10 mL), filtered anddried under vacuum to yield compound 6k as an orange solid (0.483 g,1.52 mmol, 46%). ¹H NMR (400 MHz, CDCl₃) δ 10.18 (s, 1H), 7.24 (d, J=3.0Hz, 1H), 7.08 (s, 1H), 6.89-6.81 (m, 6H), 4.19 (s, 2H), 3.91 (s, 3H),3.86 (s, 6H). LCMS (ESI+ve) m/z [M+Na]⁺ found 340.1.

Synthesis of Acids 7

Methyl 2-(N,4-dimethylphenylsulfonamido)acetate (12a)

To a stirred solution of N-methylglycine methyl ester (11) (0.500 g,3.58 mmol) in acetonitrile (15 mL) was added DIPEA (1.87 mL, 10.75 mmol)and TsCl (0.819 g, 4.3 mmol) was added in portions at 0° C. After theaddition was complete, the ice bath was removed and the reaction wasstirred at room temperature overnight. The solvents were evaporated andthe crude mixture was taken up in CH₂Cl₂ and washed with 0.1 N HCl, Sat.NaHCO₃ and brine. The organic layer was dried over Na₂SO₄ and evaporatedin vacuo. The product 12a (0.791 g, 86%) was directly carried to thenext step without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.69(d, J=8.3 Hz, 2H), 7.31 (d, J=8.5 Hz, 2H), 3.96 (s, 2H), 3.66 (s, 3H),2.87 (s, 3H), 2.42 (s, 3H).

Methyl 2-(N,4-dimethylphenylsulfonamido)acetate (12b)

This was obtained as an oil from N-methylglycine methyl ester (11) (1.5g, 10.75 mmol) and biphenylsulfonyl chloride (3.269 g, 12.9 mmol) in thesame manner as described for 12a. ¹H NMR (400 MHz, CD₃OD) δ 7.87 (d,J=8.6 Hz, 2H), 7.83 (d, J=8.6 Hz, 2H), 7.69 (d, J=8.5 Hz, 2H), 7.49 (d,J=8. Hz, 2H), 4.04 (s, 2H), 3.64 (s, 3H), 2.90 (s, 3H).

Methyl 2-(N-methylbiphenyl-4-ylsulfonamido)acetate (12c)

This was obtained as an oil from N-methylglycine methyl ester (11) (1.5g, 10.75 mmol) and 4-phenyl-benzenesulfonyl chloride (3.705 g, 12.9mmol) in the same manner as described for 12a. ¹H NMR (400 MHz, CDCl₃) δ7.87 (d, J=8.5 Hz, 2H), 7.72 (d, J=8.5 Hz, 2H), 7.61 (d, J=1.5 Hz, 2H),7.50-7.45 (m, 2H), 7.43-7.38 (m, 1H), 4.02 (s, 2H), 3.66 (s, 3H), 2.93(s, 3H).

Methyl 2-(4′-fluoro-N-methylbiphenyl-4-ylsulfonamido)acetate (12d)

This was obtained as a viscous oil (2.2 g) from N-methylglycine methylester (11) (1.9 g, 7.16 mmol) and 4-phenyl-benzenesulfonyl chloride(2.33 g, 8.6 mmol) in the same manner as described for 12a.

Methyl 2-(N-benzyl-4-methylphenylsulfonamido)acetate (12e)

This was obtained as a viscous oil from N-benzylglycine methyl ester(10) (1.0 g, 5.58 mmol) and tosyl chloride (1.27 g, 6.70 mmol) in thesame manner as described for 12a.

Methyl 2-(N-benzylbiphenyl-4-ylsulfonamido)acetate (12f)

This was obtained as a viscous oil from N-benzylglycine methyl ester(10) (1.59 g, 8.37 mmol) and 4-phenyl-benzenesulfonyl chloride (2.53 g,10.05 mmol) in the same manner as described for 12a.

2-(N,4-Dimethylphenylsulfonamido)acetic acid (7a)

Lithium hydroxide (0.146 g, 6.10 mmol) was added to a solution of 12a(0.705 g, 3.05 mmol) in MeOH-THF-H₂O (10 mL, 3:1:1) and was stirredovernight at room temperature. The organic solvent was then removedunder reduced pressure. The resulting solution was acidified with HCl(aq. 1 M) and extracted with AcOEt. The organic extracts were combined,dried (Na₂SO₄), filtered, and the solvent removed under reduced pressureto afford 7a (97%). ¹H NMR (400 MHz, CDCl₃) δ 8.79 (s, 1H), 7.69 (d,J=8.3 Hz, 2H), 7.32 (d, J=8.1 Hz, 2H), 3.98 (s, 2H), 2.87 (s, 3H), 2.43(s, 3H).

2-(4′-Chloro-N-methylbiphenyl-4-ylsulfonamido)acetic acid (7b)

This was obtained as a solid from 12b (2.4 g, 7.16 mmol) in the samemanner as described for 7a. ¹H NMR (400 MHz, CDCl₃) δ 7.88 (d, J=8.5 Hz,2H), 7.69 (d, J=8.6 Hz, 2H), 7.54 (d, J=8.6 Hz, 2H), 7.46 (d, J=8.6 Hz,2H), 4.04 (s, 2H), 2.93 (s, 3H). HRMS (ESI−ve) Calcd for C₁₅H₁₆ClNO₄S340.0404 [M+H]⁺, found 340.0408.

2-(N-Methylbiphenyl-4-ylsulfonamido)acetic acid (7c)

This was obtained as a solid (70%) 12c (0.551 g, 1.72 mmol) in the samemanner as described for 7a. ¹H NMR (400 MHz, CD₃OD) δ 7.76 (d, J=8.3 Hz,2H), 7.38 (d, J=8.2 Hz, 2H), 7.33-7.25 (m, 3H), 7.23-7.18 (m, 2H), 4.47(s, 3H), 2.44 (s, 3H). HRMS (ESI−ve) Calcd for C₁₅H₁₆NO₄S 306.0794[M+H]⁺, found 306.0808.

2-(4′-Fluoro-N-methylbiphenyl-4-ylsulfonamido)acetic acid (7d)

This was obtained as a solid (0.500 g, 85%) from 12d (0.500 g, 1.41mmol) in the same manner as described for 7a. ¹H NMR (400 MHz, CD₃OD) δ7.89 (d, J=8.7 Hz, 2H), 7.81 (d, J=8.6 Hz, 2H), 7.71 (dd, J=8.9, 5.2 Hz,2H), 7.22 (t, J=8.8 Hz, 2H), 3.97 (s, 2H), 2.89 (s, 3H). HRMS (ESI−ve)Calcd for C₁₅H₁₅NFO₄S 324.0700 [M+H]⁺, found 324.0708.

2-(N-Benzyl-4-methylphenylsulfonamido)acetic acid (7e)

This was obtained (1.119 g, 62%) from 12e (1.896 g, 5.58 mmol) in thesame manner as described for 7a. ¹H NMR (400 MHz, CD₃OD) δ 7.76 (d,J=8.3 Hz, 2H), 7.38 (d, J=8.2 Hz, 2H), 7.31-7.25 (m, 3H), 7.23-7.19 (m,2H), 4.47 (s, 2H), 3.85 (s, 2H), 2.44 (s, 3H).

2-(N-Benzylbiphenyl-4-ylsulfonamido)acetic acid (7f)

This was obtained as solid (0.500 g, 85%) from 12f (0.500 g, 1.41 mmol)in the same manner as described for 7a. ¹H NMR (400 MHz, CD₃OD) δ 7.94(d, J=8.5 Hz, 2H), 7.81 (d, J=8.6 Hz, 2H), 7.71-7.66 (m, 2H), 7.48 (t,J=7.4 Hz, 2H), 7.41 (t, J=7.4 Hz, 1H), 7.33-7.20 (m, 6H), 4.53 (s, 3H),3.90 (s, 2H).

Synthesis of Methyl Esters 8

Methyl 5-(N-benzyl-2-(N-benzyl-4-methylphenylsulfonamido)acetamido)-2hydroxybenzoate (8a)

To a solution of an amine 6a (0.100 g, 0.388 mmol) in CH₂Cl₂ (2 ml) wasadded the acid 7e (0.130 g, 0.408 mmol) and coupling reagent Ph₃PCl₂(0.010 g, 0.932 mmol) under argon atmosphere. The resultant mixture washeated at 80° C. in a microwave reactor (Biotage) for 1 h. The reactionwas cooled to room temperature, diluted with CH₂Cl₂ and washed with sat.NaHCO₃. The organic fractions are dried (Na₂SO₄) and evaporated invacuo. The crude mixture was purified by column chromatography to affordthe ester 8a (0.100 g, 0.179 mmol, 50%). ¹H NMR (400 MHz, CDCl₃) δ 10.76(s, 1H), 7.82 (d, J=8.3 Hz, 2H), 7.32 (d, J=8.0 Hz, 2H), 7.29-7.21 (m,7H), 7.21-7.15 (m, 2H), 7.08-7.00 (m, 2H), 6.73 (d, J=8.8 Hz, 1H), 6.53(dd, J=8.8, 2.7 Hz, 1H), 4.68 (s, 2H), 4.53 (s, 2H), 3.90 (s, 3H), 3.63(s, 2H), 2.45 (s, 3H). HRMS (ESI−ve) Calcd for C₃₁H₃₁N₂O₆S 559.1897[M+H]⁺, found 559.1871

Methyl 5-(N-benzyl-2-(N-benzylbiphenyl-4-ylsulfonamido)acetamido)-2hydroxybenzoate (8b)

This was obtained as a solid (0.108 g, 75%) from acid 7f (0.093 g, 0.244mmol) and amine 6a (0.060 g, 0.233 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.77 (s, 1H), 8.00 (d, J=10.4 Hz,1H), 7.73 (d, J=10.3 Hz, 1H), 7.65-7.62 (m, 1H), 7.49 (t, J=7.4 Hz, 2H),7.44-7.39 (m, 1H), 7.30-7.16 (m, 9H), 7.07-7.04 (m, 2H), 6.74 (d, J=8.8Hz, 1H), 6.55 (dd, J=8.8, 2.7 Hz, 1H), 4.69 (s, 2H), 4.58 (s, 2H), 3.91(s, 3H), 3.68 (s, 2H). HRMS (ESI−ve) Calcd for C₃₆H₃₃N₂O₆S 621.2053[M+H]⁺, found 621.2022.

Methyl5-(2-(N-benzyl-4-methylphenylsulfonamido)-N-(4-chlorobenzyl)acetamido)-2-hydroxybenzoate(8c)

This was obtained as a solid (0.170 g, 70%) from acid 7c (0.153 g, 0.482mmol) and amine 6d (0.120 g, 0.411 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.78 (s, 1H), 7.80 (d, J=8.3 Hz, 2H),7.31 (d, J=7.9 Hz, 2H), 7.26-7.22 (m, 6H), 7.18-7.13 (m, 2H), 6.99 (d,J=8.4 Hz, 2H), 6.76 (d, J=8.9 Hz, 1H), 6.56 (dd, J=8.7, 2.7 Hz, 1H),4.64 (s, 2H), 3.92 (s, 2H), 3.63 (s, 3H), 2.45 (s, 3H). HRMS (ESI−ve)Calcd for C₃₁H₂₉ClN₂O₆S 593.1507 [M−H]⁻, found 593.1482.

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(4-chlorobenzyl)acetamido)-2-hydroxybenzoate(8d)

This was obtained as a solid (0.114 g, 75%) from acid 7f (0.093 g, 0.244mmol) and amine 6d (0.068 g, 0.233 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.79 (s, 1H), 7.99 (d, J=8.5 Hz, 2H),7.73 (d, J=8.5 Hz, 2H), 7.64 (d, J=7.2 Hz, 2H), 7.54-7.47 (m, 1H),7.44-7.38 (m, 1H), 7.25-7.20 (m, 4H), 7.02-7.16 (m, 4H), 7.00 (d, J=8.4Hz, 1H). 6.78 (d, J=8.8 Hz, 1H), 6.58 (dd, J=8.8, 2.7 Hz, 1H), 4.65 (s,2H), 4.57 (s, 2H), 3.92 (s, 3H), 3.67 (s, 2H). HRMS (ESI−ve) Calcd forC₃₆H₃₂ClN₂O₆S 655.1664 [M+H]⁺, found 655.1634.

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(4-methoxybenzyl)acetamido)-2-hydroxybenzoate(8f)

This was obtained as a solid (0.111 g, 89%) from acid 7f (0.084 g, 0.219mmol) and amine 6c (0.060 g, 0.209 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.77 (s, 1H), 8.00 (d, J=8.4 Hz, 2H),7.74 (d, J=8.5 Hz, 2H), 7.65 (d, J=7.2 Hz, 2H), 7.51-7.45 (m, 1H),7.44-7.37 (m, 1H), 7.29-7.14 (m, 7H), 6.96 (d, J=8.6 Hz, 1H), 6.77-6.70(m, 3H), 6.53 (dd, J=8.8, 2.7 Hz, 1H), 4.63 (s, 2H), 4.59 (s, 2H), 3.74(s, 3H), 3.66 (s, 2H). HRMS (ESI−ve) Calcd for C₃₇H₂₅N₂O₇S 651.2159[M+H]⁺, found 651.2126.

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(4-cyclohexylbenzyl)acetamido)-2-hydroxybenzoate(8g)

This was obtained as a solid (0.146 g, 71%) from acid 7f (0.118 g, 0.309mmol) and amine 6b (0.100 g, 0.294 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.78 (s, 1H), 8.01 (d, J=10.3 Hz,1H), 7.75 (d, J=8.5 Hz, 2H), 7.66 (d, J=7.0 Hz, 2H), 7.53-7.46 (m, 2H),7.45-7.38 (m, 1H), 7.24-7.20 (m, 7H), 7.05 (d, J=8.0 Hz, 2H), 6.96 (d,J=8.1 Hz, 2H), 6.76 (d, J=8.8 Hz, 1H), 6.58 (dd, J=8.8, 2.7 Hz, 1H),4.65 (s, 2H), 4.61 (s, 2H), 3.91 (s, 3H), 3.67 (s, 2H), 2.49-2.35 (m,1H), 1.78 (m, 6H), 1.44-1.14 (m, 4H).

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(4-heptylbenzyl)acetamido)-2-hydroxybenzoate(8h)

This was obtained as a solid (0.160 g, 79%) from acid 7f (0.112 g, 0.295mmol) and amine 6i (0.100 g, 0.282 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.78 (s, 1H), 8.01 (d, J=8.4 Hz, 2H),7.75 (d, J=8.5 Hz, 2H), 7.65 (d, J=7.8 Hz, 1H), 7.50 (t, J=7.5 Hz, 2H),7.43 (t, J=7.3 Hz, 1H), 7.29-7.13 (m, 6H), 7.03 (d, J=7.9 Hz, 2H), 6.96(d, J=8.0 Hz, 2H), 6.75 (d, J=8.8 Hz, 1H), 6.55 (dd, J=8.8, 2.6 Hz, 1H),4.66 (s, 2H), 3.92 (s, 2H), 3.68 (s, 3H), 2.66-2.35 (m, 2H), 1.66-1.46(m, 1H), 1.35-1.17 (m, 9H), 0.88 (t, J=6.9 Hz, 3H). HRMS (ESI−ve) Calcdfor C₄₃H₄₇N₂O₆S 719.3149 [M+H]⁺, found 719.3146.

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(4-isobutylbenzyl)acetamido)-2-hydroxybenzoate(8i)

This was obtained as a solid (0.120 g, 70%) from acid 7f (0.102 g, 0.344mmol) and amine 6g (0.100 g, 0.319 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.78 (s, 1H), 8.02 (d, J=8.5 Hz, 2H),7.75 (d, J=8.5 Hz, 2H), 7.65 (d, J=8.0 Hz, 2H), 7.49 (t, J=7.5 Hz, 2H),7.42 (t, J=7.3 Hz, 1H), 7.27-7.17 (m, 7H), 6.99 (d, J=8.0 Hz, 2H), 6.94(d, J=8.1 Hz, 2H), 6.75 (d, J=8.8 Hz, 1H), 6.57 (dd, J=8.8, 2.6 Hz, 1H),4.66 (s, 2H), 4.60 (s, 2H), 3.89 (s, 3H), 3.67 (s, 2H), 2.41 (d, J=7.2Hz, 2H), 1.89-1.68 (m, 1H), 0.87 (d, J=6.6 Hz, 5H). HRMS (ESI−ve) Calcdfor C₄₀H₄₁N₂O₆S 677.2679 [M+H]⁺, found 677.2686.

Methyl5-(N-benzyl-2-(N,4-dimethylphenylsulfonamido)acetamido)-2-hydroxybenzoate(8j)

This was obtained as a solid from acid 7f (0.083 g, 0.342 mmol) andamine 6a (0.084 g, 0.326 mmol) in the same manner as described for 8aand used immediately in the next step.

Methyl5-(N-benzyl-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoate(8k)

This was obtained as a solid (50-55%) from acid 7c (0.250 g, 0.818 mmol)and amine 6a (0.200 g, 0.778 mmol) in the same manner as described for8a. ¹H NMR (400 MHz, CDCl₃) δ 10.86 (s, 1H), 7.84 (d, J=8.5 Hz, 2H),7.69 (d, J=8.5 Hz, 2H), 7.60 (dd, J=8.3, 1.2 Hz, 3H), 7.51 (d, J=2.6 Hz,1H), 7.48 (t, J=7.3 Hz, 2H), 7.41 (d, J=2.3 Hz, 0H), 7.28-7.23 (m, 4H),7.12 (d, J=2.6 Hz, 1H), 7.00 (dd, J=8.8, 2.6 Hz, 1H), 6.94 (d, J=8.8 Hz,1H), 4.79 (s, 2H), 3.94 (s, 3H), 3.78 (s, 2H), 2.93 (s, 3H).

Methyl5-(N-(4-chlorobenzyl)-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoate(81)

This was obtained as a solid from acid 7c and amine 6d in the samemanner as described for 8a and used immediately in the next step.

Methyl5-(N-(4-cyclohexylbenzyl)-2-(N,4-dimethylphenylsulfonamido)acetamido)-2-hydroxybenzoate(8m)

This was obtained as a solid (40-45%) from acid 7a (0.075 g, 0.309 mmol)and amine 6b (0.100 g, 0.294 mmol) in the same manner as described for8a. ¹H NMR (400 MHz, CDCl₃) δ 10.85 (s, 1H), 7.64 (d, J=8.3 Hz, 2H),7.45 (d, J=2.6 Hz, 1H), 7.27 (d, J=7.9 Hz, 2H), 7.10 (d, J=8.1 Hz, 2H),7.05-6.97 (m, 3H), 6.93 (d, J=8.8 Hz, 1H), 4.73 (s, 2H), 3.93 (s, 3H),3.70 (s, 2H), 2.86 (s, 3H), 2.47 (s, 3H), 2.48-2.41 (m, 1H), 1.79 (m,6H), 1.46-1.15 (m, 4H).

Methyl5-(N-(4-cyclohexylbenzyl)-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxy-benzoate(8n)

This was obtained as a solid (0.060 g, 0.096 mmol, 45%) from acid 7c(0.076 g, 0.248 mmol) and 6b (0.080 g, 0.236 mmol) in the same manner asdescribed for 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.86 (s, 1H), 7.84 (d,J=8.4 Hz, 2H), 7.69 (d, J=8.5 Hz, 2H), 7.63-7.59 (m, 3H), 7.50-7.45 (m,2H), 7.44-7.40 (m, 1H), 7.07 (m, J=8.1 Hz, 2H), 7.03-6.98 (m, 3H), 6.94(d, J=8.8 Hz, 1H), 4.73 (s, 2H), 3.93 (s, 3H), 2.93 (s, 3H), 2.44-2.42(m, 1H), 1.82-1.73 (m, 6H), 1.42-1.14 (m, 2H). HRMS (ESI−ve) Calcd forC₃₆H₃₉N₂O₆S 627.2523 [M+H]⁺, found 637.2529.

5-(N-(4-Heptylbenzyl)-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoicacid (8o)

This was obtained as a solid (0.088 g, 50%) from acid 7c (0.090 g, 0.294mmol) and amine 6i (0.100 g, 0.282 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.86 (s, 1H), 7.84 (d, J=8.5 Hz, 2H),7.69 (d, J=6.7 Hz, 1H), 7.63-7.59 (m, 2H), 7.52-7.45 (m, 2H), 7.44-7.39(m, 1H), 7.10-6.97 (m, 5H), 6.93 (d, J=8.8 Hz, 1H), 4.75 (s, 2H), 3.93(s, 3H), 3.76 (s, 2H), 2.93 (s, 3H), 2.63-2.42 (m, 2H), 1.60-1.46 (m,1H), 1.37-1.18 (m, 9H), 1.03-0.71 (m, 3H).

Methyl5-(2-(4′-chloro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-isobutylbenzyl)acetamido)-2-hydroxy-benzoate(8p)

This was obtained as a solid (0.141 g, 87%) from acid 7b (0.091 g, 0.268mmol) and amine 6g (0.080 g, 0.255 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.86 (s, 1H), 7.87 (d, J=1.5 Hz, 1H),7.65 (d, J=1.5 Hz, 1H), 7.54 (d, J=8.5 Hz, 1H), 7.47-7.42 (m, 3H),7.02-7.98 (m, 4H), 6.94 (d, J=8.8 Hz, 1H), 4.75 (s, 2H), 3.92 (s, 3H),3.78 (s, 2H), 2.93 (s, 3H), 2.42 (d, J=7.2 Hz, 2H), 1.76-1.86 (m, 1H),0.87 (d, J=6.6 Hz, 6H). HRMS (ESI−ve) Calcd for C₃₄H₃₆ClN₂O₆S 635.1977[M+H]⁺, found 635.1982.

Methyl5-(2-(4′-chloro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-chlorobenzyl)acetamido)-2-hydroxy-benzoate(8q)

This was obtained as a solid (0.085 g, 60%) from acid 7b (0.083 g, 0.244mmol) and amine 6d (0.068 g, 0.233 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.87 (s, 1H), 7.83 (d, J=8.5 Hz, 2H),7.64 (d, J=8.5 Hz, 2H), 7.52 (d, J=8.7 Hz, 1H), 7.48 (d, J=2.5 Hz, 1H),7.44 (d, J=8.7 Hz, 1H), 7.22 (d, J=8.4 Hz, 1H), 7.07 (d, J=6.7 Hz, 1H),7.03-6.90 (m, 2H), 4.74 (s, 2H), 3.94 (s, 3H), 3.76 (s, 2H), 2.89 (s,3H).

Methyl5-(2-(4′-chloro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-methoxybenzyl)acetamido)-2-hydroxy-benzoate(8r)

This was obtained as a solid (0.100 g, 73%) from acid 7b (0.075 g, 0.219mmol) and amine 6c (0.060 g, 0.209 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.85 (s, 1H), 7.84 (d, J=8.4 Hz, 2H),7.64 (d, J=8.5 Hz, 2H), 7.53 (d, J=8.6 Hz, 2H), 7.49 (d, J=2.3 Hz, 1H),7.44 (d, J=8.6 Hz, 1H), 7.02 (d, J=8.6 Hz, 1H), 6.98-6.87 (m, 2H), 6.75(d, J=8.6 Hz, 1H), 4.71 (s, 2H), 3.94 (s, 3H), 3.76 (s, 5H), 2.90 (s,3H). HRMS (ESI−ve) Calcd for C₃₁H₂₉ClN₂O₇S 609.1456 [M+H]⁺, found609.1448.

Methyl5-(2-(4′-fluoro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-heptylbenzyl)acetamido)-2-hydroxy-benzoate(8s)

This was obtained as a solid from acid 7d (0.095 g, 0.295 mmol) andamine 6i (0.100 g, 0.282 mmol) in the same manner as described for 8a.¹H NMR (400 MHz, CDCl₃) δ 10.86 (s, 1H), 7.85 (d, J=8.5 Hz, 2H), 7.66(d, J=8.5 Hz, 2H), 7.58 (dd, J=8.8, 5.2 Hz, 2H), 7.50 (d, J=2.5 Hz, 1H),7.17 (t, J=8.6 Hz, 2H), 7.05 (d, J=8.1 Hz, 2H), 7.03-6.90 (m, 4H), 4.75(s, 2H), 3.94 (s, 3H), 3.78 (s, 2H), 2.92 (s, 3H), 2.64-2.46 (m, 2H),1.56 (s, 1H), 1.42-1.17 (m, 9H), 0.99-0.77 (m, 3H).

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(4-(piperidin-1-yl)benzyl)acetamido)-2-hydroxy-benzoate(8t)

This was obtained as a solid (0.113 g, 55%) from acid 7f (0.117 g, 0.308mmol) and amine 6h (0.100 g, 0.294 mmol) in the same manner as describedfor 8a and was used in the next step without purification. ¹H NMR (400MHz, CDCl₃) δ 10.78 (s, 1H), 8.01 (d, J=8.5 Hz, 2H), 7.75 (d, J=8.5 Hz,2H), 7.68-7.65 (m, 3H), 7.53-7.46 (m, 2H), 7.30-7.20 (m, 6H), 6.90-6.87(m, 2H), 6.74 (dd, J=8.7, 1.7 Hz, 2H), 6.55 (dd, J=8.8, 2.7 Hz, 1H),4.63 (s, 2H), 3.94 (s, 2H), 3.92 (s, 3H), 3.66 (s, 2H), 3.21-2.84 (m,4H), 1.77-1.42 (m, 6H). HRMS (ESI−ve) Calcd for C₄₁H₄₂N₃O₆S 704.2788[M+H]⁺, found 704.2788.

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(3-(pyridin-4-yl)benzyl)acetamido)-2-hydroxy-benzoate(8u)

This was obtained as a solid (0.085 g, 50%) from acid 7f (0.119 g, 0.313mmol) and amine 6f (0.100 g, 0.299 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.80 (s, 1H), 8.63 (s, 2H), 8.00 (d,J=8.5 Hz, 2H), 7.73-7.60 (m, 8H), 7.59-7.33 (m, 16H), 7.29-7.12 (m, 7H),6.80 (d, J=8.8 Hz, 1H), 6.65 (dd, J=8.8, 2.7 Hz, 1H), 4.79 (s, 2H), 4.56(s, 2H), 3.90 (s, 2H), 3.71 (s, 3H). HRMS (ESI−ve) Calcd for C₄₁H₃₆N₃O₆S698.2319 [M+H]⁺, found 698.2330.

Methyl5-(2-(N-benzylbiphenyl-4-ylsulfonamido)-N-(4-morpholinobenzyl)acetamido)-2-hydroxybenzoate(8v)

This was obtained as a solid (0.100 g, 60%) from acid 7f (0.117 g,0.308) and amine 6e (0.100 g, 0.294 mmol) in the same manner asdescribed for 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.78 (s, 1H), 8.01 (d,J=8.5 Hz, 2H), 7.75 (d, J=8.5 Hz, 2H), 7.69-7.62 (m, 3H), 7.53-7.48 (m,2H), 7.45-7.39 (m, 1H), 7.34-7.20 (m, 7H), 6.92 (d, J=8.7 Hz, 2H), 6.77(s, 1H), 6.71 (d, J=8.7 Hz, 2H), 6.57 (dd, J=8.9, 2.7 Hz, 1H), 4.64 (s,3H), 3.93 (s, 4H), 3.87-3.81 (m, 7H), 3.66 (s, 2H), 3.12-3.02 (m, 7H).

Methyl2-hydroxy-5-(2-(N-methylbiphenyl-4-ylsulfonamido)-N-(4-(piperidin-1-yl)benzyl)acetamido)-benzoate(8w)

This was obtained as a solid (0.080 g, 45%) from acid 7c (0.094 g g,0.308 mmol) and amine 6h (0.100 g, 0.294 mmol) in the same manner asdescribed for 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.85 (s, 1H), 7.83 (d,J=8.5 Hz, 2H), 7.69 (d, J=8.5 Hz, 2H), 7.63-7.58 (m, 2H), 7.51-7.44 (m,3H), 7.41-7.40 (m, 1H), 6.99-6.89 (m, 5H), 6.76 (d, J=8.7 Hz, 2H), 4.67(s, 2H), 3.95 (s, 3H), 3.74 (s, 2H), 3.13-3.01 (m, 4H), 2.93 (s, 3H),1.67-1.65 (m, 4H), 1.59-1.48 (m, 1H). HRMS (ESI−ve) Calcd forC₃₅H₃₆N₃O₆S 628.2475 [M+H]+, found 628.2575.

Methyl2-hydroxy-5-(2-(N-methylbiphenyl-4-ylsulfonamido)-N-(3-(pyridin-4-yl)benzyl)acetamido)-benzoate(8x)

This was obtained as a solid (0.050 g, 27%) from acid 7c (0.096 g, 0.313mmol) and amine 6f (0.100 g, 0.299 mmol) in the same manner as describedfor 8a. ¹H NMR (400 MHz, CDCl₃) δ 10.88 (s, 1H), 8.67-8.57 (m, 2H), 7.83(d, J=8.4 Hz, 1H), 7.66-7.65 (m, 3H), 7.61-7.51 (m, 5H), 7.51-7.32 (m,8H), 7.24 (d, J=7.7 Hz, 1H), 7.08 (dd, J=8.8, 2.7 Hz, 1H), 6.98 (d,J=8.8 Hz, 1H), 4.88 (s, 2H), 3.92 (s, 3H), 3.78 (s, 2H), 2.98 (s, 3H).

Synthesis of Carboxylic Acids 9

General Protocol:

Methyl ester 8 (0.1 mmol) was dissolved in THF (2 ml) and 2M NaOH(excess) was added. The resultant biphasic mixture was refluxedovernight and then acidified to pH 2 with 4N HCl. The precipitatedsolids were collected by filtration and dried to afford the desiredacids in 70-80% yields.

5-(N-Benzyl-2-(N-benzyl-4-methylphenylsulfonamido)acetamido)-2-hydroxybenzoicacid (9a)

A mixture of 8a (0.107 g, 0.107 mmol) in THF (2 mL) and sodium hydroxide(aq. 1 M, 2 mL) was refluxed overnight. The solvent was then removedunder reduced pressure. The resulting solid was slurried in HCl (aq. 4M), filtered, washed with HCl and dried under vacuum to afford 9a as asolid (0.046 g, 79%). ¹H NMR (400 MHz, DMSO-d₆) δ 7.69 (d, J=8 Hz, 2H),7.36 (d, J=8 Hz, 2H), 7.26-7.16 (m, 7H), 7.15 (m, 2H), 7.05 (m, 2H),6.70 (m, 1H), 6.57 (m, 1H), 4.63 (s, 2H), 4.42 (s, 2H), 2.55 (s, 2H),2.38 (s, 3H); HPLC 99.58% (t_(R)=9.3 min, 60% acetonitrile in water);HRMS (ESI−ve) m/z calcd for C₃₀H₂₇N₂O₆S 543.15953 [M−H]⁻, found543.15962; LC-MS (ESI−ve) 543.16.

5-(N-Benzyl-2-(N-benzylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoicacid (9b)

This was obtained as a solid (0.054 g, 92%) from 8b (0.060 g, 0.097mmol) in the same manner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆)δ 7.87 (q, J=8 Hz, 4H), 7.75 (d, J=8 Hz, 2H), 7.51 (t, J=8 Hz, 2H), 7.44(m, 1H), 7.33-7.18 (m, 9H), 7.05 (d, J=8 Hz, 2H), 6.72-6.50 (m, 2H),4.63 (s, 2H), 4.49 (s, 2H), 3.65 (s, 1H); HPLC 99.95% (t_(R)=17.8 min,60% acetonitrile in water); HRMS (ESI−ve) calcd for C₃₅H₂₉N₂O₆S605.17518 [M−H]⁻, found 605.17545; LC-MS (ESI) 605.18.

5-(2-(N-Benzyl-4-methylphenylsulfonamido)-N-(4-chlorobenzyl)acetamido)-2-hydroxybenzoicacid (9c)

This was obtained as a solid (0.050 g, mmol, 86%) from 8c (0.060 g,0.101 mmol) in the same manner as described for 9a. ¹H NMR (400 MHz,DMSO-d₆) δ 7.68 (d, J=8 Hz, 2H), 7.36-7.25 (m, 8H), 7.16 (m, 2H), 7.08(d, J=8 Hz, 2H), 6.67 (m, 1H), 6.55 (m, 1H), 4.61 (s, 2H), 4.42 (s, 2H),3.58 (s, 2H), 3.35 (s, 3H); HPLC 99.96% (t_(R)=8.9 min, 60% acetonitrilein water); HRMS (ESI−ve) calcd for C₃₀H₂₆ClN₂O₆S 577.12056 [M−H]⁻, found577.12096; LC-MS (ESI−ve) 577.11.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(4-chlorobenzyl)acetamido)-2-hydroxybenzoicacid (9d)

This was obtained as a solid (0.052 g, mmol, 88%) from 8d (0.060 g,0.092 mmol) in the same manner as described for 9a. ¹H NMR (400 MHz,DMSO-d₆) δ 7.86 (q, J=8 Hz, 4H), 7.75 (d, J=8 Hz, 2H), 7.51 (t, J=8 Hz,2H), 7.45 (m, 1H), 7.30-7.26 (m, 6H), 7.19 (m, 2H), 7.1 (d, J=8 Hz, 2H),6.70 (m, 1H), 6.57 (m, 1H), 4.61 (s, 2H), 4.49 (s, 2H), 3.65 (s, 2H);HPLC 98.96% (t_(R)=9.9 min, 70% acetonitrile in water); HRMS (ESI−ve)calcd for C₃₅H₂₈ClN₂O₆S 639.13621 [M−H]⁻, found 639.13644; LC-MS(ESI−ve) 639.13.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(4-methoxybenzyl)acetamido)-2-hydroxybenzoicacid (9f)

This was obtained as a solid (0.054 g, 92%) from 8f (0.060 g, 0.092mmol) in the same manner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆)δ 7.87 (m, 1H), 7.76 (m, 2H), 7.52 (m, 2H), 7.44 (m, 1H), 7.28-7.25 (m,4H), 7.18 (m, 2H), 6.93 (d, J=8 Hz, 2H), 6.74 (d, J=8 Hz, 2H), 6.56 (m,1H), 6.49 (m, 1H), 4.54 (s, 2H), 4.51 (s, 2H), 3.65 (s, 3H), 3.60 (s,2H); HPLC 97.98% (t_(R)=16.51 min, 60% acetonitrile in water); HRMS(ESI−ve): calcd for C₃₆H₃₁N₂O₇S 635.18575 [M−H]⁻, found 635.18566; LC-MS(ESI−ve) 635.138.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(4-cyclohexylbenzyl)acetamido)-2-hydroxybenzoicacid (9g)

This was obtained as a solid (69%) from 8g (0.100 g) in the same manneras described for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.89 (m, 4H), 7.76 (m,2H), 7.53-7.44 (m, 3H), 7.32-7.18 (m, 4H), 7.0 (d, J=8 Hz, 2H), 6.90 (d,J=8 Hz, 2H), 6.80 (m, 1H), 6.65 (m, 1H), 4.57 (s, 2H), 4.53 (s, 2H),3.65 (s, 3H), 2.36 (m, 1H), 1.72-1.68 (m, 6H), 1.29-1.25 (m, 4H); HPLC99.10% (t_(R)=7.32 min, 80% acetonitrile in water); HRMS (ESI−ve) calcdfor C₄₁H₄₀N₂O₆S 687.25343 [M−H]⁻, found 635.25259; LC-MS (ESI) 687.26.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(4-heptylbenzyl)acetamido)-2-hydroxybenzoicacid (9h)

This was obtained as a solid (0.058 g) from 8h in the same manner asdescribed for 9a. ¹H NMR: (400 MHz, DMSO-d₆) δ 7.87 (m, 4H), 7.76 (m,2H), 7.52-7.41 (m, 3H), 7.24-7.08 (m, 5H), 6.99 (d, J=8 HZ, 2H), 6.91(d, J=8 Hz, 2H), 6.73 (m, 1H), 6.59 (m, 1H), 4.58 (s, 2H), 4.51 (s, 2H),3.64 (s, 2H), 2.44 (m, 2H), 1.46 (m, 2H), 1.21 (m, 8H), 0.82 (t, J=8 Hz,3H); HPLC purity 97.82% (t_(R)=7.97 min, 90% acetonitrile in water);HRMS (ESI+ve) Calcd for C₄₂H₄₅N₂O₆S 705.29928 [M+H]⁺, found 705.29862;Calcd for C₄₂H₄₄N₂O₆SNa 727.28123 [M+Na], found 727.28083; LC-MS(ESI+ve) 705.32.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(4-isobutylbenzyl)acetamido)-2-hydroxybenzoicacid (9i)

This was obtained as a solid (0.050 g) from 8i in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.87 (m, 4H), 7.76 (m,2H), 7.53-7.41 (m, 3H), 7.28-7.17 (m, 6H), 6.95 (dd, J=8, 24 Hz, 4H),6.59 (m, 1H), 6.48 (m, 1H), 4.57 (s, 1H), 4.52 (s, 1H), 3.62 (s, 1H),2.33 (d, J=4 Hz, 2H), 1.71 (m, 1H), 0.79 (s, 3H), 0.77 (s, 3H); HPLC98.27% (t_(R)=7.89 min, 80% acetonitrile in water); HRMS (ESI) Calcd forC₃₉H₃₉N₂O₆S 663.25233 [M+H]⁺, found 663.25210; Calcd for C₃₉H₃₈N₂O₆SNa685.23428 [M+Na], found 685.23256; LC-MS (ESI) 663.27.

5-(N-Benzyl-2-(N,4-dimethylphenylsulfonamido)acetamido)-2-hydroxybenzoicacid (9j)

This was obtained as a solid (0.030 g, 78%) from 8j (0.040 g, 0.083mmol) in the same manner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆)δ 7.52 (m, 3H), 7.36-7.24 (m, 6H), 7.15 (m, 2H), 6.96 (m, 2H), 4.76 (s,2H), 3.70 (s, 2H), 2.78 (s, 3H), 2.37 (s, 3H); HPLC 99.45% (t_(R)=10.98min, 50% acetonitrile in water); HRMS (ESI−ve) Calcd for C₂₄H₂₄N₂O₆S467.12823, [M−H]⁻, found 467.12914; LC-MS (ESI−ve) 469.15.

5-(N-Benzyl-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoicacid (9k)

This was obtained as a solid (0.034 g, 0.064 mmol, 87%) from 8k (0.040g, 0.074 mmol) in the same manner as described for 9a. ¹H NMR (400 MHz,DMSO-d₆) δ 7.84-7.71 (m, 6H), 7.51-7.42 (m, 4H), 7.32-7.22 (m, 4H), 7.15(m, 2H), 6.97 (m, 1H), 4.76 (s, 2H), 3.79 (s, 2H), 2.86 (s, 3H); HPLC96.06% (t_(R)=7.93 min, 60% acetonitrile in water); HRMS (ESI−ve) Calcdfor C₂₉H₂₅N₂O₆S 529.14388 [M−H]⁻, found 529.14508; LC-MS (ESI+ve)531.17.

5-(N-(4-Chlorobenzyl)-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoicacid (9l)

This was obtained as a solid from 81 (0.060 g, 0.104 mmol) in the samemanner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.83 (d, J=8 Hz,2H), 7.73-7.70 (m, 4H), 7.51-7.42 (m, 3H), 7.30 (m, 2H), 7.15 (d, J=8Hz, 2H), 7.08 (m, 1H), 6.78 (d, J=8 Hz, 2H), 4.70 (s, 1H), 3.75 (s, 2H),2.84 (s, 3H); HPLC purity 94.5% (t_(R)=6.97 min, 65% acetonitrile inwater); HRMS (ESI+ve) Calcd for C₂₉H₂₅ClN₂O₆S 565.11946 [M+H]+, found565.11781; Calcd for C₂₉H₂₄ClN₂O₆SNa [M+Na] 587.10141, found 587.10001.

5-(N-(4-Cyclohexylbenzyl)-2-(N,4-dimethylphenylsulfonamido)acetamido)-2-hydroxybenzoicacid (9m)

This was obtained as a solid (80%) from (0.030 g, 0.053 mmol) in thesame manner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.51 (d,J=8 Hz, 2H), 7.45 (d, J=4 Hz, 1H), 7.33 (d, J=8 Hz, 2H), 7.24 (dd, J=4,8 Hz, 1H), 7.11 (d, J=8 Hz, 2H), 7.02 (d, J=8 Hz, 2H), 6.91 (d, J=8 Hz,1H), 4.68 (s, 2H), 3.66 (s, 2H), 2.75 (s, 3H), 2.42 (m, 1H), 2.35 (s,3H), 1.73 (m, 5H), 1.33-121 (m, 5H); HPLC purity 97.8% (t_(R)=8.83 min,70% acetonitrile in water); HRMS (ESI−ve): Calcd for C₃₀H₃₃N₂O₆S549.20648 [M−H]⁻, found 549.20724; LC-MS (ESI−ve) 549.21.

5-(N-(4-Cyclohexylbenzyl)-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoicacid (9n)

This was obtained as a solid from 8n (0.045 g, 0.0719 mmol) in the samemanner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.85 (d, J=8 Hz,2H), 7.74 (m, 4H), 7.53-7.44 (m, 4H), 7.25 (dd, J=4, 8 Hz, 1H), 7.07 (d,J=8 Hz, 2H), 6.97 (d, J=8 Hz, 2H), 6.93 (d, J=8 Hz, 1H), 4.68 (s, 2H),3.77 (s, 2H), 2.87 (s, 3H), 2.40 (m, 1H), 1.74-1.69 (m, 5H), 1.31-1.50(m, 5H); HPLC 93.41% (t_(R)=14.74 min, 70% acetonitrile in water); HRMS(ESI−ve) Calcd for C₃₅H₃₅N₂O₆S 611.22213 [M−H], found 611.22258; LC-MS(ESI) 611.23.

5-(N-(4-Heptylbenzyl)-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)-2-hydroxybenzoicacid (9o)

This was obtained as a solid from 80o (0.050 g) in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.84 (d, J=8 Hz, 2H), 7.70(m, 4H), 7.51-7.42 (m, 4H), 7.12-6.98 (m, 5H), 6.81 (d, J=8 Hz, 1H),4.67 (s, 2H), 3.75 (s, 2H), 2.85 (s, 3H), 2.45 (m, 2H), 1.47 (m, 2H),1.21 (m, 8H), 0.82 (t, J=8 Hz, 3H); HPLC 96.5% (t_(R)=10.72 min, 80%acetonitrile in water); HRMS (ESI+ve) Calcd for C₃₆H₄₁N₂O₆S [M+H]⁺629.26798, found 629.26692; Calcd for C₃₆H₄₀N₂O₆S [M+Na] 651.24993,found 651.24895; LC-MS (ESI) 629.28.

5-(2-(4′-Chloro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-isobutylbenzyl)acetamido)-2-hydroxybenzoicacid (9p)

This was obtained as a solid (0.040 g) from 8p (0.050 g, 0.079 mmol) inthe same manner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.84(d, J=8 Hz, 2H), 7.75 (m, 4H), 7.55 (d, J=8 Hz, 2H), 7.41 (d, J=4 Hz,1H), 7.05 (dd, J=4, 8 Hz, 1H), 6.97 (M, 4H), 6.76 (d, J=8 Hz, 1H), 4.65(s, 2H), 3.74 (s, 2H), 2.86 (s, 3H), 2.34 (d, J=8 Hz, 2H), 1.72 (m, 1H),0.79 (s, 3H), 0.78 (s, 3H); HPLC purity 99.10% (t_(R)=6.01 min, 80%acetonitrile in water); HRMS (ESI+ve): Calcd for C₃₃H₃₄ClN₂O₆S 621.18206[M+H]⁺, found 621.18084; Calcd for C₃₃H₃₃ClN₂O₆SNa 643.16401 [M+Na]⁺,found 643.16841; LC-MS (ESI+ve) 621.02.

5-(2-(4′-Chloro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-chlorobenzyl)acetamido)-2-hydroxybenzoicacid (9q)

This was obtained as a solid (0.043 g, 73%) from 8q (0.060 g, 0.98 mmol)in the same manner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.83(m, 2H), 7.74 (m, 4H), 7.55 (d, J=8 Hz, 2H), 7.44 (d, J=4H, 1H), 7.30(d, J=8 Hz, 2H), 7.14 (d, J=8 Hz, 2H), 7.03 (dd, J=8, 4 Hz, 1H), 6.74(d, J=8 Hz, 1H), 4.69 (s, 2H), 3.74 (s, 2H), 2.84 (s, 3H); HPLC purity94.8% (t_(R)=17.33 min, 60% acetonitrile in water); HRMS (ESI−ve) Calcdfor C₂₉H₂₃ClN₂O₆S 597.06594 [M−H]⁻, found 597.06616; LC-MS (ESI−ve)597.07.

5-(2-(4′-Chloro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-methoxybenzyl)acetamido)-2-hydroxybenzoicacid (9r)

This was obtained as a solid (0.035 g, 60%) from 8r (0.060 g, 0.099mmol) in the same manner as described for 9a. ¹H NMR (400 MHz, DMSO-d₆)δ 7.84 (d, J=8 Hz, 2H), 7.74 (m, 4H), 7.55 (d, J=8 Hz, 2H), 7.43 (d, J=4Hz, 1H), 7.0 (m, 4H), 6.78 (d, J=8 Hz, 2H), 4.63 (s, 2H), 3.72 (s, 2H),3.67 (s, 3H), 2.84 (s, 3H); HPLC 96.31% (t_(R)=11.31 min, 60%acetonitrile in water); HRMS (ESI−ve) Calcd for C₃₀H₂₆ClN₂O₆S 593.11547[M−H]⁻, found 593.11538; LC-MS (ESI−ve) 593.11.

5-(2-(4′-Fluoro-N-methylbiphenyl-4-ylsulfonamido)-N-(4-heptylbenzyl)acetamido)-2-hydroxybenzoicacid (9s)

This was obtained as a solid from 8s (0.080 g) in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d₆) δ 7.83-7.71 (m, 6H), 7.45(d, J=4 Hz, 1H), 7.33 (m, 2H), 7.04-6.97 (m, 5H), 6.75 (d, J=8 Hz, 1H),4.66 (s, 2H), 3.74 (s, 2H), 2.85 (s, 3H), 1.41 (m, 2H), 1.22 (m, 10H),0.83 (m, 3H); HPLC purity 95.05% (t_(R)=7.3 min, 60% acetonitrile inwater); HRMS (ESI−ve) Calcd for C₃₆H₃₈FN₂O₆S 645.24401 [M−H]⁻, found645.24325; LC-MS (ESI−ve) 645.23.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(4-(piperidin-1-yl)benzyl)acetamido)-2-hydroxybenzoicacid (9t)

This was obtained as a solid (0.050 g) from 8t in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d6) δ 7.91-7.86 (m, 4H),7.77-7.75 (m, 2H), 7.53-7.49 (m, 2H), 7.47-7.42 (m, 1H), 7.32-7.26 (m,4H), 7.21-7.15 (m, 2H), 6.95-6.91 (m, 1H), 6.81-6.78 (m, 3H), 6.73 (d,J=8.4 Hz, 2H), 4.52 (s, 2H), 4.51 (s, 2H), 3.63 (s, 2H), 3.01-2.98 (m,4H), 1.72-1.34 (m, 6H). HPLC purity 71.7% (t_(R)=2.753 min, 65%acetonitrile in water); HRMS (ESI−ve) Calcd for C₄₀H₄₀N₃O₆S 690.2632[M+H]⁺, found 690.2638.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(3-(pyridin-4-yl)benzyl)acetamido)-2-hydroxybenzoicacid (9u)

This was obtained as a solid (0.050 g) from 8u in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d6) δ 8.67 (d, J=6.3 Hz, 2H),7.90 (d, J=8.5 Hz, 2H), 7.83-7.77 (m, 4H), 7.73-7.68 (m, 4H), 7.64-7.41(m, 15H), 7.27-7.17 (m, 6H), 7.12 (d, J=2.7 Hz, 1H), 6.85 (d, J=8.8 Hz,1H), 4.78 (s, 2H), 4.46 (s, 2H), 3.65 (s, 2H). HPLC purity 95.7%(t_(R)=3.96 min, 60% acetonitrile in water); HRMS (ESI−ve) Calcd forC₄₀H₃₄N₃O₆S 684.2162 [M+H]⁺, found 684.2163.

5-(2-(N-Benzylbiphenyl-4-ylsulfonamido)-N-(4-morpholinobenzyl)acetamido)-2-hydroxybenzoicacid (9v)

This was obtained as a solid (0.056 g) from 8v in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d6) δ 7.91-7.86 (s, 4H), 7.77(d, J=7.4 Hz, 1H), 7.52 (t, J=7.5 Hz, 2H), 7.44 (t, J=7.3 Hz, 1H), 7.32(d, J=2.7 Hz, 1H), 7.29-7.23 (m, 3H), 7.21-7.17 (m, 2H), 6.95 (dd,J=8.7, 2.7 Hz, 1H), 6.82 (dd, J=8.7, 2.4 Hz, 4H), 6.71 (d, J=8.7 Hz,2H), 4.53 (s, 4H), 3.68-3.65 (m, 2H), 3.64 (s, 2H), 2.97-2.90 (m, 4H).HPLC purity 92.1% (t_(R)=7.94 min, 50% acetonitrile in water); HRMS(ESI−ve) Calcd for C₃₉H₃₆N₃O₇S 690.2279 [M−H]⁻, found 690.2278.

2-Hydroxy-5-(2-(N-methylbiphenyl-4-ylsulfonamido)-N-(4-(piperidin-1-yl)benzyl)acetamido)benzoicacid (9w)

This was obtained as a solid from 8w (0.050 g) in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d6) δ 7.84 (m, 3H), 7.75-7.67(m, 4H), 7.56-7.40 (m, 4H), 7.26 (d, J=7.2 Hz, 1H), 7.06-6.94 (m, 4H),4.65 (s, 2H), 3.75 (s, 2H), 3.14 (s, 4H), 2.85 (s, 3H), 1.64-1.52 (m,6H). HPLC purity 98.3% (t_(R)=13.5 min, 40% acetonitrile in water); HRMS(ESI−ve) Calcd for C₃₄H₃₄N₃O₆S 614.2319 [M−H]⁻, found 614.2305

2-Hydroxy-5-(2-(N-methylbiphenyl-4-ylsulfonamido)-N-(3-(pyridin-4-yl)benzyl)acetamido)benzoicacid (9x)

This was obtained as a solid from 8x (0.050 g) in the same manner asdescribed for 9a. ¹H NMR (400 MHz, DMSO-d6) δ 8.65 (d, J=6.2 Hz, 2H),7.83-7.78 (m, 1H), 7.76-7.67 (m, 8H), 7.64-7.57 (m, 3H), 7.53-7.41 (m,5H), 7.37 (dd, J=8.7, 2.8 Hz, 1H), 7.30 (d, J=7.7 Hz, 1H), 6.97 (d,J=8.8 Hz, 1H), 4.86 (s, 2H), 3.81 (s, 3H), 2.83 (s, 4H). HPLC purity95.30% (t_(R)=11.9 min, 40% acetonitrile in water); HRMS (ESI−ve) Calcdfor C₃₄H₂₈N₃O₆S 608.1849 [M−H]⁻, found 608.1832.

Synthesis of Diethyl Phosphonylanilines 25

Diethyl 4-nitrophenylphosphonate

1-bromo-4-nitrobenzene (2.02 g, 10 mmol) was suspended in EtOH (10 ml)and THF (5 ml) was added to afford a homogeneous solution. The solutionwas degassed, a vacuum applied to the flask, which was then filled withargon. This process was repeated 3 times. The catalyst Pd(Ph₃P)₄ (0.578g, 0.5 mmol) was added under argon atmosphere and the mixture was againdegassed, a vacuum applied to the flask which was then refilled withargon. Triethylamine (2.8 ml, 20 mmol) and diethyl phosphite (1.93 ml,15 mmol) were added via syringe. The resulting solution was refluxed for24 h under argon and cooled to room temperature. The insoluble materialwas filtered and the filtrate concentrated to provide the crude productwhich was dissolved in EtOAc (50 ml) and filtered. The residue waswashed with EtOAc (2×25 ml) The combined filtrates were concentrated andthe crude product was purified via flash chromatography (50 silica gel,DCM/CH₃OH gradient) affording diethyl 4-nitrophenylphosphonate (3.44 g,containing ca. 14% diethyl phosphite in weight) as a yellow oil. ¹H NMR(400 MHz, CDCl₃) δ 8.33-8.28 (m, 2H), 8.04-7.97 (m, 2H), 4.25-4.07 (m,4H), 1.34 (t, J=7.1 Hz, 6H). LC-MS (ESI+) m/z 204.01 (M+H-2×C₂H₄)+; HRMS(ESI+) m/z calculated for C₁₀H₁₅NO₅P (M+H)⁺260.0682, found 260.0679.

Diethyl 4-aminophenylphosphonate (13a)

Diethyl 4-nitrophenylphosphonate (1.700 g, containing ca. 14% diethylphosphite) was dissolved in methanol (20 ml) and was stirred in thepresence of Pd (10% on carbon, 0.100 g) under H₂ (balloon) at roomtemperature for 14 h. The Pd/C was filtered through a pad of celite. Thefiltrate was concentrated to dryness affording the title compound 13a(1.200 g, 80%) as a brown solid. ¹H NMR (400 MHz, CDCl₃) δ 7.63-7.54 (m,2H), 6.76-6.70 (m, 2H), 4.16-3.96 (m, 4H), 3.81 (br s, 2H), 1.30 (2t,J=7.5 Hz, 6H). LC-MS (ESI+) m/z 174.04 (M+H-2×C₂H₄)+; HRMS (ESI+) m/zcalculated for C₁₀H₁₇NO₃P (M+H)⁺230.0941, found 230.0936.

Diethyl 3-aminophenylphosphonate (13b)

Anhydrous EtOH (10 mL), 3-bromoaniline (3.16 g, 18.36 mmol), diethylphosphite (3.11 g, 22.53 mmol), and anhydrous Et₃N (3.9 mL) were addedunder Argon at room temperature to a round-bottom flask previouslycharged with Pd(OAc)₂ (0.245 g, 1.09 mmol) and PPh₃ (0.764 g, 2.91mmol). The reaction mixture was stirred at 80° C. (oil bath temperature)for 18 h. The solvent was removed under reduced pressure to provide ayellow oil. Flash chromatography (SiO₂) afforded 13b as a yellow oil(1.54 g, 35%). ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.21 (m, 1H), 7.18-7.09(m, 2H), 6.86-6.82 (m, 1H), 4.30-3.99 (m, 4H), 1.40-0.97 (m, 6H). LC-MS(ESI+ve) m/z found 230.2.

Diethyl 3-nitrobenzylphosphonate

3-nitrobenzyl bromide (1.080 g, 5.00 mmol) was mixed with triethylphosphite (1.04 ml, 6.00 mmol). The mixture was heated to 140° C. in anoil bath for 2 h and cooled to room temperature. The excess of triethylphosphite and the byproduct ethyl bromide were evaporated in vacuo toprovide diethyl 3-nitrobenzylphosphonate as a yellow oil (1.460 g, 100%)which did not require further purification. ¹H NMR (400 MHz, CDCl₃) δ8.17-8.14 (m, 1H), 8.14-8.10 (m, 1H), 7.69-7.62 (m, 1H), 7.50 (t, J=7.9Hz, 1H), 4.09-4.02 (m, 4H), 3.23 (d, J=21.8 Hz, 2H), 1.26 (t, J=7.1 Hz,6H). LC-MS (ESI+) m/z 218.02 (M+H-2×C₂H₄)⁺; HRMS (ESI+) m/z calculatedfor C₁₁H₁₇NO₅P (M+H)⁺274.0839, found 274.0843.

Diethyl 3-aminobenzylphosphonate (13d)

Diethyl 3-nitrobenzylphosphonate (1.366 g, 5.00 mmol) was dissolved inTHF (5 ml). The solution was hydrogenated with Pd/C (10%, 0.100 g)catalyst under H₂ atmosphere at room temperature overnight. The catalystwas filtered off through a pad of celite and washed with THF (5 ml×2).The filtrate was concentrated to dryness affording the aniline 13c(1.300 g, 100%) as yellow oil which was used without furtherpurification.

Compounds 14

Diethyl 4-(4-phenoxybenzamido)phenylphosphonate (14a)

This compound was synthesized according to the procedure used to prepare14c using 4-phenoxybenzoic acid (0.214 g, 1 mmol), 13a (0.229 g, 1mmol), EDC (0.211 g, 1.1 mmol) and DMAP (0.012 g, 0.1 mmol) in DCM (5ml). The reaction mixture was concentrated and the residue suspended inEtOAc (50 ml) and washed with HCl (1 N, 3×10 ml), water (2×10 ml) andbrine (10 ml). The organic phase was dried over Na₂SO₄ and concentratedto give the crude product. Flash chromatography (SiO₂, DCM/CH₃OHgradient) afforded the title compound 14a (0.180 g, 42%) as a yellowoil. ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.89-7.85 (m, 2H),7.85-7.74 (m, 4H), 7.43-7.37 (m, 2H), 7.23-7.18 (m, 1H), 7.10-7.03 (m,4H), 4.20-4.01 (m, 4H), 1.34-1.30 (m, 6H). LC-MS (ESI+) m/z 426.15(M+H)+; HRMS (ESI+) m/z calculated for C₂₃H₂₅NO₅P (M+H)⁺426.1465, found426.1458.

Diethyl 3-(4-phenoxybenzamido)phenylphosphonate (14b)

Anhydrous DCM (2 mL) was added at 0° C. under Argon to a round-bottomflask previously charged with 13b (0.504 g, 2.20 mmol), 4-phenoxybenzoicacid (0.364 g, 1.69 mmol), DMAP (0.035 g, 0.286 mmol), EDC hydrochloride(0.399 g, 2.08 mmol). The reaction mixture was first allowed to warm upto room temperature without removing the ice-bath and then stirred atroom temperature overnight. HCl (aq., 1M, 20 mL) was added, the organiclayer extracted with DCM (2×20 mL), separated, dried (Na₂SO₄), filteredand the solvent removed under reduced pressure. Chromatography (SiO₂)afforded 14b as a yellow solid (0.643 g, 1.51 mmol, 90%). ¹H NMR (400MHz, CDCl₃) δ 8.84-8.71 (m, 1H), 8.29 (s, 1H), 8.03-7.88 (m, 3H),7.52-7.45 (m, 2H), 7.44-7.36 (m, 2H), 7.23-7.17 (m, 1H), 7.08-7.06 (m,4H), 4.07-3.99 (m, 4H), 1.40-1.13 (m, 6H). HRMS (ESI+ve) m/z calculatedfor C₂₃H₂₅N₂O₅P (M+H)⁺426.1464, found 426.1458.

Diethyl 4-(4-phenoxybenzamido)benzylphosphonate (14c)

1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.211 g, 1.1 mmol) andDMAP (0.012 g, 0.1 mmol) were added sequentially to a cooled mixture (0°C.) of 4-phenoxybenzoic acid (0.243 g, 1 mmol) and diethyl4-aminobenzylphosphonate (Acros Organic)(0.214 g, 1 mmol) in DCM (5 ml).The mixture was stirred at room temperature for 16 h and concentrated.The residue was slurried in HCl (1 N, 20 ml) and sonicated. The solidwas isolated by filtration, washed with water (3×10 ml) and dried undervacuum to afford the title compound 14c (0.423 g, 96%) as a white solid.m.p. 144-146° C. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (br s, 1H), 7.89-7.84(m, 2H), 7.60 (d, J=8.5 Hz, 2H), 7.42-7.37 (m, 2H), 7.31-7.26 (m, 2H),7.22-7.17 (m, 1H), 7.09-7.02 (m, 4H), 4.06-3.94 (m, 4H), 3.13 (d, J=21.4Hz, 2H), 1.24 (t, J=7.1 Hz, 6H). ³¹P NMR (162 MHz, CDCl₃) δ 27.38. LC-MS(ESI+) m/z 440.17 (M+H)+; HRMS (ESI+) m/z calculated for C₂₄H₂₇NO₅P(M+H)⁺440.1621, found 440.1625.

Diethyl 3-(4-phenoxybenzamido)benzylphosphonate (14d)

This compound was synthesized according to the procedure used to prepare14c using 4-phenoxybenzoic acid (0.0.428 g, 2 mmol), 13d (0.600 g, 2.5mmol), EDC (0.383 g, 2 mmol) and DMAP (0.024 g, 0.2 mmol) in DCM (5 ml).The workup and purification procedure was following that for 14aaffording the title compound 14d (0.860 g, 98%) as colorless oil. ¹H NMR(400 MHz, CDCl₃) δ 7.91 (br s, 1H), 7.88-7.83 (m, 2H), 7.68 (d, J=7.4Hz, 1H), 7.53 (d, J=1.8 Hz, 1H), 7.44-7.36 (m, 2H), 7.31 (t, J=7.8 Hz,1H), 7.22-7.16 (m, 1H), 7.10-7.02 (m, 5H), 4.08-3.97 (m, 4H), 3.16 (d,J=21.6 Hz, 2H), 1.25 (t, J=7.1 Hz, 6H). LC-MS (ESI+) m/z 440.20 (M+H)+;HRMS (ESI+) m/z calculated for C₂₄H₂₇NO₅P (M+H)⁺440.1621, found440.1628.

Compound 15

Methyl 4-cyclohexylbenzoate

4-Cyclohexylbenzoic acid (3.94 g, 18.28 mmol) in MeOH (35 mL) wasrefluxed under Argon for 40 h in presence of H₂SO₄ (conc., 0.40 mL). Thereaction mixture was concentrated and NaHCO₃ (aq., sat., 100 ml) addedto the residue. The mixture was extracted with EtOAc (100 mL×2). Theorganic phase was dried over Na₂SO₄ and concentrated to give methyl4-cyclohexylbenzoate (4.014 g, 96%) as a white solid. ¹H NMR (400 MHz,CDCl₃) δ 7.95 (d, J=8.4 Hz, 1H), 7.27 (d, J=8.4 Hz, 1H), 3.89 (s, 2H),2.66-2.39 (m, 1H), 1.92-1.72 (m, 5H), 1.52-1.18 (m, 5H).

(4-Cyclohexylphenyl)methanol

Methyl 4-cyclohexylbenzoate (3.934 g, 18.04 mmol) in anhydrous THF (10mL) was added dropwise to a suspension of LiAlH₄ (1.693 g, 44.55 mmol)in anhydrous THF (15 mL) under Argon at 0° C. The reaction mixture wasfirst allowed to warm up to room temperature and then stirred at roomtemperature for 16 h. The reaction mixture was then cooled to 0° C. andsodium sulfate decahydrate (20 g) was added portionwise, followed by theaddition of Et₂O (160 mL). The formed solid was filtered, washed withEt₂O (3×30 mL). The organic extracts were combined, washed with water(2×100 mL), separated, dried (Na₂SO₄), filtered and the solvent removedunder reduced pressure to provide (4-cyclohexylphenyl)methanol (2.908 g,85%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, J=8.2 Hz, 2H),7.21 (d, J=8.1 Hz, 2H), 4.64 (s, 2H), 2.53-2.49 (m, 1H), 1.90-1.70 (m,5H), 1.50-0.99 (m, 5H).

1-(Bromomethyl)-4-cyclohexylbenzene (15)

Supported triphenylphosphine PS-Ph₃P (1 g, 2 mmol) was added to(4-cyclohexylphenyl)methanol (0.190 g, 1 mmol) in DCM (10 ml). After 30min, CBr₄ (0.332 g, 1 mmol) was added. The mixture was shaken at roomtemperature for 16 h and filtered. The resin was washed with DCM and thecombined filtrates were concentrated to dryness affording the titlecompound 15 (0.260 g, 100%) as a colorless oil. ¹H NMR (400 MHz, CDCl₃)δ 7.31 (d, J=8.1 Hz, 2H), 7.17 (d, J=8.2 Hz, 2H), 4.49 (s, 2H),2.54-2.43 (m, 1H), 1.91-1.70 (m, 5H), 1.46-1.15 (m, 5H).

Compounds 16

Diethyl 4-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)phenylphosphonate(16a)

This compound was prepared, according to the procedure used to make 16d,from 14a (0.115 g, 0.27 mmol), NaH (0.011 g, 0.27 mmol), 15 (0.076 g,0.3 mmol) affording the title compound 16a (0.041 g, 25%) as a colorlessoil and the starting 14a (0.041 g, 36%) was recovered. ¹H NMR (400 MHz,CDCl₃) δ 7.61 (dd, J=12.9, 8.1 Hz, 2H), 7.37-7.29 (m, 4H), 7.20 (d,J=7.9 Hz, 2H), 7.16-7.10 (m, 3H), 7.04 (dd, J=8.1, 3.5 Hz, 2H),6.99-6.94 (m, 2H), 6.75 (d, J=8.4 Hz, 2H), 5.11 (s, 2H), 4.16-3.98 (m,4H), 2.53-2.40 (m, 1H), 1.90-1.70 (m, 5H), 1.45-1.30 (m, 5H), 1.27 (t,J=7.1 Hz, 6H). LC-MS (ESI+) m/z 598.27 (M+H)+; HRMS (ESI+) m/zcalculated for C₃₆H₄₁NO₅P (M+H)⁺598.2717, found 598.2711.

Diethyl 3-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)phenylphosphonate(16b)

Compound 14b (0.256 g, 0.602 mmol) was added to a suspension of NaH(0.029 g, 0.727 mmol, 60% dispersion in mineral oil) in anhydrous THF(0.6 mL) under Argon at 0° C. The reaction mixture was stirred at 0° C.under Argon for 1 h, followed by the addition of a solution of 15 (0.175g, 0.694 mmol) in anhydrous THF (0.6 mL). After stirring at roomtemperature overnight, the reaction mixture was quenched with aq. HCl (1M, 5 mL) and extracted with DCM (5 mL×2). The organic layers werecombined, dried (Na₂SO₄), filtered and the solvent removed under reducedpressure. Chromatography (SiO₂) afforded 16b as a yellow oil (0.124 g,0.207 mmol, 35%). ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, J=8.1 Hz, 1H), 7.58(dd, J=12.8, 7.5 Hz, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.34-7.28 (m, 4H),7.22-7.18 (m, 3H), 7.14-7.06 (m, 3H), 7.00 (d, J=8.1 Hz, 1H), 6.92 (d,J=8.0 Hz, 1H), 6.74 (d, J=8.7 Hz, 2H), 5.10 (s, 2H), 3.97-3.89 (m, 2H),3.85-3.78 (m, 2H), 2.47-2.47 (m, 1H), 1.82-1.61 (m, 5H), 1.41-1.31 (m,4H) 1.25-1.18 (m, 7H). HRMS (ESI+ve) m/z calculated for C₃₆H₄₁N₂O₅P(M+H)⁺598.2716, found 598.2721.

Diethyl 3-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)benzylphosphonate(16c)

This compound was prepared, according to the procedure used to make 16d,from 14c (0.439 g, 1 mmol), NaH (0.04 g, 1 mmol), 15 (0.253 g, 1 mmol)affording the title compound 16c (0.441 g, 72%) as a colorless oil. ¹HNMR (400 MHz, CDCl₃) δ 7.36-7.28 (m, 4H), 7.21 (d, J=8.1 Hz, 2H),7.14-7.03 (m, 5H), 7.01 (s, 1H), 6.96-6.90 (m, 2H), 6.79-6.69 (m, 3H),5.07 (s, 2H), 3.99-3.80 (m, 4H), 3.01 (d, J=21.7 Hz, 2H), 2.48-2.42 (m,1H), 1.83-1.71 (m, 5H), 1.45-1.22 (m, 5H). LC-MS (ESI+) m/z 612.29(M+H)+; HRMS (ESI+) m/z calculated for C₃₇H₄₃NO₅P (M+H)⁺612.2873, found612.2872.

Diethyl 4-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)benzylphosphonate(16d)

Sodium hydride (60% in mineral oil, 0.012 g, 0.3 mmol) was suspended inTHF (3 ml) and the mixture cooled to 0° C. The phosphonate 14c (0.132 g,0.3 mmol) was added and the mixture stirred at 0° C. for 1 h. The alkylbromide 15 (0.091 g, 0.36 mmol) was then added and the mixture wasstirred at room temperature for 16 h. The reaction mixture was dilutedwith EtOAc (30 ml) and washed with water (2×10 ml) and brine (10 ml).The organic phase was dried over Na₂SO₄ and concentrated. The crudeproduct was purified via flash chromatography (SiO₂, DCM/CH₃OH gradient)affording the title compound 16d (0.126 g, 69%) as a colorless oil. ¹HNMR (400 MHz, CDCl₃) δ 7.35-7.29 (m, 4H), 7.20 (d, J=8.2 Hz, 2H),7.14-7.07 (m, 5H), 6.96-6.92 (m, 2H), 6.88 (d, J=7.9 Hz, 2H), 6.74-6.69(m, 2H), 5.06 (s, 2H), 3.99-3.80 (m, 4H), 3.04 (d, J=21.7 Hz, 2H),2.50-2.39 (m, 1H), 1.88-1.69 (m, 5H), 1.44-1.19 (m, 5H), 1.16 (t, J=7.1Hz, 6H). ³¹P NMR (162 MHz, CDCl₃) δ 26.90. LC-MS (ESI+) m/z 612.29(M+H)+; HRMS (ESI+) m/z calculated for C₃₇H₄₃NO₅P (M+H)⁺612.2873, found612.2855.

Compounds 17

4-(N-(4-Cyclohexylbenzyl)-4-phenoxybenzamido)phenylphosphonic acid (17a)

This compound was prepared, according to the procedure used to make 17c,from 16a (0.030 g, 0.05 mmol) and bromotrimethylsilane (0.1 ml, 0.5mmol) in DCM (3 ml) affording the title compound 17a (0.015 mg, 56%) asa white solid. m.p. 182.7° C. (dec.). ¹H NMR (400 MHz, CD₃OD) δ 7.62(dd, J=12.8, 8.3 Hz, 2H), 7.40-7.30 (m, 4H), 7.20-7.11 (m, 7H), 6.94 (d,J=7.8 Hz, 2H), 6.76 (d, J=8.7 Hz, 2H), 5.14 (s, 2H), 2.51-2.40 (m, 1H),1.90-1.70 (m, 5H), 1.49-1.20 (m, 5H). LC-MS (ESI−) m/z 540.20 (M−H)⁻;HRMS (ESI−) m/z calculated for C₃₂H₃₁NO₅P (M−H)⁻540.1945, found540.1935.

3-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)phenylphosphonic acid (17b)

This was prepared from the amide 16b (0.119 g, 0.199 mmol) in a similarmanner as described for 18b. The obtained crude material was slurriedwith hexane/EtOAc (9/1, 1 ml), filtered, washed with hexane (1 mL),dried under vacuum to afford pure 17b as an off-white solid (0.059 g,0.108 mmol, 55%). m.p 92.3-94.9° C. ¹H NMR (400 MHz, CD₃OD) δ 7.59-7.44(m, 2H), 7.38-7.25 (m, 5H), 7.21-7.09 (m, 6H), 6.93 (d, J=8.0 Hz, 2H),6.74 (d, J=8.4 Hz, 2H), 5.11 (s, 2H), 2.47-2.42 (m, 1H), 1.81-1.71 (m,5H), 1.41-1.23 (m, 5H). HRMS (ESI+ve) m/z calculated for C₃₂H₃₃N₂O₅P(M+H)⁺542.2090, found 542.2084.

4-(N-(4-Cyclohexylbenzyl)-4-phenoxybenzamido)benzylphosphonic acid (17c)

TMSBr (0.216 ml, 1.63 mmol) was added to a solution of 16c (0.100 g,0.163 mmol) in DCM (3 ml) at 0° C. The mixture was stirred at roomtemperature for 4 h and concentrated. The residue was stirred with 90%CH₃OH/H₂O (10 ml) at room temperature for 1 h and concentrated. Thecrude product was slurried in acetone (2 ml) and filtered. The solid waswashed with acetone (2×1 ml) and dried affording the title compound 17c(0.046 g, 51%) as an off-white solid. m.p. 188° C. (dec.). ¹H NMR (400MHz, CD₃OD) δ 7.40-7.27 (m, 4H), 7.23-7.08 (m, 7H), 6.96 (t, J=8.6 Hz,4H), 6.75 (d, J=8.7 Hz, 2H), 5.08 (s, 2H), 3.03 (d, J=21.7 Hz, 2H),2.54-2.40 (m, 1H), 1.92-1.70 (m, 5H), 1.51-1.21 (m, 5H). ³¹P NMR (162MHz, CD₃OD) δ 24.54. LC-MS (ESI+) m/z 556.22 (M+H)+; HRMS (ESI+) m/zcalculated for C₃₃H₃₅NO₅P (M+H)⁺556.2247, found 556.2250.

3-(N-(4-Cyclohexylbenzyl)-4-phenoxybenzamido)benzylphosphonic acid (17d)

This compound was prepared, according to the procedure used to make 17c,from 16d (0.109 g, 0.18 mmol) and bromotrimethylsilane (0.24 ml, 1.78mmol) in DCM (5 ml). Flash chromatography (SiO₂, DCM/CH₃OH gradient)afforded the title compound 17d (0.080 g, 81%) as a brown solid. m.p.97° C. (dec.). ¹H NMR (400 MHz, CD₃OD) δ 7.36-7.30 (m, 4H), 7.20 (d,J=8.1 Hz, 3H), 7.15-7.11 (m, 4H), 7.07 (t, J=7.6 Hz, 1H), 6.94 (d, J=7.9Hz, 2H), 6.75 (d, J=8.5 Hz, 2H), 6.68 (d, J=7.4 Hz, 1H), 5.08 (s, 2H),3.04 (d, J=21.7 Hz, 2H), 2.49-2.42 (m, 1H), 1.92-1.70 (m, 5H), 1.48-1.23(m, 5H). LC-MS (ESI−) m/z 554.21 (M−H)⁻; HRMS (ESI−) m/z calculated forC₃₃H₃₃NO₅P (M−H)⁻ 554.2102, found 554.2088.

Compounds 18

Diethyl 4-(4-phenoxybenzamido)phenylphosphonate (18a)

This compound was synthesized according to the procedure used to prepare14c using 4-phenoxybenzoic acid (0.214 g, 1 mmol), 14a (0.229 g, 1mmol), EDC (0.211 g, 1.1 mmol) and DMAP (0.012 g, 0.1 mmol) in DCM (5ml). The reaction mixture was concentrated and the residue suspended inEtOAc (50 ml) and washed with HCl (1 N, 3×10 ml), water (2×10 ml) andbrine (10 ml). The organic phase was dried over Na₂SO₄ and concentratedto give the crude product. Flash chromatography (SiO₂, DCM/CH₃OHgradient) afforded the title compound 18a (0.180 g, 42%) as a yellowoil. ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 7.89-7.85 (m, 2H),7.85-7.74 (m, 4H), 7.43-7.37 (m, 2H), 7.23-7.18 (m, 1H), 7.10-7.03 (m,4H), 4.20-4.01 (m, 4H), 1.34-1.30 (m, 6H). LC-MS (ESI+) m/z 426.15(M+H)+; HRMS (ESI+) m/z calculated for C₂₃H₂₅NO₅P (M+H)⁺426.1465, found426.1458.

3-(4-Phenoxybenzamido)phenylphosphonic acid (18b)

Bromotrimethylsilane (0.464 g, 3.03 mmol) was added dropwise under Argonto a solution of 14b (0.137 g, 0.322 mmol) in anhydrous DCM (0.5 mL).After stirring at room temperature overnight, the solvent and excess ofTMS-Br were removed under reduced pressure. A mixture of MeOH/water(9/1, 2 mL) was added and the reaction mixture was stirred at roomtemperature for 1 h. The solvent was removed under reduced pressure toprovide an orange oil. Water (10 mL) was added and the solid thatprecipitated was filtered, washed with water (5 mL) and dried undervacuum to afford pure 18b as an off-white solid (0.096 g, 0.260 mmol,81%). m.p. 103.2-104.6° C. ¹H NMR (400 MHz, CD₃OD) δ 8.15 (d, J=14.1 Hz,1H), 7.95 (d, J=8.7 Hz, 2H), 7.91 (d, J=7.8 Hz, 1H), 7.59-7.57 (m, 1H),7.52-7.46 (m, 1H), 7.42 (t, J=7.9 Hz, 2H), 7.21 (t, J=7.4 Hz, 1H), 7.08(d, J=8.1 Hz, 2H), 7.05 (d, J=8.7 Hz, 2H). HRMS (ESI+ve) m/z calculatedfor C₁₉H₁₅NO₅P (M+H)⁺370.0838, found 370.0831.

4-(4-Phenoxybenzamido)benzylphosphonic acid (18c)

This compound was prepared according to the procedure used to make 17cfrom 14c (0.088 g, 0.2 mmol) and TMSBr (0.264 ml, 2.0 mmol). The crudeproduct was slurried in DCM (20 ml) and filtered affording the titlecompound 18c (0.077 g, 100%) as a white solid. m.p. >250° C. ¹H NMR (400MHz, CD₃OD) δ 7.96-7.91 (m, 2H), 7.61 (d, J=8.1 Hz, 2H), 7.45-7.39 (m,2H), 7.31 (dd, J=8.6, 2.5 Hz, 2H), 7.23-7.18 (m, 1H), 7.11-7.02 (m, 4H),3.11 (d, J=21.5 Hz, 2H). ³¹P NMR (162 MHz, CD₃OD) δ 25.23. LC-MS (ESI+)m/z 384.11 (M+H)+; HRMS (ESI+) m/z calculated for C₂₀H₁₉NO₅P(M+H)⁺384.0995, found 384.0991.

Compound 19

Methyl 5-(N-benzyl-4-phenoxybenzamido)-2-hydroxybenzoate (19a)

This was prepared as a yellow oil (0.301 g, 0.664 mmol, 83%) from 6a(0.205 g, 0.797 mmol) and 4-phenoxybenzoyl chloride (0.200 g, 0.862mmol) in the same manner as described for 19g. ¹H NMR (400 MHz, CDCl₃) δ10.67 (s, 1H), 7.45 (d, J=2.5 Hz, 1H), 7.34-7.26 (m, 9H), 7.14-7.07 (m,1H), 6.95-6.92 (m, 2H), 6.89 (dd, J=2.2, 9.1 Hz, 1H), 6.78-6.72 (m, 3H),5.07 (s, 2H), 3.89 (s, 3H). HRMS (ESI+ve) m/z calculated for C₂₈H₂₄NO₅(M+H)⁺454.1649, found 454.1656.

Methyl 2-hydroxy-5-(N-(4-methoxybenzyl)-4-phenoxybenzamido)benzoate(19b)

This was prepared as a yellow oil (0.267 g, 0.552 mmol, 93%) from 6c(0.170 g, 0.592 mmol) and 4-phenoxybenzoyl chloride (0.044 g, 0.655mmol) in the same manner as described for 19g. ¹H NMR (400 MHz, CDCl₃) δ10.68 (s, 1H), 7.43 (d, J=2.5 Hz, 1H), 7.34-7.27 (m, 4H), 7.18 (d, J=8.6Hz, 2H), 7.15-7.08 (m, 1H), 6.96-6.90 (m, 2H), 6.86 (dd, J=1.9, 8.8 Hz,1H), 6.81 (d, J=8.7 Hz, 2H), 6.75 (t, J=8.8 Hz, 3H), 5.00 (s, 2H), 3.90(s, 1H), 3.78 (s, 3H). HRMS (ESI+ve) m/z calculated for C₂₉H₂₆NO₆(M+H)+484.1755, found 484.1743.

Methyl 2-hydroxy-5-(N-(4-methoxybenzyl)-4-phenoxybenzamido)benzoate(19c)

A solution of 4-phenoxybenzoyl chloride (0.098 g, 0.422 mmol) inanhydrous THF (0.4 mL) was added to a mixture of 6k (0.113 g, 0.356mmol), and NaHCO₃ (0.066 g, 0.785 mmol) in anhydrous THF (0.3 mL) atroom temperature under argon overnight. The reaction mixture wasquenched by the addition of NaHCO₃ (aq, sat, 5 mL) and extracted withEtOAc (5 mL). The organic layer was then washed HCl (aq., 1 M, 5 mL),separated, dried (Na₂SO₄) and the solvent removed under reducedpressure. Chromatography afforded 30c as a yellow oil (0.100 g, 0.194mmol, 54%). ¹H NMR (400 MHz, CDCl₃) δ 10.68 (s, 1H), 7.42 (s, 1H),7.34-7.26 (m, 3H), 7.14-7.09 (m, 1H), 6.97-6.84 (m, 4H), 6.80-6.71 (m,5H), 4.99 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.82 (s, 3H). HRMS(ESI+ve) m/z 514.1863 [M+H]⁺ (calcd for C₃₀H₂₈NO₇ 514.1860).

Methyl 5-(N-(4-chlorobenzyl)-4-phenoxybenzamido)-2-hydroxybenzoate (19d)

This was prepared as a yellow oil (0.251 g, 0.515 mmol, 86%) from 6d(0.174 g, 0.597 mmol) and 4-phenoxybenzoyl chloride (0.152 g, 0.655mmol) in the same manner as described for 19g. ¹H NMR (400 MHz, CDCl₃) δ10.69 (s, 1H), 7.42 (d, J=2.6 Hz, 1H), 7.36-7.18 (m, 8H), 7.15-7.08 (m,1H), 6.94-6.92 (m, 2H), 6.89 (dd, J=8.8, 2.5 Hz, 1H), 6.78-6.75 (m, 3H),5.02 (s, 2H), 3.90 (s, 3H). HRMS (ESI+ve) m/z calculated for C₂₈H₂₃ClNO₅(M+H)⁺488.1259, found 488.1261.

Methyl 5-(N-(4-bromobenzyl)-4-phenoxybenzamido)-2-hydroxybenzoate (19e)

This was prepared as a yellow oil (0.326 g, 0.612 mmol, 74%) from 6j(0.279 g, 0.830 mmol) and 4-phenoxybenzoyl chloride (0.222 g, 0.956mmol) in the same manner as described for 19g. ¹H NMR (400 MHz, CDCl₃) δ10.69 (s, 1H), 7.43-7.39 (m, 3H), 7.35-7.27 (m, 4H), 7.18-7.08 (m, 3H),6.95-6.92 (s, 2H), 6.89 (dd, J=8.8, 2.7 Hz, 1H), 6.7-6.75 (m, 3H), 5.01(s, 2H), 3.90 (s, 3H). HRMS (ESI+ve) m/z calculated for C₂₈H₂₃BrNO₅(M+H)⁺532.0754, found 532.0674.

Methyl 5-(N-(4-heptylbenzyl)-4-phenoxybenzamido)-2-hydroxybenzoate (19f)

To amine 6i (0.100 g, 0.282 mmol) in CH₂Cl₂ (2 ml) was added4-phenoxybenzoic acid (0.062 g, 0.294 mmol) and Ph₃PCl₂ (0.225 g, 0.677mmol) under argon atmosphere. The mixture was heated at 80° C. in amicrowave reactor (Biotage) for 1 h. The reaction was cooled to roomtemperature, diluted with CH₂Cl₂ and washed with sat. NaHCO₃. Theorganic fractions were dried (Na₂SO₄) and evaporated in vacuo. The crudemixture was purified by column chromatography to afford the amide 19f(0.130 g, 84%). ¹H NMR (400 MHz, CDCl₃) δ 10.67 (s, 1H), 7.44 (d, J=2.3Hz, 1H), 7.36-7.25 (m, 4H), 7.17 (d, J=8.0 Hz, 2H), 7.13-7.07 (m, 3H),6.97-6.86 (m, 3H), 6.67-6.72 (m, 3H), 5.03 (s, 2H), 3.89 (s, 3H),2.63-2.39 (m, 2H), 1.60-1.59 (m, 2H), 1.34-1.20 (m, 8H), 0.96-0.75 (m,3H).

Methyl 5-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)-2-hydroxybenzoate(19g)

4-Phenoxybenzoyl chloride (0.106 g, 0.456 mmol) was added to a mixtureof 6b (0.130 g, 0.383 mmol) and NaHCO₃ (0.106 g, 1.26 mmol) in anhydrousTHF (1.5 mL) at room temperature under Argon. After stirring at roomtemperature overnight, the reaction mixture was quenched with water (20mL) and extracted with AcOEt (20 mL). The organic layer was then washedwith water (20 mL), HCl (aq., 1M, 20 mL), separated, dried (Na₂SO₄),filtered and the solvent removed under reduced pressure. Chromatography(SiO₂) afforded 19g as a yellow oil (0.201 g, 0.375 mmol, 98%). ¹H NMR(400 MHz, CDCl₃) δ 10.67 (s, 1H), 7.43 (d, J=2.9 Hz, 1H), 7.36-7.27 (m,4H), 7.18 (d, J=8.0 Hz, 2H), 7.16-7.08 (m, 4H), 7.04-6.99 (m, 1H), 6.94(d, J=9.6 Hz, 2H), 6.75 (t, J=8.9 Hz, 2H), 5.02 (s, 2H), 3.88 (s, 3H),2.50-2.40 (m, 1H), 1.87-1.68 (m, 5H), 1.14-1.35 (m, 4H), 1.27-2.21 (m,1H). HRMS (ESI+ve) m/z calculated for C₃₄H₃₅NO₅ (M+H)⁺536.2431, found536.2415.

Methyl 5-(N-(4-heptylbenzyl)benzamido)-2-hydroxybenzoate (19h)

This was prepared as a yellow oil (0.052 g, 0.119 mmol, 42%) from 6i(0.097 g, 0.284 mmol) and 4-phenoxybenzoyl chloride (0.044 g, 0.293mmol) in the same manner as described for 19g. ¹H NMR (400 MHz, CDCl₃) δ10.63 (s, 1H), 7.42 (s, 1H), 7.31-7.28 (m, 2H), 7.25-7.16 (m, 5H), 7.09(d, J=8.0 Hz, 2H), 6.87 (s, 1H), 6.70 (d, J=8.6 Hz, 1H), 5.00 (s, 2H),3.88 (s, 3H), 2.56 (t, J=7.5 Hz, 2H), 1.31-1.25 (m, 10H), 0.87 (t, J=6.8Hz, 3H). HRMS (ESI+ve) m/z calculated for C₂₉H₃₄NO₄ (M+H)⁺460.2432,found 460.2503.

Methyl 5-(N-(4-heptylbenzyl)-3-methoxybenzamido)-2-hydroxybenzoate (19i)

This was prepared as a yellow oil (0.062 g, 0.130 mmol, 38%) from 6i(0.118 g, 0.345 mmol) and 3-methoxybenzoylchloride (0.064 g, 0.378 mmol)in the same manner as described for 19g. ¹H NMR (400 MHz, CDCl₃) δ 10.65(s, 1H), 7.42 (s, 1H), 7.17 (d, J=7.9 Hz, 2H), 7.11-7.03 (m, 3H),6.96-6.68 (m, 5H), 5.02 (s, 2H), 3.88 (s, 3H), 3.69 (s, 3H), 2.56 (t,J=7.6 Hz, 2H), 1.31-1.25 (m, 10H), 0.87 (t, J=7.1 Hz, 3H). HRMS (ESI+ve)m/z calculated for C₃₀H₃₆NO₅ (M+H)⁺490.2588, found 490.2580.

Methyl 5-(N-(4-heptylbenzyl)isonicotinamido)-2-hydroxybenzoate (19j)

This was prepared as a yellow oil (0.083 g, 0.180 mmol, 53%) from 6i(0.115 g, 0.337 mmol) and isonicotinoyl chloride hydrochloride (0.072 g,0.404 mmol) in the same manner as described for 19g. ¹H NMR (400 MHz,CDCl₃) δ 10.70 (s, 1H), 8.47 (s, 2H), 7.35 (d, J=2.7 Hz, 1H), 7.18-7.13(m, 4H), 7.10 (d, J=8.1 Hz, 2H), 6.87 (dd, J=8.7, 2.3 Hz, 1H), 6.74 (d,J=8.9 Hz, 1H), 5.01 (s, 2H), 3.88 (s, 3H), 2.55 (t, J=7.0 Hz, 2H),1.35-1.18 (m, 10H), 0.86 (t, J=7.1 Hz, 3H). HRMS (ESI+ve) m/z calculatedfor C₂₈H₃₃N₂O₄ (M+H)⁺461.2434, found 461.2419.

Methyl 5-(N-(4-heptylbenzyl)picolinamido)-2-hydroxybenzoate (19k)

This was prepared as a yellow oil (0.037 g, 0.080 mmol, 30%) from 6i(0.065 g, 0.269 mmol) and picolinoyl chloride hydrochloride (0.057 g,0.320 mmol) in the same manner as described for 19g. ¹H NMR (400 MHz,CDCl₃) δ 10.63 (s, 1H), 8.32 (s, 1H), 7.63-7.54 (m, 1H), 7.48-7.38 (m,2H), 7.20 (d, J=7.8 Hz, 2H), 7.12-7.07 (m, 4H), 6.91 (dd, J=9.3, 1.9 Hz,1H), 6.66 (d, J=8.9 Hz, 1H), 5.05 (s, 2H), 3.85 (s, 3H), 2.56 (t, J=7.8Hz, 2H), 1.28-1.24 (m, 10H), 0.86 (t, J=7.1 Hz, 3H). HRMS (ESI+ve) m/zcalculated for C₂₈H₃₃N₂O₄ (M+H)⁺461.2434, found 461.2434.

Methyl 5-(N-(4-heptylbenzyl)nicotinamido)-2-hydroxybenzoate (191)

This was prepared as a yellow oil (0.060 g, 0.130 mmol, 40%) from 6i(0.110 g, 0.322 mmol) and nicotinoyl chloride (0.057 g, 0.403 mmol) inthe same manner as described for 19g. ¹H NMR (400 MHz, CDCl₃) δ 10.69(s, 1H), 8.53 (s, 1H), 7.63 (d, J=7.8 Hz, 1H), 7.41 (s, 1H), 7.15-7.08(m, 5H), 7.09 (d, J=7.9 Hz, 2H), 6.86 (d, J=8.7 Hz, 1H), 6.73 (d, J=8.8Hz, 1H), 5.02 (s, 2H), 3.87 (s, 3H), 2.55 (t, J=7.9 Hz, 2H), 1.27-1.24(m, 10H), 0.86 (t, J=6.8 Hz, 3H). HRMS (ESI+ve) m/z calculated forC₂₈H₃₃N₂O₄ (M+H)⁺461.2434, found 461.2431.

Compounds 20

5-(N-Benzyl-4-phenoxybenzamido)-2-hydroxybenzoic acid (20a)

This was prepared as a white solid (0.155 g, 0.353 mmol, 92%) from 19a(0.174 g, 0.384 mmol) in the same manner as described for 20g. m.p.>191°C. (dec.). ¹H NMR (400 MHz, CD₃OD) δ 7.46 (d, J=2.2 Hz, 1H), 7.37-7.19(m, 9H), 7.15-7.08 (m, 1H), 6.98 (dd, J=8.7, 2.4 Hz, 1H), 6.91 (d, J=8.4Hz, 2H), 6.78 (d, J=8.6 Hz, 2H), 6.68 (d, J=8.8 Hz, 1H), 5.09 (s, 2H).HPLC purity 96.6% {t_(R)=3.97 min, flow 1 ml/min, [(CH₃CN/(0.1% TFA inH₂O):70/30]}. HRMS (ESI−ve) m/z calculated for C₂₇H₂₀NO₅ (M−H)⁻438.1347, found 438.1349.

2-Hydroxy-5-(N-(4-methoxybenzyl)-4-phenoxybenzamido)benzoic acid (20b)

This was prepared from 19b (0.097 g, 0.200 mmol) in the same manner asdescribed for 20g. The crude product was slurried with methanol (1 mL),filtered and dried under vacuum to afford pure 20b as a white solid(0.035 g, 0.074 mmol, 37%). m.p. 187-189° C. ¹H NMR (400 MHz, CD₃OD) δ7.42-7.25 (m, 5H), 7.18 (d, J=8.3 Hz, 2H), 7.12 (t, J=7.4 Hz, 1H), 7.06(dd, J=8.8, 2.7 Hz, 1H), 6.91 (d, J=8.0 Hz, 2H), 6.86-6.81 (m, 2H),6.79-6.73 (m, 3H), 5.02 (s, 2H), 3.75 (s, 3H). HPLC purity 97.3%{t_(R)=2.733 min, flow 1 ml/min, [(CH₃CN/(0.1% TFA in H₂O):70/30]}. HRMS(ESI−ve) m/z calculated for C₂₈H₂₂NO₆ (M−H)⁻ 468.1452, found 468.1451.

2-Hydroxy-5-(N-(3,4-dimethoxybenzyl)-4-phenoxybenzamido)benzoic acid(20c)

A mixture of 19c (0.081 g, 0.157 mmol) in THF (1 mL) and sodiumhydroxide (aq. 1 M, 1 mL) was heated at 70° C. in a sealed tubeovernight. The solvent was then removed under reduced pressure.Hydrochloric acid (aq. 1 M, 2 mL) was added to the mixture which wasthen extracted with EtOAc (2×5 mL). The organic extracts were combined,dried (Na₂SO₄), filtered and the solvent removed under reduced pressureto provide 13c as a white solid (0.053 g, 0.106 mmol, 68%). ¹H NMR (400MHz, CD₃OD) δ 7.54 (s, 1H), 7.37-7.26 (m, 4H), 7.16-7.05 (m, 1H),6.96-6.87 (m, 3H), 6.86-6.70 (m, 5H), 6.58 (d, J=8.6 Hz, 1H), 5.01 (s,2H), 3.78 (s, 3H), 3.75 (s, 3H); HRMS (ESI+ve) m/z 500.1683 [M+H]⁺(calcd for C₂₉H₂₆NO₇ 500.1704); HPLC purity 97% {t_(R)=8.5 min, flow 1ml/min, [CH₃CN:(0.1% TFA in H₂O), 50:50]}.

5-(N-(4-Chlorobenzyl)-4-phenoxybenzamido)-2-hydroxybenzoic acid (20d)

This was prepared as a white solid (0.060 g, 0.126 mmol, 73%) from 19d(0.084 g, 0.172 mmol) in the same manner as described for 20g.m.p. >150° C. (dec.). ¹H NMR (400 MHz, CD₃OD) δ 7.42 (d, J=2.4 Hz, 1H),7.35-7.26 (m, 8H), 7.14-7.07 (m, 2H), 6.92 (d, J=8.3 Hz, 2H), 6.80-6.75(m, 3H), 5.08 (s, 2H). HPLC purity 95.2% {t_(R)=3.27 min, flow 1 ml/min,[(CH₃CN/(0.1% TFA in H₂O):70/30]}. HRMS (ESI−ve) m/z calculated forC₂₇H₁₉ClNO₅ (M−H)⁻ 472.0957, found 472.0955.

5-(N-(4-Bromobenzyl)-4-phenoxybenzamido)-2-hydroxybenzoic acid (20e)

This was prepared as a white solid (0.105 g, 0.202 mmol, 87%) from 19e(0.125 g, 0.234 mmol) in the same manner as described for 20g.m.p. >198° C. (dec.). ¹H NMR (400 MHz, CD₃OD) δ 7.46-7.43 (m, 3H),7.35-7.33 (m, 4H), 7.22 (d, J=8.3 Hz, 2H), 7.14-7.10 (m, 1H), 7.01 (dd,J=8.5, 2.6 Hz, 1H), 6.92 (d, J=7.8 Hz, 2H), 6.78 (d, J=8.6 Hz, 2H), 6.72(d, J=8.7 Hz, 1H), 5.06 (s, 2H). HPLC purity 95.3% {t_(R)=3.39 min, flow1 ml/min, [(CH₃CN/(0.1% TFA in H₂O):70/30]}. HRMS (ESI−ve) m/zcalculated for C₂₇H₁₉BrNO₅ (M−H)⁻ 516.0452, found 516.0455.

5-(N-(4-heptylbenzyl)-4-phenoxybenzamido)-2-hydroxybenzoic acid (20f)

This was prepared from 19f (0.050 g g, 0.090 mmol) in the same manner asdescribed for 20g. ¹H NMR (400 MHz, DMSO-d₆) δ 7.40-7.33 (m, 2H),7.30-7.28 (m, 3H), 7.15-7.11 (m, 3H), 7.09-7.05 (m, 3H), 6.94 (d, J=8.6Hz, 2H), 6.80 (d, J=8.6 Hz, 2H), 6.67 (d, J=8.7 Hz, 1H), 4.97 (s, 2H),1.61-1.42 (m, 2H), 1.22 (d, J=8.2 Hz, 10H), 0.9-0.70 (m, 3H). HPLCpurity 99.8% {t_(R)=10.460 min, flow 1 ml/min, [(CH₃CN/(0.1% TFA inH₂O):80/20]}. HRMS (ESI−ve) m/z calculated for C₃₄H₃₆NO₅ (M+H)+538.2580,found 538.2595.

5-(N-(4-Cyclohexylbenzyl)-4-phenoxybenzamido)-2-hydroxybenzoic acid(20g)

A mixture of 19g (0.160 g, 0.299 mmol) in THF (1 mL) and sodiumhydroxide (aq. 1 M, 1 mL) was heated at 70° C. in a sealed tube for 7 h.The solvent was then removed under reduced pressure. The resulting solidwas slurried in HCl (aq. 1 M, 10 mL), filtered, washed with HCl (aq. 1M, 5 mL), water (10 mL) and dried under vacuum to afford 20g as a whitesolid (0.139 g, 0.261 mmol, 90%). m.p.>208° C. (dec.). ¹H NMR (400 MHz,CD₃OD) δ 7.47 (d, J=1.7 Hz, 1H), 7.37-7.26 (m, 4H), 7.19 (d, J=8.1 Hz,2H), 7.13-7.09 (m, 3H), 6.91 (d, J=8.0 Hz, 3H), 6.77 (d, J=8.6 Hz, 2H),6.65 (d, J=8.7 Hz, 1H), 5.04 (s, 2H), 2.49-2.44 (m, 1H), 1.88-1.17 (m,5H), 1.43-1.38 (m, 4H), 1.32-1.21 (m, 1H). HPLC purity 98.3% {t_(R)=6.28min, flow 1 ml/min, [(CH₃CN/(0.1% TFA in H₂O):80/20]}. HRMS (ESI−ve) m/zcalculated for C₃₃H₃₀NO₅ (M−H)⁻ 520.2129, found 520.2130.

5-(N-(4-Heptylbenzyl)benzamido)-2-hydroxybenzoic acid (20h)

The ester 19h (0.045 g, 0.101 mmol) in THF (1 mL) and NaOH (aq. 1 M, 1mL) were heated at 70° C. overnight in a sealed tube. The solvent wasthen removed under reduced pressure. The resulting solid was slurried inHCl (aq. 1M, 2 mL), filtered, water (3 mL) and dried under vacuum toafford pure 20h as a white solid (0.039 g, 0.090 mmol, 89%). m.p.142.8-143.6° C. ¹H NMR (400 MHz, CD₃OD) δ 7.38 (s, 1H), 7.35-7.13 (m,7H), 7.11 (d, J=8.0 Hz, 2H), 7.01 (s, 1H), 6.67 (d, J=8.8 Hz, 1H), 5.06(s, 2H), 2.55 (t, J=6.4 Hz, 2H), 1.70-1.51 (m, 2H), 1.40-1.14 (m, 8H),0.88 (t, J=7.1 Hz, 3H). HPLC purity 96.6% {t_(R)=15.55 min, flow 1ml/min, [(CH₃CN/(0.1% TFA in H₂O):70/30]}. HRMS (ESI−ve) m/z calculatedfor C₂₈H₃₀NO₄ (M−H)⁻ 444.2180, found 444.2187.

5-(N-(4-Heptylbenzyl)-3-methoxybenzamido)-2-hydroxybenzoic acid (20i)

This was prepared as a white solid (0.046 g, 0.099 mmol, 81%) from 19i(0.058 g, 0.122 mmol) in the same manner as described for 20h. m.p. >81°C. (dec.). ¹H NMR (400 MHz, CD₃OD) δ 7.33 (s, 1H), 7.14-7.04 (m, 8H),6.83-6.80 (m, 4H), 5.03 (s, 2H), 3.66 (s, 3H), 2.56 (t, J=7.6 Hz, 2H),1.59-1.53 (m, 2H), 1.29-1.26 (m, 8H), 0.87 (t, J=6.9 Hz, 3H). HPLCpurity 99.3% {t_(R)=11.73 min, flow 1 ml/min, [(CH₃CN/(0.1% TFA inH₂O):70/30]}. HRMS (ESI−ve) m/z calculated for C₂₉H₃₂NO₅ (M−H)⁻474.2286, found 474.2277.

5-(N-(4-Heptylbenzyl)isonicotinamido)-2-hydroxybenzoic acid (20j)

This was prepared from 19j (0.079 g, 0.182 mmol) in the same manner asdescribed for 20h. The solvent was then removed under reduced pressure.The obtained solid was slurried in citric acid (aq. sat., 10 mL),filtered, water (2×5 mL) and dried under vacuum to afford 20j as ayellow solid (0.067 g, 0.154 mmol, 85%). m.p. 157.3-158.9° C. ¹H NMR(400 MHz, CD₃OD) δ 8.42 (s, 2H), 7.41 (d, J=2.7 Hz, 1H), 7.32 (d, J=5.0Hz, 2H), 7.18 (d, J=8.0 Hz, 2H), 7.12 (d, J=7.9 Hz, 2H), 7.06 (dd,J=8.8, 2.8 Hz, 1H), 6.70 (d, J=8.8 Hz, 1H), 5.05 (s, 2H), 2.57 (t, J=7.7Hz, 2H), 1.59-1.55 (m, 2H), 1.35-1.18 (m, 8H), 0.88 (t, J=6.7 Hz, 3H).HPLC purity 97.8% {t_(R)=4.23 min, flow 1 ml/min, [(CH₃CN/(0.1% TFA inH₂O):70/30]}. HRMS (ESI−ve) m/z calculated for C₂₇H₂₉N₂O₅ (M−H)⁻445.2132 found 445.2134.

5-(N-(4-Heptylbenzyl)picolinamido)-2-hydroxybenzoic acid (20k)

This was obtained as a yellow solid (0.027 g, 0.062 mmol, 87%) from 19k(0.045 g, 0.101 mmol) in the same manner as described for 20j. m.p.required ¹H NMR (400 MHz, CD₃OD) δ 8.35 (s, 1H), 7.71 (t, J=7.7 Hz, 1H),7.42-7.38 (m, 2H), 7.26 (s, 1H), 7.21 (d, J=7.7 Hz, 2H), 7.11 (d, J=7.8Hz, 2H), 7.05 (d, J=9.3 Hz, 1H), 6.64 (d, J=8.9 Hz, 1H), 5.07 (s, 2H),2.57 (t, J=7.7 Hz, 2H), 1.51-1.53 (m, 2H), 1.30-1.26 (m, 8H), 0.88 (t,J=6.6 Hz, 3H). HPLC purity 98.8% {t_(R)=8.72 min, flow 1 ml/min,[(CH₃CN/(0.1% TFA in H₂O):70/30]}. HRMS (ESI−ve) m/z calculated forC₂₇H₂₉N₂O₅ (M−H)⁻ 445.2132, found 445.2133.

5-(N-(4-Heptylbenzyl)nicotinamido)-2-hydroxybenzoic acid (201)

This was obtained as a yellow solid (0.027 g, 0.062 mmol, 37%) from 191(0.050 g, 0.111 mmol) in the same manner as described for 20j. ¹H NMR(400 MHz, CD₃OD) δ 8.46 (s, 1H), 7.76 (d, J=9.7 Hz, 1H), 7.43 (s, 1H),7.32 (s, 1H), 7.18 (d, J=7.7 Hz, 2H), 7.11 (d, J=8.1 Hz, 2H), 7.06 (d,J=7.8 Hz, 1H), 6.71 (d, J=8.6 Hz, 1H), 5.07 (s, 2H), 2.56 (t, J=7.6 Hz,2H), 1.64-1.52 (m, 2H), 1.34-1.23 (m, 8H), 0.88 (t, J=6.8 Hz, 3H). HPLCpurity 97.0% {t_(R)=5.283 min, flow 1 ml/min, [(CH₃CN/(0.1% TFA inH₂O):70/30]}. HRMS (ESI−ve) m/z calculated for C₂₇H₂₉N₂O₅ (M−H)⁻445.2132, found 445.2132.

Synthesis of Carboxylic Acid 33

Methyl 4-(4-cyclohexylbenzylamino)-2-hydroxybenzoate (31)

To a solution of methyl 4-amino-2-hydroxybenzoate (0.283 g, 1.69 mmol)and 4-cyclohexylbenzaldehyde (0.318 g; 1.68 mmol) in AcOH (1 M in1,2-dichloroethane, 1.68 mL) was added NaBH(OAc)₃ (0.508 g; 2.39 mmol)in one portion and the reaction mixture was stirred at room temperaturefor 48 h. Water (10 mL) was added and the mixture neutralized usingNaHCO₃ (sat. aq., 10 mL). The organic layer was extracted with DCM (2×10mL), dried and evaporated. Chromatography afforded the ester 31 (0.191g, 33%) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 10.99 (s, 1H), 7.59(d, J=9.3 Hz, 1H), 7.25 (d, J=7.2 Hz, 2H), 7.19 (d, J=8.2 Hz, 2H),6.14-6.08 (m, 1H), 4.47 (t, J=5.4 Hz, 1H), 4.30 (d, J=5.3 Hz, 2H), 3.87(s, 3H), 2.55-2.43 (m, 1H), 1.90-1.68 (m, 5H), 1.49-1.17 (m, 6H); HRMS(ESI+ve) m/z 340.1902 [M+H]⁺ (calcd for C₂₁H₂₆NO₃ 340.1907).

Methyl 4-(N-(4-cyclohexylbenzyl)-4-phenoxybenzamido)-2-hydroxybenzoate(32)

This was prepared from 31 (0.093 g, 0.274 mmol) and 4-phenoxybenzoylchloride (0.083 g, 0.357 mmol) in the same manner as described for 30c.Chromatography afforded pure 32 as a colorless oil (0.035 g, 0.065 mmol,24%). ¹H NMR (400 MHz, CDCl₃) δ 10.77 (s, 1H), 7.59 (d, J=8.6 Hz, 1H),7.38 (d, J=8.8 Hz, 2H), 7.35-7.31 (m, 1H), 7.22 (d, J=8.1 Hz, 2H),7.14-7.11 (m, 3H), 7.00-6.93 (m, 2H), 6.79 (d, J=8.8 Hz, 2H), 6.66 (d,J=2.1 Hz, 1H), 6.42 (dd, J=8.6, 2.2 Hz, 1H), 5.09 (s, 2H), 3.90 (s, 3H),2.63-2.35 (m, 1H), 1.89-1.65 (m, 5H), 1.48-1.08 (m, 6H); HRMS (ESI+ve)m/z 558.2277 (M+Na)⁺ (calcd for C₃₄H₃₄NO₅ 558.2251).

4-(N-(4-Cyclohexylbenzyl)-4-phenoxybenzamido)-2-hydroxybenzoate (33)

This was prepared from 32 (0.033 g, 0.061 mmol) in the same manner asdescribed for 13c as a white solid oil (0.025 g, 0.047 mmol, 77%). ¹HNMR (400 MHz, CD₃OD) δ 7.65 (d, J=8.4 Hz, 1H), 7.42-7.32 (m, 4H), 7.21(d, J=8.1 Hz, 2H), 7.17-7.08 (m, 3H), 6.99-6.89 (m, 2H), 6.80 (d, J=8.8Hz, 2H), 6.55 (d, J=2.0 Hz, 1H), 6.50 (d, J=2.0 Hz, 1H), 5.10 (s, 2H),2.63-2.35 (m, 1H), 2.011.75 (m, 5H), 1.49-1.09 (m, 6H); HRMS (ESI+ve)m/z 522.2264 [M+H]+(calcd for C₃₃H₃₂NO₅ 522.2275); HPLC purity 97%{t_(R)=6.51 min, flow 1 ml/min, [(MeCN:(0.1% TFA in H₂O), 80:20]}.

Generation of HA-STAT3 and FLAG-STAT3 Constructs and Generation ofHEK293 Cells Stably Expressing HA-STAT3 and FLAG-STAT3

FLAG-Stat3 plasmid was obtained from Addgene (Cambridge, Mass., USA).HA-Stat3 DNA was amplified from FLAG-Stat3 using PCR with HA-pcDNA3 as avector as described for RhoB. The primers used for PCR were STAT3F-BamH1CGCGGATCCGCCACCATGGCTCAGTGGAACCAGCTG (SEQ ID NO:1) and STAT3R-EcoRICCGGAATTCTCACATGGGGGAGGTAGCACA (SEQ ID NO:2). The PCR product wasdigested with BamH1 and EcoR1, and cloned into HA-pcDNA3 vector, furtherconfirmed by sequencing. Ratio (1:1) of pFLAGSTAT3 and pHA-STAT3 plasmidDNAs were co-transfected into HEK-293 cells, and stable G418-resistant(800 μg/ml) clones were selected. Transfections were carried out withLipofectAmine Plus (Invitrogen, Carlsbad, Calif.), according to themanufacturers protocol.

Nuclear Extract Preparation and STAT3 Filter Plate Assay

Nuclear extract preparation was carried out as described in Yu, et al.,Science 1995; 269(5220):81-83. The STAT3-DNA binding filter plate assaywas performed following the manual of the filter plate assay kit(Signosis, Sunnyvale, Calif.), as described for NFkB (Ying, et al.,Blood 2011; 117(4):1301-1307). The TF Binding buffer was mixed with theSTAT3 probe (biotin labeled STAT3 DNA binding sequence) and nuclearextract and incubated at 16° C. for 30 minutes to form the STAT3-DNAcomplex. The STAT3-DNA complex was then separated from free probe byusing a filter plate. After several steps of binding and washing, boundSTAT3 probe is retained on the filter in the corresponding well of FilerPlate and the free DNA probe is removed. The bound pre-labeled STAT3probe was then eluted from the filter plate by centrifuge with elutionbuffer. Eluted probes were then hybridized into 96-well HybridizationPlate for quantitative analysis. The captured STAT3 probe was furtherdetected by conjugation with streptavidin-HRP. The chemiluminescence ofeach well was detected by 2104 EnVisionR Multilabel Reader ofPerkinElmer (Pekin Elmer, Waltham, Mass., USA) within 5 minutes aftermixture with substrates.

Fluorescence Polarization Assay

Fluorescence polarization (FP) assay was conducted based on fluorescencesignal differences between free and STAT3-bound fluorescently labeledpeptide as described by Schust and Berg (Anal. Biochem. 2004;330(1):114-118; Chem. Biol. 2006; 13(11):1235-1242). All reactionscontained 10 nM of the fluorescent peptide 5-FAM-G(pTyr) LPQTV-CONH₂(Genscript, Piscataway, N.J., USA) and 100 nM GST-tagged, full-lengthhuman STAT3 protein (SignalChem, Richmond, BC, Canada) in 96-wellhalf-area black plates (Corning, Tewksbury, Mass., USA). For evaluatingcompounds, STAT3 protein was incubated with various concentrations ofS3I-1757 or S3I-1756 at room temperature for 60 min in the assay buffer(50 mM NaCl, 10 mM Hepes, pH 7.5, 1 mM EDTA, 0.01% Triton-X100, 2 mMdithiothreitol). Fluorescent peptide was added at a final concentrationof 10 nM and incubated for 30 min at room temperature following whichthe FP measurements were examined by 2104 EnVisionR Multilabel Reader(Pekin Elmer, Waltham, Mass., USA) using FITC FP Dual module withexcitation filter of FITC FP 480 and emission filter of FITC FP P-pol535and S-pol535. The Z′ value was derived per the equationZ′=1-(3SD_(bound)+3SD_(free))/(mP_(bound)-mP_(free)), where SD is thestandard deviation and mP is the average of fluorescence polarization.

STAT3 Transcriptional Activity

MDA-MB-468 cells were plated into 12-well plate with 4×10⁵ cells perwell. The cells were transiently transfected with pLucSRE, pLucTKS3 orSTAT3-C with β-gal and then were treated with vehicle, S3I-1756 orS3I-1757 for 48 hours. Then cytosolic extracts of equal total proteinwere prepared from S3I-1757-treated or -untreated and analyzed forluciferase activity using a TD-20/20 luminometer (Turner Designs,Sunnyvale, Calif., USA) described by us previously.

Co-Localization

HEK-293/FLAG-Stat3/HA-Stat3 cells were cultured (4000 cells per well)with G418 400 ug/ml in 8 well chamber slide. The cells were treated withS3I-1757 or S3I-1756 for 1 hour, 2 hours, or 4 hours. The cells werethen rinsed with phosphate buffered saline (PBS), fixed with ice-coldmethanol for 15 minutes, washed 3 times in PBS, permeabilized with 0.2%Triton X-100 for 15 minutes, and further washed 3-4 times with PBS.Cells were then blocked in 1% bovine serum albumin (BSA) for 30 min andincubated with anti-HA (Santa Cruz, Santa Cruz, Calif., USA) oranti-FLAG (Sigma, St. Louis, Mo., USA) primary antibody at 1:100dilution at 4° C. overnight. Subsequently, cells were rinsed 4-5 timesin PBS, incubated with Alexa fluor secondary antibody (Invitrogen,Carlsbad, Calif., USA) for 1 hour at room temperature in the dark. Cellswere then washed 5 times with PBS, covered with cover slides withVECTASHIELD mounting medium containing DAPI (Vector Lab, Inc.,Burlingame, Calif.), and examined immediately under Zeiss UprightFluorescence Microscope (Zeiss, Thornwood, N.Y., USA).

STAT3 Nuclear Accumulation

MDA-MB-468 cells were plated at 4000 cells/well in 8-chamber slide. Thecells were treated the following day with Vehicle, S3I-1756 or S3I-1757for 2 hours, 4 hours, or 18 hours. Cells were fixed, washed, andpermeabilized as describe above. Specimens were then blocked in 1%bovine serum albumin (BSA) for 30 min and incubated with anti-pSTAT3(Cell Signaling), antibody at 1:50 dilution at 4° C. overnight.Subsequently, cells were rinsed 4-5 times in PBS, incubated with AlexaFluor secondary antibody for 1 hour at room temperature in the dark.Specimens were then washed 5 times with PBS, covered with cover slideswith VECTASHIELD mounting medium containing DAPI (Vector Lab, Inc.,Burlingame, Calif.), and examined immediately under Zeiss UprightFluorescence Microscope (Zeiss, Thornwood, N.Y., USA).

MTT Assay

MTT assay was performed exactly as described by Balasis, et al., Clin.Cancer Res. 2011; 17(9):2852-2862, to determine the effects of S3I-1757on cell proliferation. Cells were plated in a 96 well tissue cultureplate (2000 cells per well) and incubated for 12 hours. After incubationthe cells were treated with vehicle S3I-1757 or S3I-1756 for 48 hours.After incubation, freshly prepared MTT (3 mg/ml) in 1×PBS was added toeach well and incubated for 3 hours and the plate was read at 570 nm.

Colony Survival Assay

Cells were cultured at 500 cells per well in 12-well plate with regulargrowth medium. Cells were treated by vehicle, and 1757 at 50 μM, 100 μMand 200 μM on the following day. And Cells were allowed to grow for 2-3weeks until the colonies were visible. 3 mg/ml MTT in PBS buffer (Sigma,St. Louis, Mo., USA) was used to stain the colonies for 4 hours.

Wound Healing Assay

A549, MDA-MB-231 and H460 cells were seeded at 6×10⁵ cells per dish into60 mm plate and allowed to grow overnight. Wounds were made thefollowing day by scratching the cells with pipette tips (1-10 μL). Cellswere treated with vehicle, S3I-1756 or S3I-1757 and allowed to migrateinto the scratched area for 16 hours in regular growth medium. Themigration of cells was visualized at 10× magnification using a LeicaMicroscope at time 0 (right before the drug was added) and 16 hoursafter vehicle, S3I-1756, or S3I-1757 treatments.

Invasion Assay

Invasion assay was performed in BD BioCoat™ Matrigel® Invasion Chamberin 24-well plates. A549, MDA-MB-468, MDA-MB-231 and H460 cells wereseeded at 25,000 cells/insert in the top chamber over the Matrigel. Thebottom chamber contains 20% FBS as the “chemoattractant.” Vehicle,S3I-1756, or S3I-1757 were added the following day. The cells wereincubated for 48 hours, after which the cells in the top chamber werecarefully removed and the filter membranes containing the invaded cellson the outside of the filter were fixed with methanol, stained withcrystal violet and photographed.

Anchorage Independent Growth by Soft Agar Assay

Soft agar colony formation assays were performed in 12-well plate asdescribed in Balasis, et al., Clin. Cancer. Res. 2011; 17(9):2852-2862.Cells were seeded at 2000 cells per well in regular growth mediacontaining 0.3% agar (Sigma) and S3I-1757 was added the following day.Colonies were allowed to grow for 3-4 weeks, and quantified by stainingwith 1 mg/mL MTT (Sigma, St. Louis, Mo., USA) overnight.

Molecular Docking and Modeling

The GLIDE docking software (available from Schrodinger, Inc.) wasemployed to dock small molecule 3D structures from NCI Plated Set to theApY*LK site derived from the X-ray crystal structure of the STAT3 dimerbound to DNA (18). Schrodinger's Maestro 9.1 was used as the primarygraphical user interface. Schrodinger's LigPrep 2.41 was used to preparemolecules for docking and Schrodinger's Protein Preparation workflow wasused in the preparation of the protein structure. Schrodinger's GLIDE5.6 was used for the generation of grid files and docking. Initially,structures were subjected to docking with GLIDE SP and then thestructures from each SP job were subjected to GLIDE XP docking.Generally at least three poses were saved for each run for visualinspection. PyMol (Schrodinger, Inc.) was used for graphicalpresentation of the results in the figures.

Effects of Inhibitors on the Levels of P-STAT3, P-Erk, P-Akt, Bcl-xL,Survivin, MMP9 and Cyclin D1 by Immunoblotting

MDA-MB-468 cells were treated with vehicle (DMSO), S3I-1757 at 50 μM,100 μM and 200 μM, and S3I-1756 at 200 μM for 18 hours. Cells were thenlysed with RIPA buffer (20 mM Tris-HCl (pH 7.4), 5 mM EDTA, 10 mMNa₄P₂O₇, 100 mM NaF, 2 mM Na₃VO₄, 1% NP-40.1 mM PMSF and 10 mg/mlaprotinin). The cell lysates were denatured by boiling with 5×SDS-PAGEsample buffer for 5 minutes and run on SDS-PAGE gel. The proteins werethen transferred to membranes that were blocked with 5% non-fat milk inTris Buffer Saline with 0.1% Tween-20 (TBST) buffer for 30 minutes atroom temperature, and incubated with primary antibodies (pY705STAT3,pAKT, AKT, pERK1/2, MMP9, and CyclinDi) 4° C. overnight at dilution of1:1000 in 3% BSA, followed by washing and incubation with secondaryantibody at dilution of 1:1000 in 5% non-milk Tris Buffer Saline with0.1% Tween-20 (TBST) buffer for 1 hours at room temperature. Themembranes were then washed with 1×PBS buffer for 10 minutes for 3 timesand developed with ECL kit (PerkinElmer, Waltham, Mass., USA).

Immunoprecipitation and Immunoblotting

HEK-293/FLAG-STAT3/HA-STAT3 cells were treated for 4 h with vehicle,S3I-1757, S3I-1756, Ac-G{pTYR}LPQTV-AAVLLPVLLAAP-NH2 (SEQ ID NO:3) orAc-GYLPQTV-AAVLLPVLLAAP-NH₂ (SEQ ID NO:4) and then lysed in 20 mMTris-HCl (pH 7.4), 5 mM EDTA, 10 mM Na₄P₂O₇, 100 mM NaF, 2 mM Na₃VO₄, 1%NP-40.1 mM PMSF and 10 mg/ml aprotinin. For EGF stimulation group,HEK-293/FLAG-STAT3/HASTAT3 cells were treated by 100 ng/ml EGF for 30minutes before making cell lysate. Protein A or G agarose (EMDMillipore, Billerica, Mass., USA) was washed twice with PBS and restoreto 50% slurry with PBS. 500 μg of lysate were pre-cleared by mixture ofprotein A and protein G-agarose for 1 h at 4° C. and then remove proteinA and G-agarose by centrifuge at 1300 rpm for 3 minutes. And then 500 μgof lysate was immunoprecipitated with 50 ng of HA antibody overnight at4° C. on shaker and then capture the immunocomplex by adding 100 μlProtein A and G agarose/sepharose bead slurry for 1 hour at 4° C.Samples were washed five times with lysis buffer and then boiled in5×SDS-PAGE sample buffer and run on SDS-PAGE gel. Protein wastransferred to nitrocellulose membrane and then blotted as describedabove for HA, FLAG, pSTAT3, EGFR, and STAT3.

S3I-1757 Inhibits the Binding of Fluorescein-Labelled GpYLPQTVPhosphotyrosine Peptide to STAT3 Much More Potently than its CloselyRelated Analogue S3I-1756

SAR studies identified several STAT3 inhibitors. Several examples hereinfocus on S3I-1757 and its closely related analogue S3I-1756 (FIG. 5A).The potency of these molecules to disrupt the binding of STAT3 tofluorescein-labelled GpYLPQTV phosphotyrosine peptide by fluorescencepolarization assays was determined (the GpYLPQTV phosphotyrosine peptidecorresponds to amino acids 903-909 from the gp-130 subunit of the IL-6receptor and is known to bind the STAT3-SH2 domain (Haan, et al., J.Biol. Chem. 1999; 274(3):1342-1348; Ren, et al., Bioorg. Med. Chem.Lett. 2003; 13(4):633-636). FIG. 5A shows that S3I-1757 inhibits thebinding of STAT3 to the phosphotyrosine peptide in aconcentration-dependent manner with an IC₅₀ value of 13.5±0.5 μM. Incontrast, the closely related analogue S3I-1756 had little effects withconcentrations as high as 400 μM (FIG. 5A). This data shows thatreplacing the cyclohexyl group in S3I-1757 with a methoxy group as inS3I-1756 resulted in great (over 26-fold) loss of potency to disruptSTAT3 phosphotyrosine-peptide binding.

Molecular Modeling Indicates that S3I-1757 Binds the STAT3-SH2 Domain inthe Same Binding Site where the Native Phosphotyrosine Peptide Binds

To determine the mode of binding of S3I-1757 to the STAT3-SH2 domain,the docking studies disclosed herein were performed. FIG. 5B shows asurface rendering of the SH2 domain of STAT3 with the active analog,S3I-1757, and the inactive analog, S3I-1756, bound based upon GLIDE XPdocking. A ligand-protein interaction diagram is also shown in FIG. 5B.FIG. 5B shows that S3I-1757 occupies the phosphotyrosine binding site ofSTAT3. Furthermore, the salicylic acid group of S3I-1757 interacts withSH2 domain amino acids (i.e. Arg-609 and Lys-591) known to interact withP-Y-705 of STAT3 (Becker, et al., Nature 1998; 394(6689):145-151). Theexperimentally observed greater potency of S3I-1757 compared to S3I-1756is most likely due to a number of factors as illustrated in FIG. 5B: (a)S3I-1757 forms 4 hydrogen bonds (H-bonds between Arg-609 and Glu-612) inthe phospho-tyrosine binding pocket, whereas S3I-1756 only forms 3(H-bonds between Val-637, Arg-609 and Lys 591); (b) S3I-1757 forms 2excellent cation-π interactions with Lys 591 (with an N to phenyl ringcentroid distance of 3.9 A for the salicylate phenyl group and an N tophenyl ring centroid distance of 3.5 A for the phenyl group to which thecyclohexyl substituent is attached); (c) S3I-1756 forms 2 weakercation-π interactions with Lys 591 (with an N to phenyl ring centroiddistance of 4.6 A for the salicylate phenyl group and an N to phenylring centroid 4.5 A for the phenyl group to which the phenoxy group isattached); (d) the surface rendering of the protein in FIG. 5B showsthat the cyclohexyl substituent of S3I-1757 is buried in a pocket with arather negative electrostatic potential whereas the phenoxy substituentof S3I-1756 is similarly buried, although not as deeply and the πelectron system of the phenoxy substituent would not interact favorablywith this negatively charged environment; (e) the methoxy-phenylsubstituent of S3I-1756 is mostly solvent exposed and forms almost nointeractions with the protein.

Co-Immunoprecipitation and Co-Localization Experiments Reveal thatS3I-1757 but not S3I-1756 Disrupts Intracellular STAT3-STAT3Dimerization and STAT3-EGFR Binding

The data from the FP assays of FIG. 5A coupled with the molecularmodeling results of FIG. 5B indicates that S3I-1757 inhibits STAT3dimerization. However, the FP assay only measured the ability ofS3I-1757 to displace the 7 amino acid fluorescein-labelled GpYLPQTVphosphotyrosine peptide from the SH2 domain of STAT3 protein in vitro.Therefore, it was determined if the intracellular reciprocal binding of2 full-length STAT3 proteins is inhibited. To this end, an assay wasdeveloped to measure directly STAT3-STAT3 dimerization in intact cellsby cloning HA-tagged STAT3 and FLAG-tagged STAT3, generating HEK293cells that stably co-express HA-STAT3 and FLAG-STAT3 and using thesecells for coimmunoprecipitation and co-localization. FIG. 6A shows thatFLAG-STAT3 co-immunoprecipitated with HA-STAT3 in HEK293 cells thatco-express FLAG-STAT3 and HA-STAT3 but not in empty vector-transfectedHEK293 cells (Vector). This assay was validated by treating theFLAG-STAT3/HA-STAT3 HEK293 cells with tyrosine phosphorylated ornonphosphorylated GYLPQTV peptide fused to a membrane-translocatingsequence (MTS) to allow cell uptake. FIG. 6A shows that, invehicle-treated cells (V), FLAG-STAT3 co-immunoprecipitated withHA-STAT3, and that treatment with phosphorylated GpYLPQTV (P-Pep) butnot non-phosphorylated GYLPQTV (Pep) inhibited FLAG-STAT3 fromco-immunoprecipitating with HA-STAT3. To determine that the compoundscan inhibit the binding of HA-STAT3 to FLAG-STAT3,HA-STAT3/FLAGSTAT3/HEK293 cells were treated with vehicle (V), S3I-1757or S3I-1756 and the cells were processed for immunoprecipitation with HAantibodies and immunoblotted with FLAG antibodies. FIG. 6A shows that invehicle-treated cells, FLAG-STAT3 co-immunoprecipitated with HA-STAT3,and that treatment with S3I-1757 inhibited the binding of FLAG-STAT3 toHA-STAT3 in a concentration-dependent manner. In contrast, S3I-1756 didnot inhibit this binding with concentrations as high as 200 μM (FIG.6A). It was also shown that S3I-1757 could disrupt the binding ofHA-STAT3 to the EGF receptor since the same STAT3-SH2 domain that isused for STAT3-STAT3 dimerization is also used to bind EGFR onp-Tyr-1068 and p-Tyr-1086 on EGFR. FIG. 6B shows that stimulation ofHA-STAT3/FLAG-STAT3/HEK293 cells with EGF increased the levels of EGFRand P-STAT3 that co-immunoprecipitated with HA-STAT3, and that treatmentof these cells with S3I-1757 inhibited these interactions. These resultsindicate that S3I-1757, and by analogy, the other compounds disclosedherein, is capable of inhibiting STAT3-STAT3 dimerization and STAT3binding to EGFR in intact cells.

HASTAT3/FLAG-STAT3/HEK 293 cells were treated with vehicle, S3I-1757 orS3I-1756 and the cells were processed for immunofluorescence stainingfor FLAG-STAT3 and HA-STAT3 and analyzed by confocal microscopy. Asshown in FIG. 6C, cells treated with vehicle harbored strong yellowcolor indicating co-localization of FLAG-STAT3 and HA-STAT3. Incontrast, cells treated with S3I-1757, but not S3I-1756, demonstratedprogressively less yellow color over time, indicating that thedimerization of FLAG-STAT3 and HA-STAT3 was disrupted.

Therefore, using methods that investigated STAT3 intracellulardimerization with tagged STAT3 proteins, it is demonstrated thatSTAT3-STAT3 protein-protein binding in intact cells was disrupted with asmall molecule designed to disrupt phosphotyrosine binding to STAT3-SH2domain.

S3I-1757 but not S3I-1756 Decreases Phosphotyrosine STAT3 Levels in theNucleus of Human MDAMB-468 Breast Cancer Cells

For STAT3 to regulate the expression of its target genes it needs totranslocate from the cytosol to the nucleus, a process that requiresSTAT3 tyrosine phosphorylation and subsequent STAT3-STAT3 dimerization.The fact that S3I-1757 was able to inhibit EGFR-STAT3 binding andSTAT3-STAT3 protein-protein binding (FIGS. 6A-6C) indicates that itwould also inhibit the levels of tyrosine phosphorylated STAT3 and itsnuclear accumulation. To confirm this is the case, MDA-MB-468 breastcancer cells, which harbor persistently Y-705 phosphorylated STAT3, weretreated with either vehicle, S3I-1757 or S3I-1756 for 2 hours and 4hours and then was subjected to immunofluorescence staining by aspecific p-Tyr-705-STAT3 primary antibody and Alexa Fluor 594 secondaryantibody in medium containing DAPI to stain the nuclei. FIG. 7A showsthat, in vehicle treated cells, pSTAT3 was localized predominantly inthe nucleus. In contrast, the levels of p-STAT3 in the nucleus weredramatically decreased in S3I-1757 treated cells particularly after 4hours of treatment. To determine whether this inhibition is sustainedover a longer period of time, MDA-MB-468 cells were treated with variousconcentrations of S3I-1757 for 18 hours. FIG. 7B shows thatS3I-1757-inhibited P-STAT3 nuclear accumulation in aconcentration-dependent manner starting at 50 μM. In contrast, S3I-1756had little effect with concentrations as high as 200 μM.

Treatment of Human Breast (MDA-MB-468) and Lung (A-549) Cancer Cellswith S3I-1757, but not S3I-1756, Decreases the Amount of Activated STAT3Capable of Binding to DNA

The ability of S3I-1757 to inhibit STAT3-EGFR binding, tyrosinephosphorylation, STAT3-STAT3 dimer formation and nuclear accumulationwould be predicted to result in blocking STAT3-DNA binding activity. Todemonstrate this, MDA-MB-468 and A-549 cells were treated with vehicle,S3I-1757 or S3I-1756 for 1, 2 or 4 hours and collected nuclear extractsfor STAT3-DNA binding activity using a STAT3 filter plate. FIG. 7C showsthat nuclear extracts from vehicle treated cells contained activatedSTAT3 capable of binding the biotin labeled STAT3 DNA binding probe. Incontrast, the nuclear extracts from S3I-1757 treated cells containedless activated STAT3 capable of binding the STAT3 DNA binding probe withthe least amount found after 4 hours of treatment. FIG. 7C also showsthat S3I-1756 did not decrease the amount of STAT3 capable of bindingDNA.

S3I-1757, but not S3I-1756, Inhibits STAT3—but not SRE-DependentTranscriptional Activation: STAT3-C Rescues this Inhibition

The ability of S3I-1757 to inhibit STAT3-dependent transcriptionalactivation was demonstrated using a luciferase reporter assay. To thisend, MDA-MB-468 cells were transiently co-transfected with aSTAT3-responsive promoter-firefly luciferase reporter (pLucTKS3) and3-gal reporter used to normalize the transfection efficacy. To determinethe selectivity of S3I-1757 to suppress STAT3-dependent overSTAT3-independent transcriptional activation, MDA-MB-468 cells were alsoco-transfected with SRE promoter-renilla luciferase reporter (pLucSRE)and β-gal reporter. FIG. 8A shows that, compared to mock transfectedcells, cells transfected with STAT3-responsive reporter (pLucTKS3) hadincreased luciferase activity in the absence of drug treatment. Incontrast, less luciferase activity was observed when the cells weretreated with S3I-1757 but not S3I-1756. S3I-1757 inhibitedSTAT3-dependent but not STAT3-independent transcriptional activity asdemonstrated by the minimal effect it had on SREdriven luciferaseactivity (FIG. 8A). A constitutively-dimerized mutant form of STAT3,STAT3-C, was used to further demonstrate the STAT3-dependence of theinhibition with S3I-1757. STAT3-C spontaneously dimerizes via disulfidebonds in the absence of tyrosine phosphorylation and is therefore notpredicted to be inhibited by a small molecule that is designed to mimicphosphotyrosine binding. FIG. 8A shows that transfection of MDA-MB-468cells with STAT3-C increased the transcriptional activity of theSTAT3—but not the SRE-responsive promoter, and rescued from the S3I-1757inhibition.

S3I-1757 but not S3I-1756 Decreases the Tyrosine Phosphorylation ofSTAT3 Selectively Over the Phosphorylation of Akt and Erk1/2, andDecreases the Expression of Genes that are Transcriptionally-Regulatedby STAT3

FIGS. 5, 6, 7 and 8A demonstrated that S3I-1757 inhibits STAT3dimerization, accumulation of nuclear P-Y705-STAT3, STAT3-DNA bindingand transcriptional activity. The ability of STAT3 to regulate theexpression of its target genes is also affected by S3I-1757. First, itwas confirmed that S3I-1757 inhibits the phosphorylation of STAT3-Y705by western blotting and it was determined whether this is selective. Tothis end, MDA-MB-468 cells were treated with vehicle, S3I-1756 orincreasing concentration of S3I-1757 and processed for western blotting.FIG. 8B shows that S3I-1757, but not S3I-1756, inhibited thephosphorylation of STAT3-Y705 in a concentration dependent mannerstarting at 50 μM. This inhibition was selective for STAT3 over Akt andErk1/2 phosphorylation. FIG. 8B also shows that S3I-1757, but notS3I-1756, inhibited the expression of STAT3 target genes such as theanti-apoptotic proteins Bcl-xL and survivin, the cell cycle proteincyclin D1 and the pro-metastatic protein MMP9.

S3I-1757 but not S3I-1756 Inhibits Anchorage-Dependent and -IndependentGrowth, Migration and Invasion Selectively in Cancer Cells HarboringConstitutively Active STAT3 Over Those that do not.

The data presented in FIGS. 5, 6, 7 and 8 demonstrated that S3I-1757effectively blocks STAT3 dimerization and constitutive activation andsuppresses its ability to persistently up-regulate the expression ofgenes known to mediate hallmarks of malignant transformation. It wasnext demonstrated that S3I-1757 can suppress uncontrolledanchorage-dependent and -independent tumor cell growth, migration andinvasion. Several cell lines were used, some with persistently Y705phosphorylated STAT3 and others without (FIG. 9A). FIG. 9A shows thatS3I-1757, but not S3I-1756, inhibited in a dose dependent manneranchorage-dependent proliferation by MTT only in cells that harbor(MDA-MB-468, MDA-MB-231, H358, A549) but not in those that do not harbor(H460, MDAMB-453, HEK293 and MCF10A) persistently activated STAT3.Similar results were obtained with colony formation on plastic (FIG.9B). The effects of S3I-1757 on cancer cell anchorage-independent growthwere next determined by soft-agar assay. The results show that S3I-1757significantly inhibited the anchorage independent growth of cancer cellswith constitutively active STAT3 such as MDA-MB-468, but had littleeffect on anchorage-independent growth of H460 cells which has lowactivated STAT3 level (FIG. 9C).

The ability of S3I-1757 to inhibit selectively the migration of cancercells that depend on STAT3 over those that do not was next evaluated bya wound healing assay. The cancer cells were cultured with serum-starvedmedium for 8 hours before scratching the cells with a pipette tip andtreating with increasing concentrations of S3I-1757 for 24 hours. FIG.10A shows that in the absence of drug, the cells migrated within 24hours to fill the scratched area. S3I-1757, but not S3I-1756, treatmentprevented this migration in cells with persistently activated STAT3(MDA-MB-231 and A-549). In contrast, the migration of H460 (with lowlevels of P-STAT3) was minimally affected by the same treatmentcondition. Finally, the ability of S3I-1757 to inhibit selectivelyinvasion was determined. FIG. 10B shows that S3I-1757 but not S3I-1756,inhibited invasion in MDA-MB-468, MDA-MB-231 and A-549 but not in H-460cells.

STAT3-C Rescues from S3I-1757 Inhibition of Gene Expression, Tumor CellGrowth, Migration and Invasion as Well as from Apoptosis Induction

The fact that S3I-1757 but not its inactive analogue S3I-1756 inhibitsmalignant transformation selectively in cells that harbor hyperactivatedSTAT3 indicates that S3I-1757 mediates its effects by inhibiting STAT3.To give further support, the effects of S3I-1757 can be rescued bySTAT3-C, a genetically engineered mutant of STAT3 that forms aconstitutively dimerized STAT3 through disulfide bonds in the absence oftyrosine phosphorylation. To this end, MDA-MB-468 were transfected cellswith STAT3-C, then treated the cells with S3I-1757 and processed thecells for western blotting, cell growth, migration and invasion. FIG.11A shows that expression of STAT3-C increased the levels of BclxL,cyclin D1 and survivin. In contrast, S3I-1757 inhibited the expressionlevels of these proteins and induced activation of caspase 3 and PARPcleavage. Furthermore, FIG. 11A also shows that ectopic expression ofSTAT3-C inhibited the ability of S3I-1757 to down regulate theexpression of BclxL, cyclin D1 and survivin and to induce apoptosis.Similarly, FIG. 11B shows that STAT3-C inhibited S3I-1757 frominhibiting the proliferation/survival of MDA-MB-468 cells as determinedby MTT assays.

The effects of STAT3-C on S3I-1757 affect migration and invasion. FIGS.12A and 12B show that S3I-1757 inhibited the migration and invasion ofMDA-MB-468 cells transfected with vector DNA. In contrast, the abilityof S3I-1757 to inhibit migration and invasion was partially rescued incells transfected with STAT3-C.

The materials and methods of the appended claims are not limited inscope by the specific materials and methods described herein, which areintended as illustrations of a few aspects of the claims and anymaterials and methods that are functionally equivalent are within thescope of this disclosure. Various modifications of the materials andmethods in addition to those shown and described herein are intended tofall within the scope of the appended claims. Further, while onlycertain representative materials, methods, and aspects of thesematerials and methods are specifically described, other materials andmethods and combinations of various features of the materials andmethods are intended to fall within the scope of the appended claims,even if not specifically recited. Thus a combination of steps, elements,components, or constituents can be explicitly mentioned herein; however,all other combinations of steps, elements, components, and constituentsare included, even though not explicitly stated.

1-23. (canceled)
 24. A compound having Formula III:

wherein R¹ is H, C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl,benzyl, 4-piperidyl, 3-(4-pyridyl), pyridinyl, or

wherein R⁴ is OH, Cl, F, Br, I, cyclohexyl, OC₁-C₁₀ alkyl, C₁-C₁₀ alkyl,C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl),morpholinyl, pyridinyl, OPh, PO(OEt)₂, or PO(OH)₂; R² is null, H, OH,Cl, F, Br, I, NH₃, OC₁-C₁₀ alkyl, cyclohexyl, C₁-C₁₀ alkyl, C(O)C₁-C₁₀alkyl, CO₂C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl,pyridinyl, phenyl, halogenated phenyl, PO(OEt)₂, PO(OH)₂ or

wherein X is O, NH, S, or CH₂, and R⁵ is H, OH, Cl, F, Br, I,cyclohexyl, or C₁-C₁₀ alkyl; R³ is H, OH, Cl, F, Br, I, OC₁-C₁₀ alkyl,C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, NO₂, NH₃, or CN; and R⁶is H, C₁-C₁₀ alkyl, or a pharmaceutically acceptable counterion; R⁸ isH, C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl, CO₂C₁-C₁₀ alkyl, or benzyl; each Yis, independent of the others, CH or N; and Z is C or N; or apharmaceutically acceptable salt thereof.
 25. The compound of claim 0,wherein the compound wherein is R¹ is H, C₁-C₁₀ alkyl, C(O)C₁-C₁₀ alkyl,CO₂C₁-C₁₀ alkyl, benzyl, 4-piperidyl, 3-(4-pyridyl), or pyridinyl. 26.The compound of claim 24, wherein R¹ is

where each Y is CH, and R⁴ is OH, Cl, F, Br, I, cyclohexyl, C₁-C₁₀alkyl, 4-piperidyl, 3-(4-pyridyl), morpholinyl, pyridinyl, or OPh. 27.The compound of claim 24, wherein R¹ is

wherein each Y is CH, and R⁴ is cyclohexyl, C₁-C₁₀ alkyl, 4-piperidyl,3-(4-pyridyl), morpholinyl, or pyridinyl.
 28. The compound of claim 27,wherein R⁴ is cyclohexyl.
 29. The compound of claim 24, wherein R² isOH, Cl, F, Br, I, OCH₃, C₁-C₁₀ alkyl, 4-piperidyl, 3-(4-pyridyl),morpholinyl, phenyl, or pyridinyl.
 30. The compound of claim 24, whereinR² is

wherein each Y is CH, and R⁵ is H, OH, Cl, F, Br, or I.
 31. The compoundof any claim 30, wherein X is O.
 32. The compound of claim 24, whereinR² is OPh.
 33. The compound of claim 24, wherein R³ is H or OCH₃. 34.The compound of claim 24, wherein R⁸ is methyl or benzyl.
 35. (canceled)36. A method of treating an individual with cancer, comprising:administering a therapeutically effective amount of the compound ofclaim 24 to the individual.
 37. The method of claim 36, wherein STAT3 ispersistently tyrosine phosphorylated and constitutively activated in thecancer.
 38. The method of claim 36, wherein the cancer is pancreaticcancer, breast cancer, lung cancer, prostrate cancer, ovarian cancer,colon cancer, gastric cancer, head and neck cancer, melanoma, leukemia,multiple myeloma or lymphoma.
 39. A method of inhibiting STAT3-STAT3dimerization and/or STAT3-EGFR binding in a cell, comprising:administering to the cell an effective amount of the compound of claim24 to the cell.
 40. A pharmaceutical composition comprising the compoundof claim 24 and a pharmaceutically acceptable carrier.